Azacyanine dyes and use thereof

ABSTRACT

The application provides fluorescent dyes, which are cyanine dyes that incorporate additional aza moieties in the indolenium heterocycles and/or in the methine chains connecting them. Symmetrical and unsymmetrical chemically reactive azacyanine dyes are described for conjugation, as well as their bioconjugates for in-vitro and in-vivo assays and fluorescence imaging.

TECHNICAL FIELD

This application relates to fluorescent dyes, which are cyanine dyesthat incorporate additional aza moieties in the indolenium heterocyclesand/or in the methine chains connecting them. Symmetrical andunsymmetrical chemically reactive azacyanine dyes are described forconjugation, as well as their bioconjugates for in-vitro and in-vivoassays and fluorescence imaging.

BACKGROUND

Fluorescent dyes form the building blocks of many reagents that are usedin a myriad of bioanalytical applications such as nucleic acid detectionand sequencing, flow cytometry for cellular characterization,fluorescence microscopy, enzymatic assays and increasingly in the fieldof optical imaging as probes to detect disease tissue and organ in vivo.There are a large number of fluorescent dyes available for use inmicroscopy, immunohistology, and other high technology research. Thesedyes have extended conjugated carbon chains embedded in their chemicalstructures. The molecules are able to absorb light energy and emit lightof a different colour. The emission wavelengths of organic dyes areusually fine-tuned to emit light of longer wavelength by incorporationof an electron sink within the molecule that allows for delocalizationof π electrons along the unsaturated chain. Even though NIR dyes havebeen developed for many years for use in high technology fields, just ahandful of them have found use for in vivo applications.

Optical imaging, in particular fluorescence offers several advantagesthat make it a powerful molecular imaging approach, both in the researchand clinical settings. Specifically, optical imaging, besides beingfast, safe, cost effective and highly sensitive, can be tailored fordiagnostic as well as therapeutic outcomes. The organic dyes typicallyused as imaging reporters are amenable to design modifications throughvarious linker chemistries to incorporate one or more targeting motifs.Fluorescence imaging is translational from the preclinical stage insmall animals to human subjects as the same agent can be used withoutmodifying the biological target. While bioluminescence has thesensitivity it is not translatable from preclinical small animal imagingto humans. Also the luciferin/luciferase based system cannot bemultiplexed to interrogate multi mode based mechanism of binding to cellsurface or of receptors in tumours for example in oncology applications.Fluorescence based methods are thus a natural choice to bridge thetranslation of imaging reagents used concurrently with the establishedPET, SPECT MRI and X-ray methods as the optical reporter dyes areamenable via multiple linker chemistry to carry similar or differentrecognition motifs. Molecular imaging involves the use of a “molecular”probe or agent that selectively targets a particular cellular receptor,nucleic acid sequences of a gene, amino acid sequences and posttranslational motifs within a protein, epigenetic modifications,cellular function and pathways, with the absence, presence or level ofthe specific target being indicative of a particular disease state.

The development of NIR fluorescent dyes has played a critical role inthe optical imaging field, allowing it to become an increasinglyimportant contributor to imaging science. In contrast to the classicalapplication of fluorescent dyes in other technologies; the design offluorescent dyes for in vivo applications needs to incorporate severalimportant criteria including (1) water solubility, (2) structural andchemical stability, (3) NIR fluorescence, (4) high quantum yield andlast but, not least (5) a functional group for bioconjugation.

Among the fluorescent dyes available for optical imaging the cyaninefamily of dyes have been the preferred class as they provide thewavelength range for in vivo fluorescence excitation and emission notcompromised by the optical properties of the tissue of interest.Hemoglobin has a strong absorption at wavelengths lower than 600 nm andsignificant background fluorescence from endogenous biomolecules can bedetected up to 650 nm. The heptamethine cyanine dyes, which absorb andemit beyond 750 nm, are classified as near infrared (NIR) dyes and arepreferred labels for in vivo imaging as near infrared light can overcomethe biological optical interference limitations by penetrating moredeeply into tissue, because light scattering decreases with increasingwavelength.

Cyanine dyes are characterized as possessing two heterocyclic moieties,acting as both electron donors and acceptors, and are joined by a singleor odd of number of methine groups in which (n+1) 2 electrons aredistributed over n atoms producing a delocalized cation across themethine chain. This unique characteristic gives cyanine dyes a widerrange of absorption than any other known class of dyes. A great numberof synthetic cyanines are known to absorb between the visible andinfrared regions of the electromagnetic spectrum. In addition, cyaninesexhibit narrow absorption bands and high extinction coefficients. Due tothese properties, cyanine dyes have been extensively employed in variousapplications such as photographic processes, laser printing, nonlinearoptical materials, and more recently fluorescent probes for biomolecularlabelling. For example, U.S. Pat. No. 5,571,388 discloses exemplarymethods of identifying strands of DNA by means of cyanine dyes. Morerecently, they have been used for optical imaging of dye-labelledbiomolecules, either in vivo or in vitro (U.S. Pat. No. 7,597,878,others). Cyanine dyes are the preferred labels in biologicalapplications because, among other reasons, many of these dyes fluorescein the near-infrared (NIR) region of the spectrum (600-1000 nm).

Development of polymethine cyanine dyes that absorb longer wavelengthsfor in vivo imaging applications, have focused on polyenes since eachdouble bond enhancement in this region increases the bathochromic shiftby 100 nm. This feature shows the advantage of cyanines compared toother dyes where tuning is contingent upon the expansion of the aromaticrings. Several lines of research have demonstrated that addition of anaromatic 6-membered ring would shift the absorbance by approximately 20nm. The major drawback to this approach is the increased hydrophobicityof the resulting compound.

Advantages of cyanine dyes include, for example: 1) strong absorptioncross sections and ability to fluoresce after excitation; 2) they do notrapidly bleach under a fluorescence microscope or plate readerexcitation sources; 3) the derivatives are amenable as effectivecoupling reagents without loss of photochemical properties; 4) manystructures and synthetic procedures have been developed over the lastsixty years, and the class of dyes are versatile reagents; 5) cyaninedyes are relatively small (a typical molecular weight is about 1,000daltons), so they do not cause appreciable steric interference in a waythat might reduce the ability of a labelled biomolecule to reach itsbinding site or carry out its function and 6) when appropriatelyderivatized are not pH sensitive.

However, many of the known cyanine dyes have a number of disadvantages,such as chemical instability in the presence of certain reagents thatare commonly found in bioassays. Such reagents include ammoniumhydroxide, dithiothreitol (DTT), primary and secondary amines, andammonium persulfate (APS). Further, some cyanine dyes lack the thermalstability and photostability that is necessary for biologicalapplications such as DNA sequencing and genotyping. Besidesphotostability, which arises due to the cis trans summarization ordisruption of the extended conjugation, aqueous solubility and chargemodification are sometimes needed to derive superior biomedicalapplications.

For these reasons, there is still a need for stable cyanine dyes for usein labelling biomolecules as well as in vivo imaging for the diagnosisand prognosis of diseases such as cancer, infectious disease imaging andmetabolic activity. Such compositions and methods would aid in theanalysis of responses to various therapies.

U.S. Pat. No. 5,217,846 photopolymerizable compositions containinginitiator systems that absorb in the longer wavelength region of thevisible spectrum. The photopolymerizable composition comprises at leastone ethylenically unsaturated monomer capable of free radical initiatedaddition polymerization and an initiator system activatable by actinicradiation, wherein said initiator system comprises ahexaarylbisimidazole, a coinitiator, and a sensitizer.

TOLMACHEV et al report in «KHIMIYA GETEROTSIKLICHESKIKHSOEDINENII”—“CHEMISTRY OF HETEROCYCLIC COMPOUNDS”, LATVIJSKIJ INSTITUTORGANICESKOGO SINTEZA, RIGA, LV, the syntheses of derivatives ofglutaconaldehydedianil hydrochloride of general formula I, whereα,α′-carbon atoms are included to dihydropyran, dihydrothiopyran, andN-methyltetrahydropyridine cycle.

It was shown that synthesized dianils give the corresponding cyaninedyes on heating with 2-methyl-3-ethylbenzothiazolium or2-methyl-3-ethylnaphtothiazolium tozylates under basic conditions(sodium acetate or triethylamine in dry ethanol) of the general formulabelow:

SUMMARY

In one aspect, the present application provides a fluorescent dye offormula A

or a salt thereof, wherein

Z is selected from the group consisting of NR¹⁷ and NR¹⁷R¹⁸;

Q is independently H or selected from the groups a), b) and c)consisting of:

a) Halide selected from Cl, Br, I; R¹⁹U, —OR¹⁹U, —SR¹⁹U and —NR¹⁹R²⁰U,wherein R¹⁹ is a single bond; or wherein R¹⁹ and R²⁰ each independentlymay be an optical properties modifying group, and are independentlyselected from the group consisting of: H, linear and branched,non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic or heterocyclic C₅-, C₆- or C₇ aromatic ring which can besubstituted by a linear or branched C₁-C₆ alkyl group; and homocyclicand heterocyclic 5-, 6- and 7-membered aromatic rings which can besubstituted by a linear or branched C₁-C₆ alkyl group, whereinpreferably one of R¹⁹ and R²⁰ is not aromatic in case of —NR¹⁹R²⁰U;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; and U is aphysiochemistry modifying group selected from the group consisting of:—(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻, —(CH₂)_(m)NH₂;—(CH₂)_(m)NHR³²; —(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6,and wherein R³² and R³³ are independently of each other an alkyl grouphaving from 1-12, preferably 1-8, more preferably 1-4 C atoms, inparticular methyl or ethyl; and wherein in case of —(CH₂)_(m)NH₂;—(CH₂)_(m)NHR³²; —(CH₂)_(m)NR³²R³³ the N atom may be bond to a furthersubstituent R³⁴ to form a quaternary N atom, and wherein R³⁴ is in allthe above cases independently selected from H, and an alkyl group havingfrom 1-12, preferably 1-8, more preferably 1-4 C atoms, in particularmethyl or ethyl,

b) R²¹L, —OR²¹L, —SR²¹L and —NR²¹R²²L wherein R²¹ and R²² eachindependently may be are an optical properties modifying group and areindependently selected from the group consisting of: H, linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic 5-, 6- or 7-memberedaromatic group which can be substituted by a linear or branched C₁-C₆alkyl group; homocyclic and heterocyclic 5-, 6- or 7-membered aromaticrings which can be substituted by a linear or branched C₁-C₆ alkylgroup, wherein preferably one of R²¹ and R²² is not aromatic in case of—NR²¹R²²; —(CH₂—O—CH₂)_(x)CH₂-L wherein x is an integer from 1 to 50;and L is a linker which can form a covalent bond with a targeting agent;

c) R¹⁹, —OR¹⁹, —SR¹⁹ and —NR¹⁹R²⁰ wherein R¹⁹ and R²⁰ each independentlymay be an optical properties modifying group and are independentlyselected from the group consisting of: H, linear and branched,non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic or heterocyclic 5-, 6- or 7-membered aromatic ring which canbe substituted by a linear or branched C₁-C₆ alkyl group; and homocyclicand heterocyclic 5-, 6- and 7-membered aromatic rings which can besubstituted by a linear of branched C₁-C₆ alkyl group, whereinpreferably one of R¹⁹ and R²⁰ is not aromatic in the case of —NR¹⁹R²⁰;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; or whereinR¹⁹ and R²⁰, together with the N atom to which they are attached, form a5- or 6-membered heterocycle optionally containing one furtherheteroatom selected from O and N, wherein the heterocycle can besubstituted by a linear or branched, cyclic or non cyclic C₁-C₆ alkylgroup, in particular 4-cyclohexylpiperazinyl;

R¹ and R² are absent, H or independently selected from the groupconsisting of:

a) linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- and7-membered aromatic rings which can be substituted by a linear ofbranched C₁-C₆ alkyl group; and —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 50,

b) R²³L wherein R²³ is selected from the group: linear and branched,non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic or heterocyclic C₅-, C₆- or C₇-aryl group which can besubstituted by a linear or branched C₁-C₆ alkyl group; homocyclic andheterocyclic 5-, 6- and 7-membered aromatic rings which can besubstituted by a linear or branched C₁-C₆ alkyl group;—(CH₂O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; and L is alinker which can form a covalent bond with a targeting agent,

c) R²³U, wherein R²³ is a single bond; or wherein R²³ is selected fromthe group: linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic rings which can be substituted by a linear orbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl. wherein m is an integer from0 to 6;

R¹⁷ and R¹⁸ are independently H or selected from the group consistingof:

a) linear and branched, non-cyclic or cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- and7-membered aromatic rings which can be substituted by a linear orbranched C₁-C₆ alkyl group, wherein preferably one of R¹⁷ and R¹⁸ is notaromatic; and —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50,

b) R²⁴L wherein R²⁴ is selected from the group: linear and branched,non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic or heterocyclic 5-, 6- or 7-membered aromatic group which canbe substituted by a linear or branched C₁-C₆ alkyl group; homocyclic andheterocyclic 5-, 6- or 7-membered aromatic groups which can besubstituted by a linear of branched C₁-C₆ alkyl group, whereinpreferably one of R¹⁷ and R²⁰ is not aromatic; —(CH₂—O—CH₂)_(x)CH₂—wherein x is an integer from 1 to 50; and L is a linker which can form acovalent bond with a targeting agent,

c) R²⁴U, wherein R²⁴ is a single bond; or wherein R²⁴ is selected fromthe group: linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear ofbranched C₁-C₆ alkyl group, wherein preferably one of R¹⁷ and R¹⁸ is notaromatic; —(CH₂O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; andU is a physiochemistry modifying group selected from the groupconsisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O—(CH₂)_(m)NH₂;—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl, wherein m is an integer from0 to 6;

A⁶, A⁷, A⁸, A⁹, A¹⁰, A¹¹, A¹², and A¹³ are C, N, or ⁺N, and either:

A)

form a 6-membered aromatic ring which together with the pyrrolin derivedring to which they are attached form an indol or an azaindol system,which indol system can comprise a total of 1 N atoms, and which azaindolsystem can comprise a total of 2 N atoms;

R³, R⁴, R⁵, R⁶, R⁷, R⁸ R⁹ R¹⁰ are independently H or selected from thegroup consisting of:

a) halide selected from Cl, Br, I; R²⁵H and OR²⁵H, wherein R²⁵ isselected from the group: linear and branched, non-cyclic and cyclic,substituted and unsubstituted C₁₋₂₀ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic or heterocyclic5-, 6- or 7-membered aromatic group which can be substituted by a linearor branched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear ofbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50,

b) R²⁵L and OR²⁵L, wherein R²⁵ is selected from the group: linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic 5-, 6- or 7-memberedaromatic group which can be substituted by a linear or branched C₁-C₆alkyl group; homocyclic and heterocyclic 5-, 6- or 7-membered aromaticgroups which can be substituted by a linear of branched C₁-C₆ alkylgroup; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; and Lis a linker which can form a covalent bond with a targeting agent, and

c) R²⁵U and OR²⁵U wherein R²⁵ is a single bond; or wherein R²⁵ isselected from the group: linear and branched, non-cyclic and cyclic,substituted and unsubstituted C₁₋₂₀ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic or heterocyclic5-, 6- or 7-membered aromatic group which can be substituted by a linearor branched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear orbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl. wherein m in an integer from0 to 6; and wherein OR²⁵H, OR²⁵L and OR²⁵U are present only when 0 isattached to a C atom;

or

B)

A⁶, A⁷, A⁸, A⁹, and A¹⁰, A¹¹, A¹², A¹³ are C, N, or ⁺N and form a6-membered aromatic ring which together with the pyrrolin derived ringto which they are attached form an indol or an azaindol system, and towhich indol or azaindol system a further 6-membered ring is annulatedwhich is formed by at least two of the substituents R³, R⁴, R⁵, R⁶, orR⁷, R⁸ R⁹ R¹⁰, resulting in a trinuclear ring in which 1, 2 or 3 C atomsmay be replaced by N or ⁺N and which are substituted by R, R¹², R¹³,R¹⁴, R¹⁵, R¹⁶;

R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, R¹⁶ are independently H or selected fromthe group consisting of:

a) halide selected from Cl, Br, I; R²⁶H and OR²⁶H, wherein R²⁶ isselected from the group: linear and branched, non-cyclic and cyclic,substituted and unsubstituted C₁₋₂₀ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic or heterocyclic5-, 6- or 7-membered aromatic group which can be substituted by a linearor branched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear ofbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50,

b) R²⁶L and OR²⁶L, wherein R²⁶ is selected from the group: linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic C₅-, C₆- or C₇-aryl groupwhich can be substituted by a linear or branched C₁-C₆ alkyl group,homocyclic and heterocyclic C₅-, C₆- or C₇-aromatic groups which can besubstituted by a linear or branched C₁-C₆ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; and L is alinker which can form a covalent bond with a targeting agent,

c) R²⁶U and OR²⁶U, wherein R²⁶ is a single bond; or wherein R²⁶ isselected from the group: linear and branched, non-cyclic and cyclic,substituted and unsubstituted C₁₋₂₀ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic or heterocyclic5-, 6- or 7-membered aromatic group which can be substituted by a linearor branched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear ofbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, and

d) —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³ is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl;

X and Y are selected from the group consisting of:

CR²⁹R³⁰, where R²⁹ and R³⁰ are each independently selected from H,unsubstituted and substituted linear or branched, cyclic or non-cyclicC₁-C₆ alkyl;

E and E′ are independently selected from H, unsubstituted andsubstituted linear or branched, cyclic or non-cyclic C₁-C₆ alkyl.

The person skilled in the art is aware that in case that any of thegroups R¹ to R³⁶ wherein a group R¹, . . . R³⁶ . . . is connected to afurther group like L or U, the term “alkyl”, refers to an alkyl group inwhich at least one H atom is substituted by L, U or an atom orfunctional group. In one embodiment of the invention, the compoundaccording to formula A contains at least 1 linker and/or 1physiochemistry modifying group as defined in the context of the presentapplication.

In case the compound according to formula A does not contain at least 1linker and/or 1 physiochemistry modifying group as defined in thecontext of the present application, then R¹⁹ in —OR¹⁹ is not H.

In a further embodiment of the invention, R¹⁹ in —OR¹⁹ is not H in allcompounds according to formula A.

In an embodiment, it is conceivable that in any alkyleneoxy group—(CH₂—O—CH₂)_(x)CH₂— which is cited in the context with R₁, R₂, R₃, R₄,R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈, R₁₉,R₂₀, R₂₁, R₂₂, R₂₃, R₂₃, R₂₄, R₂₅, R₂₆, wherein x is an integer from 1to 50, x is 2500.

In the most general embodiment of the subject matter of the presentapplication, linkers L are selected from the group consisting of: —NH₂,—OH, —SH, —C(O)O⁻, —C(O)Cl, —(CO)O(CO)R²⁷, —C(O)NHNH₂, —C(O), —C(O)OR²⁸,wherein R²⁷ is selected from the group consisting of H, alkyl and aryl;wherein R²⁸ is derived from substituted and unsubstitutedN-hydroxysuccinimide, substituted and unsubstitutedN-hydroxysulfosuccinimide, nitrophenol, fluorophenol each bound via —O—;azide N₃ ⁻, —NCO, —NCS, —CHO, —COCH₂I, phosphoramidityl, phthalamidyl,maleimide, an alkyne group in particular —C≡CR³¹ wherein R³¹ is H or aC₁-C₈ alkyl group, sulfonate esters, alkyl halides, acyl halides.propargylglycine, a pentanoyl group, in particular pentanoyl chloride,pentynoic acid, propargylic acid,6-aminobenzo[d]thiazole-2-carbonitrile,6-hydroxybenzo[d]thiazole-2-carbonitrile, a 1,2-aminothiol group, inparticular L-cysteine or D-cysteine.

Further aspects, objects and advantages of the subject matter of thepresent application will become apparent upon consideration of thedetailed description and figures that follow.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A shows absorption and quantum yield QY of Compound I, FIG. 1Bshows fluorescence spectra and quantum yield QY of Compound I.

FIG. 2A shows absorption and quantum yield QY of Compound II, FIG. 2Bshows fluorescence spectra and quantum yield QY of Compound II.

FIG. 3A shows absorption and quantum yield QY of Compound III, FIG. 3Bshows fluorescence spectra and quantum yield QY of Compound III.

FIG. 4A shows absorption and quantum yield QY of Compound IV, FIG. 4Bshows fluorescence spectra and quantum yield QY of Compound IV.

FIG. 5A shows absorption and quantum yield QY of Compound V, FIG. 5Bshows fluorescence spectra and quantum yield QY of Compound V.

FIG. 6A shows absorption and quantum yield QY of Compound VI, FIG. 6Bshows fluorescence spectra and quantum yield QY of Compound VI.

FIG. 7A shows absorption and quantum yield QY of Compound VII, FIG. 7Bshows fluorescence spectra and quantum yield QY of Compound VII.

FIG. 8A shows absorption and quantum yield QY of Compound VIII, FIG. 8Bshows fluorescence spectra and quantum yield QY of Compound VIII.

FIG. 9A shows absorption and quantum yield QY of Compound IX, FIG. 9Bshows fluorescence spectra and quantum yield QY of Compound IX.

FIG. 10A and FIG. 10B show three representative mice bearing anestablished 4T1-luc2 tumours implanted subcutaneously into the rightflank were injected with the indicated imaging agent. FIG. 10A showsmice imaged by IVIS Spectrum to show tumour localization and FIG. 10Bshows NIR fluorescence images to show specific biomarker detection,after intravenously receiving 0.7 nmol of antibody conjugate XXVIII.

FIG. 11 shows NIR fluorescence images of 4T1-luc2 tumour bearing mice atthe indicated time points after intravenous injection of probe XXI,IntegriSense™ 750, and RGD-ICG.

FIG. 12A and FIG. 12B show the optimal background/noise ratio calculatedfrom the region of interest of 4T1 tumour bearing mice at 2 h postinjection of probe XXI (FIG. 12A) and 24 h post injection ofIntegriSense™ 750 (FIG. 12B).

FIG. 13A shows I.V. catheter injection in a 30 kg dog 6 h before surgerywith 180 nmol/kg of probe XXI, and FIG. 13B shows localization ofmastocytoma tumour in dog's right leg.

FIG. 14A shows fluorescence image-guided surgical procedure ofmastocytoma tumour resection. A mastocytoma tumour (solid arrow) isclearly identified by a rim around the tumor in vivo, 6 h afterinjection of probe XXI. Normal tissue (dashed arrow) shows negligiblebackground uptake of probe XXI. The enhanced ability to visualize tumormargins in fluorescence image-guided surgery led to more completeresection of the tumor (round dot arrow), and FIG. 14B shows occultmalignant lesion.

FIG. 15A shows no apparent fluorescence from residual tumour could beobserved after the operation, and FIG. 15B shows after resection carriedout under the guidance of fluorescent light and slicing of the samespecimen, the rim around the tumor can be visualized ex vivo.

FIG. 16A shows I.V. catheter injection in a 33 Kg dog 10 h beforesurgery with 92 nmol/kg of probe XXI, and FIG. 16B shows localization ofmastocytoma tumour in dog's nose.

FIG. 17A show fluorescence image-guided surgical procedure of dog'smastocytoma tumour and FIG. 17B shows after resection carried out underthe guidance of fluorescent light and slicing of the same specimen, therim around the tumor can be visualized ex vivo.

FIG. 18A shows cryogenic tissue damage with dye VI, the cells at thesite of focal dry-ice treatment showed strong fluorescence signalwhereas no signal was obtained from the viable cells, and FIG. 18B showstotal photon flux of treated cells at different concentrations.

FIG. 19A shows cryogenic tissue damage with dye XIV, fluorescence of thedye XIV showed strong accumulation of fluorescence at the site of focaldry-ice treatment in the cryogenic tissue, and FIG. 19B shows totalphoton flux of treated tissue at different concentrations.

FIG. 20 shows the measured signal as a function of time post injection.

FIG. 21 shows the signal and the control as a function of time.

FIG. 22 shows the ratio of signal to control as a function of time.

FIG. 23 shows the multi-well plate and the level of fluorescence.

FIG. 24 shows the fluorescence spectra of Compound VIII and Compound VI.

DETAILED DESCRIPTION

All publications, patent applications, patents, and other referencesmentioned herein are incorporated by reference in their entirety. Thepublications and applications discussed herein are provided solely fortheir disclosure prior to the filing date of the present application.Nothing herein is to be construed as an admission that the presentsubject matter is not entitled to antedate such publication by virtue ofprior invention. In addition, the materials, methods, and examples areillustrative only and are not intended to be limiting.

In the case of conflict, the present specification, includingdefinitions, will control. Unless defined otherwise, all technical andscientific terms used herein have the same meaning as is commonlyunderstood by one of skill in art to which the subject matter hereinbelongs. As used herein, the following definitions are supplied in orderto facilitate the understanding of the subject matter of the presentapplication.

The term “comprise” is generally used in the sense of include, that isto say permitting the presence of one or more features or components.Also as used in the specification and claims, the language “comprising”can include analogous embodiments described in terms of “consisting of”and/or “consisting essentially of”.

As used in the specification and claims, the singular form “a”, “an” and“the” include plural references unless the context clearly dictatesotherwise.

As used in the specification and claims, the term “and/or” used in aphrase such as “A and/or B” herein is intended to include “A and B”, “Aor B”, “A”, and “B”.

The dyes according to formula A can contain various substituents invarious positions. The person skilled in the art is aware of someprinciple differences between these substituents, according to theirchemical properties and to the impact on the physical and chemicalproperties of the respective dye in which they are present. The skilledartisan will differentiate between the following types of substituents:

Substituents Having an Impact on the Optical Properties of the Dye(Optical Properties Modulation Groups, Optical Properties ModifyingGroups)

Substituents of this type are attached in position Q of the dye. Here,they are attached to the conjugated double bonds responsible for theoptical properties and will, hence, influence them. In general, thesesubstituents are inorganic or organic groups, which are known to theperson skilled in the art as modulating optical properties in dyeshaving the structural characteristics of the dyes of the presentapplication, in particular a conjugated double bond system. In thecontext of the present application, optical properties include:absorption, fluorescence, fluorescence quantum yield, stokes shift,lifetime, photostability and further properties known to the personskilled in the art. According to the subject matter of the presentapplication, a fluorescence modulation is a change in the emissionwavelength of a dye containing such fluorescence modifying substituent,with respect to the dye not containing the fluorescence modifyingsubstituent.

Examples for this type of substituents (optical properties modifyinggroup) include: Cl, Br; I; R¹⁹, —OR¹⁹, —SR¹⁹ and —NR¹⁹R²⁰ wherein R¹⁹and R²⁰ are independently selected from the group consisting of: H,linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic ring which can be substituted by a linear orbranched C₁-C₆ alkyl group; and homocyclic and heterocyclic 5-, 6- and7-membered aromatic rings which can be substituted by a linear orbranched C₁-C₆ alkyl group.

The above definition is not limited to R¹⁹ and/or R²⁰ which is anorganic residue in a substituent of the heterocycle being part of theconjugated double bond system, but of course applies to all otherpositions and substituents in the molecule which have been defined inconnection with the dyes according to A, in the general and allpreferred embodiments, to which an optical properties modifyingsubstituent can be attached and/or at which position the substituent hasan impact on the optical properties.

As the case may be, an optical properties modifying group as definedbeforehand may also contain a physiochemistry modifying group and/or alinker, see below.

The person skilled in the art is furthermore aware that not all of theabove cited groups will have an effect on the optical properties of thedyes of the subject matter of the present application in each and everycase, as this depends on the chemical and/or fluorescent properties ofthe respective dye.

Examples for preferred optical properties modifying groups include: Cl,Br, I; 1-cyclohexylpiperazine, phenyl; —O-phenyl; —S-phenyl;—N(H)-phenyl; and wherein each of the groups phenyl, —O-phenyl,S-phenyl, —N(H)-phenyl can be single or multiple substituted by C₁-C₆alkyl; and wherein the phenyl group can be substituted by aphysiochemistry modifying group U selected from the group consisting of:—(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂—(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integerfrom 0 to 6, i.e. 0, 1, 2, 3, 4, 5, and 6; and wherein R³², R³³, is analkyl group having from 1-12, preferably 1-8, i.e. 1, 2, 3, 4, 5, 6, 7and 8; more preferably 1-4 C atoms, in particular methyl or ethyl; Theabove groups are preferred in combination with the general, preferred,and most preferred embodiments for the other substituents Z, Q, R¹-R³⁰,A⁶-A¹⁶ and X and Y.

Substituents Having an Impact on the Physiochemical Properties of theDye (“Physiochemistry Modifiers”, “Physiochemistry Modifying Group”,“Physiochemical Properties Modifying Group”, “Physiochemistry ModulatingGroup”)

Substituents of this type, generally denoted U throughout thisapplication, have an impact on various properties of the dye. Theseproperties are in particular: solubility of the dye, stability of thedye, and, as the case may be, other properties known to the personskilled in the art. Thus, in particular these substituents render therespective dye more water soluble or more dispersible, in particular inmedia for administration. Furthermore, and depending on the case, aphysiochemistry modifying group can increase binding specificity,increase or decrease net molecular charge, decrease immunogenicity ortoxicity, or modify cellular uptake, pharmacokinetic or biodistributionprofiles, compared to the unmodified bioconjugate targeting or imagingagents.

Further effects of physiochemistry modifiers may be enhancement of thebinding selectivity of the targeting agent for receptors on the cellsurface, negatively charged, apoptotic cell surfaces over othernegatively charged endogenous cell surfaces, reduction of thenonspecific cell membrane permeability of the targeting agent, andreduction of nonspecific tissue accumulation of the targeting agent whenadministered to a live animal.

The physiochemistry modifiers can have a pronounced impact on in vivobiodistribution and clearance, in particular when modulating solubility.

In general, physiochemistry modifiers are functional groups which areknown to the person skilled in the art as having an influence onsolubility. Examples include the groups —SO₃ ⁻, —C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³ is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl; and wherein in case of—(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; —(CH₂)_(m)NR³²R³³ the N atom may be bondto a further substituent R³⁴ to form a quaternary N atom, and whereinR³⁴ is in all the above cases independently selected from H, and analkyl group having from 1-12, preferably 1-8, more preferably 1-4 Catoms, in particular methyl or ethyl. In case —(CH₂)_(m)NH₂,—(CH₂)_(m)NHR³² and —(CH₂)_(m)NR³²R³³ contain a further substituent R³⁴connected to the N atom to form a quaternary N atom, this substituentR³⁴ is preferably identical with the other substituents, i.e. at leastone of them if R³² and R³³ are different, or with both in case R³² andR³³ are the same. This means that R³² and R³³ and R³⁴ are identical andform a group —(CH₂)_(m)N⁺R³²R³³ R³⁴, or a group —(CH₂)_(m)N⁺H₃, with mbeing an integer from 0 to 6, and wherein R³², R³³, and R³⁴ are an alkylgroup having from 1-12, preferably 1-8, more preferably 1-4 C atoms, inparticular methyl or ethyl.

The above-named functional groups can be attached directly to a C or Natom which is part of the basic structure of the dye according to A, orthese groups can be attached to such N or C atom via an alkyl group, asexpressed by the formulae —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, i.e. 1, 2, 3, 4,5, and 6; and wherein R³², R³³, and R³⁴ are an alkyl group having from1-12, preferably 1-8, i.e. 1, 2, 3, 4, 5, 6, 7 and 8; more preferably1-4 C atoms, in particular methyl or ethyl; or these groups can beattached to a substituent of a C or a N atom which is part of the basicstructure of the dye, as expressed by —R¹⁹U, —OR¹⁹U, —SR¹⁹U and—NR¹⁹UR²⁰ wherein R¹⁹ and R²⁰ are independently selected from the groupconsisting of: H, linear and branched, non-cyclic and cyclic,substituted and unsubstituted C₁₋₂₀ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic or heterocyclic5-, 6- or 7-membered aromatic ring which can be substituted by a linearof branched C₁-C₆ alkyl group; and homocyclic and heterocyclic 5-, 6-and 7-membered aromatic rings which can be substituted by a linear ofbranched C₁-C₆ alkyl group; or a group —(CH₂—O—CH₂)_(x)CH₂— wherein x isan integer from 1 to 50; and U is a physiochemistry modifying groupselected from those as defined hereinabove. The groups attached to a Cor N atom of the dye, on the one hand side, and to the physiochemistrymodifying group, on the other hand side, are also referred to as“spacer” or “spacer group” in the present context. The above definitionis not limited to R¹⁹ which is an organic residue in a substituent ofthe heterocycle being part of the conjugated double bond system, but ofcourse applies to all other positions and substituents in the moleculewhich have been defined in connection with the dyes according to S, inthe general and all preferred embodiments, to which a physiochemistrymodifying group can be attached.

Substituents Serving as “Linker” and being Converted into a “LinkingGroup”

Substituents of this type, generally denoted L throughout thisapplication, serve to link the dye to the targeting agent. In general,these linkers are functional groups which are known to the personskilled in the art as being capable of linking a molecule to anothermolecule in a chemical reaction, under formation of a “linking group”between the dyes of the subject matter of the present application and atargeting agent. The chemical reaction preferably forms a covalent bondbetween the dye and the targeting agent. Examples for linkers includethe groups —NH₂, —OH, —SH, —C(O)O⁻, —C(O)Cl, —(CO)O(CO)R²⁷ wherein R²⁷is selected from the group consisting of H, alkyl and aryl; —C(O)NHNH₂,—C(O)OR²⁸ wherein R²⁸ is derived from substituted and unsubstitutedN-hydroxysuccinimide, substituted and unsubstitutedN-hydroxysulfosuccinimide, nitrophenol, fluorophenol each bound via —O—;azide N₃ ⁻, —NCO, —NCS, —CHO, —COCH₂I, phosphoramidityl, phthalamidyl,maleimide, an alkyne group in particular —C≡CR³¹ wherein R³¹ is H or aC₁-C₈ alkyl group. Examples for further functional groups which canserve as a linker include sulfonate esters, alkyl halides, acyl halides,propargylglycine, a pentanoyl group (like in pentanoyl chloride),pentynoic acid, propargylic acid,6-aminobenzo[d]thiazole-2-carbonitrile,6-hydroxybenzo[d]thiazole-2-carbonitrile, a 1,2-aminothiol group, inparticular L-cysteine or D-cysteine. These linkers can react withcomplementary groups present on the targeting agent in reactions knownas such to the skilled person.

These groups can be attached directly to a C or N atom which is part ofthe basic structure of the dye according to A, or these groups can belinked to the basic structure by a further group attached to a C or a Natom which is part of the basic structure of the dye, as expressed byR²³L wherein R²³ is selected from the group: linear and branched,non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic or heterocyclic C₅-, C₆- or C₇-aryl group; homocyclic andheterocyclic 5-, 6- or 7-membered aromatic rings; —(CH₂—O—CH₂)_(x)CH₂—wherein x is an integer from 1 to 50; and L is a linker which can form acovalent bond with a targeting agent. The groups attached to a C or Natom of the dye, on the one hand side, and to the linker, on the otherhand side, are also referred to as “spacer” or “spacer group” in thepresent context. The above definition is not limited to R²³ which is anorganic residue in a substituent of the heterocycle being part of theconjugated double bond system, but of course applies to all otherpositions and substituents in the molecule which have been defined inconnection with the dyes according to S, in the general and allpreferred embodiments, to which a solubility modifying group can beattached.

“Click” chemistry provides one possible way for linking the fluorescentdyes of the subject matter of the present application to targetingagents. In a further embodiment of the application, “click chemistry”can be used to connect the dye to the targeting agent via a chemicalreaction of the linker. “Click” chemistry uses simple, robust reactions,such as the copper-catalyzed cycloaddition of azides and alkynes, tocreate intermolecular linkages. For a review of “Click” chemistry, seeKolb, H. C; Finn, M. G.; Sharpless, K. B. Angew. Chem. 2001, 40, 2004.Connection (or ligation) of two fragments to make a larger molecule orstructure is often achieved with the help of so-called “click chemistry”described by Sharpless et al. Angew. Chem, Int. Ed. 40: 2004 (2001).This term is used to describe a set of bimolecular reactions between twodifferent reactants such as azides and acetylenes. The formation of1,2,3-triazoles in 1,3-dipolar cycloaddition of azides to a triple bondis known to the person skilled in the art, and it is known that thereaction can even be carried out under physiological conditions, seee.g., U.S. Pat. No. 7,807,619 to Bertozzi. Another novel thiol-based“click” reaction involves the efficient condensation between the cyanogroup of 2-cyano-6-aminobenzothiazole (CBT) (or2-cyano-6-hydroxybenzothiazole) and 1,2-aminothiol group of L-cysteine(or D-cysteine) to yield a thiazole functionality, which can becontrolled by pH, reduction and enzyme reported by White, et al. J. Am.Chem. Soc. 85 (1963). To date, this click condensation reaction has beensuccessfully employed to design smart optical imaging probes.

Other Type Substituents

The definition of A cites other substituents, which do not have any ofthe above effects, or only to a minor extent. These other typesubstituents may e.g., be present in the molecule due to theavailability of starting compounds, or they may facilitate the synthesisof the respective dye, or they are present due to other reasons known tothe person skilled in the art. Groups, which do not have the aboveeffects and thus belong into the present group, are known to the skilledperson.

As a difference to other fields where a slight modification of themolecule will often have a pronounced effect on the molecule's property(e.g., in the field of pharmaceutically active compounds), the moleculesof the present application (dyes) provide various possibilities for theattachment of various substituents, which do not or not substantiallychange the molecules' properties. It is contemplated that substituent Qis an exception to this, due to its proximity to the conjugated doublebond system in the substituents Q, meaning that a modification of Q mayhave an impact on the optical properties of the molecule. This, however,depends on each single case.

In the other positions of the molecule where a substituent can bepresent, the effect of a modification of the substituent with respect tofluorescence properties will not be very pronounced, in the very mostcases. As a consequence, and for example, a physiochemistry modifyinggroup and/or a linker may be attached to a large number of positions,sometimes in practice even any position, in the molecules A which aresynthetically accessible and which does not negatively affect thepurpose of the respective substituent. For example, a linker (serving toattach a targeting agent to the dye) should not be attached to aposition which is not easily accessible, e.g., due to stericalhindrance. Another example is that inert groups, like e.g., alkyl groupsof various lengths, can often be attached to the dyes of the presentapplication, and the dye still lends itself for its intended purposeswith respect to its analogue not substituted in the respective position,as important properties like the solubility and/or the opticalproperties are not or not substantially effected. Thus, the skilledartisan is aware that a large number of groups can be attached tovarious sites without (substantially) changing the molecules' properties(namely physiochemistry, solubility, optical properties, e.g.,fluorescence properties).

The above groups often serve as a “spacer”.

When in the foregoing it has been quoted that “R” is a single bond(e.g., in connection with R²³U, where it is quoted that R²³, “R²³U is asingle bond”), this relates to the case that the group U is directlyconnected to the respective site of the dye via a chemical bond, ingeneral via a single bond.

The skilled person is aware that he present application includes notonly the case that the 1 linker L (generally attached via a spacergroup) or 1 physiochemistry modifying group U (which may be attached viaa spacer group or not) is/are present, but also to the case that 2, 3, 4or more groups U and 2, 3, 4 or more groups L are present in the dye. Ina preferred embodiment, 1 or 2 groups L are present in the dyesaccording to the subject matter of the present application.

The person skilled in the art knows that the dyes according to theapplication should be inert and stable under physiological conditions,as a reaction during monitoring or diagnosing a disease is notdesirable, in particular when monitoring or diagnosing is carried out invitro. This means that it should be avoided to prepare dyes carryingreactive groups under the conditions of monitoring/diagnosis (i.e. thatthese groups undrgo chemical reactions when exposed to the typicalconditions applied during the monitoring or the diagnosis process), inparticular physiological conditions. In general, the groups attached tothe dyes according to the present subject matter, if not serving tomodulate physiochemical properties and/or optical properties, are inertgroups which show only a low reactivity at maximum, and which in generaldo not affect the physiochemical properties and/or optical properties.Often, these groups serve as a “spacer”, holding a physiochemicalproperties modulating group and/or a linker in or at the end of theirchain. In particular in case of a linker, a respective linker attachedto the chain (where the chain is often linear and branched, non-cyclicand cyclic, substituted and unsubstituted C₁₋₂₀ alkyl, wherein the saidalkyl group can be single or multiple substituted by a homocyclic orheterocyclic 5-, 6- or 7-membered aromatic ring which can be substitutedby a linear of branched C₁-C₆ alkyl group; and homocyclic andheterocyclic 5-, 6- and 7-membered aromatic rings which can besubstituted by a linear of branched C₁-C₆ alkyl group, or a group—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50) must not betoo close to the basic structure, in order to avoid steric interactionsbetween the dye and the targeting agent to be bound.

Accordingly, a spacer group must show no or only a low chemicalreactivity (which also applies for the basic structure of the dye) andmust not influence in particular the optical properties of the resultingdye, or only to a minor extent which has no practical relevance.Accordingly, a huge amount of spacers having various alkyl chain lengthsand/or various sizes and various natures of the aromatic group may beused in the context of the present application, which do not or onlyminimally alter the optical properties of the dye.

With respect to the physiochemical properties of the dye, its relationto the spacer may be more delicate. As solubility is a component ofphysiochemical properties, and the solubility of a dye may change withthe length and nature of the spacer (alkyl, aralkyl or aromatic group,alkyleneoxy group; chain length in case of alkyl, and ring size andpresence of heteroatoms in an aromatic ring), these parameters may alsoaffect physiochemical properties. Alkyleneoxy groups enhancewater-solubility of a molecule in general, where aromatic groups reducewater-solubility, in general. However, the effect of these parameters,in general, will only be observed to a lesser extent than forphysiochemical property modulating groups.

From the above, it follows that the nature of the spacers can be widelyvaried within the limits given by its respective definitions, withoutsubstantially affecting the optical and/or physiochemical properties ofthe dye. These latter are adjusted, in general, by the choice of theoptical property modulators and/or the physiochemical propertymodulators. The person skilled in the art is aware how to adjust desiredproperties of a dye by selecting the above parameters.

The term “alkyl” refers to an aliphatic saturated hydrocarbon groupwhich may be linear or branched, including methyl (C₁ alkyl), ethyl (C₂alkyl), n-propyl, iso-propyl (C₃ alkyl), n-butyl, iso-butyl, sec.-butyland tert.-butyl (C₄ alkyl), n-pentyl (amyl), 2-pentyl (sec-pentyl),3-pentyl; 2-methylbutyl, 3-methylbutyl (iso-pentyl or iso-amyl),3-methylbut-2-yl, 2-methylbut-2-yl; 2,2-dimethylpropyl (neopentyl) (C₅alkyl), a hexyl group (C₆ alkyl) including all isomers, a heptyl group(C₇ alkyl) including all isomers, an octyl group (C₅ alkyl) includingall isomers, a nonyl group including all isomers (C₉ alkyl), a decylgroup including all isomers (C₁₀ alkyl), an undecyl group including allisomers (C₁₁ alkyl), a dodecyl group including all isomers (C₁₂ alkyl),a tridecyl group including all isomers (C₁₃ alkyl), a tetradecyl groupgroup including all isomers (C₁₄ alkyl), a pentadecyl group includingall isomers (C₁₅ alkyl), a hexadecyl group including all isomers (C₁₆alkyl), a heptadecyl group including all isomers (C₁₇ alkyl), aoctadecyl group including all isomers (C₁₈ alkyl), a nonadecyl groupincluding all isomers (C₁₉ alkyl), and a C₂₀ alkyl group including alisomers, as known to the person skilled in the art.

The term “alkyl” also refers to an aliphatic saturated cyclichydrocarbon group, which may have alkyl substituents. Examples includecyclopropyl (C₃ cycloalkyl), cyclobutyl (C₄ cycloalkyl), cyclopentyl (C₅cycloalkyl), cyclohexyl (C₆ cycloalkyl), cycloheptyl (C₇ cycloalkyl),and cyclooctyl (C₈ cycloalkyl). Each hydrogen of a cycloalkyl carbon maybe replaced by an alkyl substituent.

The term “phenyl” refers to the group —C₆H₅ as known to the personskilled in the art. The aromatic ring of the phenyl group may besubstituted 1 or 2 times by C₁-C₄ alkyl and/or 1 or 2 times by Cl, Br.I.

The term “homocyclic 5-, 6- or 7-membered aromatic group” is known tothe person skilled in the art. Aromatic groups are known to the personskilled in the art, who is also aware that typical representatives have5, 6 or 7 members in its cycle, and of the heteroatoms which may bepresent. Typical examples for heteroatoms in the context of the presentapplication are N, O and A. In the context of the present application, Nand O are preferred. Non-limiting examples include phenyl, pyridyl(6-membered), pyrrol, furyl, thiophen (5-membered), cycloheptatrienyl(7-membered). The aromatic heterocycle can be connected to therespective place in the dye via the heteroatom or via a C-atom.

A homocyclic 6-membered aromatic group is phenyl of pyridyl, preferablyphenyl.

“Aryl” or “Ar” or “aromatic group” refers to a monovalent aromaticcarbocyclic group of from 5 to 18 carbon atoms having a single ring suchas C₆ in phenyl or anion such as C₅ cyclopentadienyl anion or a ringsystem having multiple condensed rings such as those in anthracenyl,napthyl, phenanthrenyl, the condensed rings may be bridged by atransition atom or ion such as iron with two cyclopentadienyl anions inferrocene, the condensed rings may or may not be aromatic, provided thatthe point of attachment is through an atom of an aromatic ring such asdihydroindolyl, dihydrobenzthiazolyl and other partially hydrogenatedaromatic groups. Unless otherwise constrained by the definition for thearyl substituent that are defined by groups obeying Huckels law of 4n+2pi electrons (n being an integer), such aryl groups can optionally besubstituted with from 1 to 5 substituents, or from 1 to 3 substituents,

“Amino” refers to the group NH₂.

“Substituted amino” refers to the group —NRR where each R isindependently selected from the group consisting of hydrogen, C₁-C₈alkyl, which can be substituted or unsubstituted, C₅-C₇ cycloalkyl whichcan be substituted or unsubstituted, and a homocyclic 5-, 6- or7-membered aromatic group, provided that at least one R is not hydrogen.

“Azido” refers to the group —N₃.

“Carboxyl,” “carboxy” or “carboxylate” refers to C(O)OH or salts thereofderived from CO₂ ⁻

“Cyano” or “nitrile” refers to the group —CN.

“Thiocyanate” refers to the group —SCN.

“Isothiocyante” refers to the group —NCS.

“Halo”, halide” or “halogen” refers to F, Cl, Br and I, preferably Cl,Br and I.

“Hydroxy” or “hydroxyl” refers to the group —OH.

“Heteroaryl” refers to an aromatic group of from 2 to 15 carbon atoms,such as from 3 to 10 carbon atoms and 1 to 10 heteroatoms selected fromthe group consisting of oxygen, nitrogen (referred to as aza in theapplication) and sulfur within the ring. Such heteroaryl groups can havea single ring (such as, pyrrole, pyridyl, imidazolyl or furyl) ormultiple condensed rings in a ring system (for example as in groups suchas, indolizinyl, quinolinyl, benzofuran, benzimidazolyl orbenzothienyl), wherein at least one ring within the ring system isaromatic and at least one ring within the ring system is aromatic,provided that the point of attachment is through an atom of an aromaticring. In certain embodiments, the nitrogen and/or sulfur ring atom(s) ofthe heteroaryl group are optionally oxidized to provide for the N-oxide(N→O), sulfinyl, or sulfonyl moieties. This term includes, by way ofexample, pyridinyl, pyrrolyl, indolyl, thiophenyl, and furanyl. Unlessotherwise constrained by the definition for the heteroaryl substituent,such heteroaryl groups can be optionally substituted with 1 to 5substituents, or from 1 to 3 substituents, selected from acyloxy,hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl,cycloalkenyl, substituted alkyl, substituted alkoxy, substitutedalkenyl, substituted alkynyl, substituted cycloalkyl, substitutedcycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl,aryl, aryloxy, azido, carboxyl, carboxylalkyl, cyano, halogen, nitro,heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy,oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy,thioheteroaryloxy, sulfinate and sulfonate esters-SO-alkyl,—SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl,SO₂-substituted alkyl, —SO₂-aryl, SO₂-heteroaryl, —SO₃-M1, phosphatediesters exemplified by —OPO₃-(M)alkyl, —OPO₃-(M)aryl,—OPO₃-(M)heteroaryl, OPO₃-heteroaryloxy, phosphate triesters—OPO₃-dialkyl, —OPO₃-(alkyl)aryl, —OPO₃-diaryl, —OPO₃-(alkyl)heteroaryl,—OPO₃-(aryl)heteroaryl, —OPO₃-diheteroaryl, —OPO₃M2, —OPO₃-2M1 where M1and M2 are monovalent and divalent cations.

“Hydroxylamino” refers to the group —NHOH.

“Nitro” refers to the group —NO₂.

“Thiol” refers to the group —SH.

“Thioxo” or the term “thioketo” refers to the atom (═S).

“Ureido” refers to the group NH—CO—NH—, and “thioureido” refers to thegroup —NH—CS—NH—.

The term “N-hydroxysuccinimide is the N-hydroxy derivative ofsuccinimide.

The term substituted and unsubstituted N-hydroxysulfosuccinimide refersto the N-hydroxy derivative of succinimide which is substituted by agroup —SO₃ ⁻ at the 5-membered cycle.

The terms “phosphoramidityl” and “phosphoramidit”, “phthalamidyl” and“phatilimide” and “maleimide” are known to the person skilled in theart.

The term “sulfonate ester”, “alkyl halide” and “acyl halide” are currentterms in the art and known to the skilled artisan.

The general and preferred embodiments of the application are definedhereinafter.

In the most general embodiment of the fluorescent dyes of theapplication, Z is selected from the group consisting of N, NR¹⁷,⁺NR¹⁷R¹⁸.

In a preferred embodiment of the application, Z is is N or ⁺N, NR¹⁷, or⁺NR¹⁷R¹⁸.

In a more preferred embodiment of the application, Z is N or ⁺N, NR¹⁷,or ⁺NR¹⁷R¹⁸.

In the most general embodiment of the application, Q is independently Hor selected from the groups a), b), and c) consisting of:

a) Halide selected from Cl, Br, I; R¹⁹U, —OR¹⁹U, —SR¹⁹U and —NR¹⁹R²⁰U,wherein R¹⁹ is a single bond; or wherein R¹⁹ and R²⁰ may independentlybe an optical properties modifying group, and are independently selectedfrom the group consisting of: H, linear and branched, non-cyclic andcyclic, substituted and unsubstituted C₁₋₂₀ alkyl, wherein the saidalkyl group can be single or multiple substituted by a homocyclic orheterocyclic C₅-, C₆- or C₇ aromatic ring which can be substituted by alinear or branched C₁-C₆ alkyl group; and homocyclic and heterocyclic5-, 6- and 7-membered aromatic rings which can be substituted by alinear or branched C₁-C₆ alkyl group, wherein preferably one of R¹⁹ andR²⁰ is not aromatic in case of —NR¹⁹R²⁰U; —(CH₂—O—CH₂)_(x)CH₂— wherein xis an integer from 1 to 50; and U is a physiochemistry modifying groupselected from the group consisting of: —(CH₂)_(m)SO₃ ⁻,—(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻, —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;—(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²and R³³ are independently of each other an alkyl group having from 1-12,preferably 1-8, more preferably 1-4 C atoms, in particular methyl orethyl; and wherein in case of —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;—(CH₂)_(m)NR³²R³³ the N atom may be bond to a further substituent R³⁴ toform a quaternary N atom, and wherein R³⁴ is in all the above casesindependently selected from H, and an alkyl group having from 1-12,preferably 1-8, more preferably 1-4 C atoms, in particular methyl orethyl;

b) R²¹L, —OR²¹L, —SR²¹L and —NR²¹R²²L wherein R²¹ and R²² may be anoptical properties modifying group and are independently selected fromthe group consisting of: H, linear and branched, non-cyclic and cyclic,substituted and unsubstituted C₁₋₂₀ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic or heterocyclic5-, 6- or 7-membered aromatic group which can be substituted by a linearor branched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic rings which can be substituted by a linear orbranched C₁-C₆ alkyl group, wherein preferably one of R²¹ and R²² is notaromatic in case of —NR²¹R²²; —(CH₂—O—CH₂)_(x)CH₂-L wherein x is aninteger from 1 to 50; and L is a linker which can form a covalent bondwith a targeting agent;

c) R¹⁹, —OR¹⁹, —SR¹⁹ and —NR¹⁹R²⁰ wherein R¹⁹ and R²⁰ wherein R¹⁹ andR²⁰ may independently be an optical properties modifying group and areindependently selected from the group consisting of: H, linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic 5-, 6- or 7-memberedaromatic ring which can be substituted by a linear or branched C₁-C₆alkyl group; and homocyclic and heterocyclic 5-, 6- and 7-memberedaromatic rings which can be substituted by a linear of branched C₁-C₆alkyl group, wherein preferably one of R¹⁹ and R²⁰ is not aromatic incase of —NR¹⁹R²⁰; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to50; or wherein R¹⁹ and R²⁰, together with the N atom to which they areattached, form a 5- or 6-membered heterocycle optionally containing onefurther heteroatom selected from O and N, wherein the heterocycle can besubstituted by a linear or branched, cyclic or non cyclic C₁-C₆ alkylgroup, in particular 4-cyclohexylpiperazinyl.

In an embodiment within this most general embodiment of the invention,R¹⁹ in —OR¹⁹ is not H. This is in particular the case if the compoundaccording to formula A does not contain at least 1 linker and/or 1physiochemistry modifying group as defined in the context of the presentapplication.

In a preferred embodiment of the application, Q is independently H orselected from the groups a), b), and c) consisting of:

a) halide selected from Cl, Br, I; R¹⁹U, —OR¹⁹U, —SR¹⁹U and —NR¹⁹R²⁰U;wherein R¹⁹ is a single bond; or wherein R¹⁹ and R²⁰ may independentlybe an optical properties modifying group, and are independently selectedfrom the group consisting of: H, linear, non-cyclic, substituted andunsubstituted C₁₋₁₂ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic 6-membered aromatic group which canbe substituted by a linear or branched C₁-C₄ alkyl group; and homocyclic6-membered aromatic rings which can be substituted by a linear orbranched C₁-C₄ alkyl group, wherein preferably one of R¹⁹ and R²⁰ is notaromatic in case of —NR¹⁹R²⁰U; —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 20; and U is a physiochemistry modifying groupselected from the group consisting of: —(CH₂)_(m)SO₃ ⁻,—(CH₂)_(m)C(O)O—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂;—(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6,and wherein R³², R³³, is an alkyl group having from 1-12, preferably1-8, more preferably 1-4 C atoms, in particular methyl or ethyl; andwherein in case of —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; —(CH₂)_(m)NR³²R³³ theN atom may be bond to a further substituent R³⁴ to form a quaternary Natom, and wherein R³⁴ is in all the above cases independently selectedfrom H, and an alkyl group having from 1-12, preferably 1-8, morepreferably 1-4 C atoms, in particular methyl or ethyl;

b) R²¹L, —OR²¹L, —SR²¹L and —NR²¹R²²L wherein R²¹ and R²² mayindependently be an optical properties modifying group and areindependently selected from the group consisting of: H; linear,non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl, wherein the saidalkyl group can be single or multiple substituted by a homocyclicC₆-aryl group which can be substituted by a linear or branched C₁-C₄alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20;and homocyclic 6-membered aromatic groups rings which can be substitutedby a linear or branched C₁-C₄ alkyl group, wherein preferably one of R²¹and R²² is not aromatic in case of —NR²¹R²²; and L is a linker which canform a covalent bond with a targeting agent;

c) R¹⁹, —OR¹⁹, —SR¹⁹ and —NR¹⁹R²⁰ wherein R¹⁹ and R²⁰ may independentlybe an optical properties modifying group and are independently selectedfrom the group consisting of: H; linear, non-cyclic, substituted andunsubstituted C₁₋₁₂ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic C₆-aryl group which can besubstituted by a linear or branched C₁-C₄ alkyl group; and homocyclic6-membered aromatic groups which can be substituted by a linear orbranched C₁-C₄ alkyl group, wherein preferably one of R¹⁹ and R²⁰ is notaromatic in case of —NR¹⁹R²⁰U; —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 20; or wherein R¹⁹ and R²⁰, together with the N atomto which they are attached, form a 5- or 6-membered heterocycleoptionally containing one further heteroatom selected from O and N,wherein the heterocycle can be substituted by a linear or branched,cyclic. or non cyclic C₁-C₆ alkyl group, in particular4-cyclohexylpiperazinyl.

In an embodiment within this preferred embodiment of the invention, R¹⁹in —OR¹⁹ is not H. This is in particular the case if the compoundaccording to formula A does not contain at least 1 linker and/or 1physiochemistry modifying group as defined in the context of the presentapplication.

In a more preferred embodiment of the application, Q is independently Hor selected from the groups a), b), and c) consisting of:

a) Halide selected from Cl, Br, I; R¹⁹U, —OR¹⁹U, —SR¹⁹U and —NR¹⁹R²⁰U,wherein R¹⁹ is a single bond; or wherein R¹⁹ and R²⁰ may independentlybe an optical properties modifying group, and are independently selectedfrom the group consisting of: H; linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; and homocyclic6-membered aromatic groups wherein preferably one of R¹⁹ and R²⁰ is notaromatic in case of —NR¹⁹R²⁰U; —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 12; and U is a physiochemistry modifying groupselected from the group consisting of: —(CH₂)_(m)SO₃ ⁻,—(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂;—(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6,and wherein R³², R³³, is an alkyl group having from 1-12, preferably1-8, more preferably 1-4 C atoms, in particular methyl or ethyl; andwherein in case of —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; —(CH₂)_(m)NR³²R³³ theN atom may be bond to a further substituent R³⁴ to form a quaternary Natom, and wherein R³⁴ is in all the above cases independently selectedfrom H, and an alkyl group having from 1-12, preferably 1-8, morepreferably 1-4 C atoms, in particular methyl or ethyl,

b) R²¹L, —OR²¹L, —SR²¹L and —NR²¹R²²L wherein R²¹ and R²² mayindependently be an optical properties modifying group and areindependently selected from the group consisting of: H; linear,non-cyclic, substituted and unsubstituted C₁₋₈ alkyl, wherein the saidalkyl group can be single substituted by a homocyclic 6-memberedaromatic group; homocyclic 6-membered aromatic groups, whereinpreferably one of R²¹ and R²² is not aromatic in case of —NR²¹R²²;—(CH₂—O—CH₂)_(x)CH₂-L wherein x is an integer from 1 to 12; and L is alinker which can form a covalent bond with a targeting agent; and L is alinker which can form a covalent bond with a targeting agent;

c) R¹⁹, —OR¹⁹, —SR¹⁹ and —NR¹⁹R²⁰ wherein R¹⁹ and R²⁰ may independentlybe an optical properties modifying group and are independently selectedfrom the group consisting of: H; linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; and homocyclic6-membered aromatic groups, wherein preferably one of R¹⁹ and R²⁰ is notaromatic in case of —NR²¹R²²; —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 12; or wherein R¹⁹ and R²⁰, together with the N atomto which they are attached, form a 6-membered heterocycle optionallycontaining one further heteroatom selected from O and N, wherein theheterocycle can be substituted by a linear or branched, cyclic or noncyclic C₁-C₆ alkyl group, in particular 4-cyclohexylpiperazinyl.

In an embodiment within this more preferred embodiment of the invention,R¹⁹ in —OR¹⁹ is not H. This is in particular the case if the compoundaccording to formula A does not contain at least 1 linker and/or 1physiochemistry modifying group as defined in the context of the presentapplication.

In a still more preferred embodiment of the application, Q isindependently H or selected from the groups a), b), and c) consistingof:

a) Halide selected from Cl, Br, I; R¹⁹U, —OR¹⁹U, and —NR¹⁹R²⁰U, whereinR¹⁹ is a single bond; or wherein R¹⁹ and R²⁰ may independently be anoptical properties modifying group, and are independently selected fromthe group consisting of: H; linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; and homocyclic6-membered aromatic groups wherein preferably one of R¹⁹ and R²⁰ is notaromatic in case of —NR¹⁹R²⁰U; —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 6; and U is a physiochemistry modifying group selectedfrom the group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl and wherein in case of—(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; —(CH₂)_(m)NR³²R³³ the N atom may be bondto a further substituent R³⁴ to form a quaternary N atom, and whereinR³⁴ is in all the above cases independently selected from H, and analkyl group having from 1-12, preferably 1-8, more preferably 1-4 Catoms, in particular methyl or ethyl,

b) R²¹L, —OR²¹L, and —NR²¹R²²L wherein R²¹ and R²² may independently bean optical properties modifying group and are independently selectedfrom the group consisting of: H; linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic groups, wherein preferably one of R²¹ and R²² is notaromatic in case of —NR²¹R²²; —(CH₂—O—CH₂)_(x)CH₂-L wherein x is aninteger from 1 to 6; and L is a linker which can form a covalent bondwith a targeting agent; and L is a linker which can form a covalent bondwith a targeting agent;

c) R¹⁹, —OR¹⁹, and —NR¹⁹R²⁰ wherein R¹⁹ and R²⁰ may independently be anoptical properties modifying group and are independently selected fromthe group consisting of: H; linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; and homocyclic6-membered aromatic groups, wherein preferably one of R¹⁹ and R²⁰ is notaromatic in case of —NR²¹R²²; —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 6; or wherein R¹⁹ and R²⁰, together with the N atom towhich they are attached, form a 6-membered heterocycle optionallycontaining one further heteroatom selected from O and N, wherein theheterocycle can be substituted by a linear or branched, cyclic or noncyclic C₁-C₆ alkyl group, in particular 4-cyclohexylpiperazinyl.

In an embodiment within this still more preferred embodiment of theinvention, R¹⁹ in —OR¹⁹ is not H. This is in particular the case if thecompound according to formula A does not contain at least 1 linkerand/or 1 physiochemistry modifying group as defined in the context ofthe present application.

In the most general embodiment of the application, R¹ and R² areabsent?, H or independently selected from the group:

a) linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- and7-membered aromatic rings which can be substituted by a linear ofbranched C₁-C₆ alkyl group; and —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 50;

b) R²³L wherein R²³ is selected from the group: linear and branched,non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic or heterocyclic C₅-, C₆- or C₇-aryl group which can besubstituted by a linear or branched C₁-C₆ alkyl group; homocyclic andheterocyclic 5-, 6- and 7-membered aromatic rings which can besubstituted by a linear or branched C₁-C₆ alkyl group;—(CH₂O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; and L is alinker which can form a covalent bond with a targeting agent;

c) R²³U, wherein R²³ is a single bond; or wherein R²³ is selected fromthe group: linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic rings which can be substituted by a linear orbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³ is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl.

In a preferred embodiment of the application, R¹ and R² are absent,independently H or selected from the group:

a) linear, non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic C₆-aromatic group which can be substituted by a linear orbranched C₁-C₄ alkyl group; homocyclic 6-membered aromatic rings whichcan be substituted by a linear or branched C₁-C₄ alkyl group; and—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20;

b) R²³L wherein R²³ is selected from the group: linear, non-cyclic,substituted and unsubstituted C₁₋₁₂ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic C₆-aromatic groupwhich can be substituted by a linear or branched C₁-C₄ alkyl group;homocyclic C₆ aromatic rings which can be substituted by a linear orbranched C₁-C₄ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 20; and L is a linker which can form a covalent bond with atargeting agent;

c) R²³U, wherein R²³ is a single bond; wherein R²³ is selected from thegroup: linear, non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic 6-membered aromatic group which can be substituted by alinear or branched C₁-C₄ alkyl group; homocyclic C₆ aromatic rings whichcan be substituted by a linear or branched C₁-C₄ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; and U is aphysiochemistry modifying group selected from the group consisting of:—(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂—(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integerfrom 0 to 6, and wherein R³², R³³, is an alkyl group having from 1-12,preferably 1-8, more preferably 1-4 C atoms, in particular methyl orethyl;

In a more preferred embodiment of the application, R¹ and R² are absent,H or independently selected from the group:

a) linear, non-cyclic, substituted and unsubstituted C₁₋₈ alkyl, whereinthe said alkyl group can be single substituted by a homocyclic6-membered aromatic group; homocyclic 6-membered aromatic rings; and—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20;

b) R²³L wherein R²³ is selected from the group: linear, non-cyclic,substituted and unsubstituted C₁₋₈ alkyl, wherein the said alkyl groupcan be single substituted by a homocyclic 6-membered aromatic group;homocyclic 6-membered aromatic group; —(CH₂—O—CH₂)_(x)CH₂— wherein x isan integer from 1 to 12; and L is a linker which can form a covalentbond with a targeting agent;

c) R²³U, wherein R²³ is a single bond; or wherein R²³ is selected fromthe group: linear, non-cyclic, substituted and unsubstituted C₁₋₈ alkyl,wherein the said alkyl group can be single substituted by a homocyclic6-membered aromatic group; homocyclic 6-membered aromatic groups;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 12; and U is aphysiochemistry modifying group selected from the group consisting of:—(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂—(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integerfrom 0 to 6, and wherein R³², R³³, is an alkyl group having from 1-12,preferably 1-8, more preferably 1-4 C atoms, in particular methyl orethyl.

In a still more preferred embodiment of the application, R¹ and R² areabsent, H or independently selected from the group:

a) linear, non-cyclic, substituted and unsubstituted C₁₋₈ alkyl, whereinthe said alkyl group can be single substituted by a homocyclic6-membered aromatic group; homocyclic 6-membered aromatic rings; and—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 6;

b) R²³L wherein R²³ is selected from the group: linear, non-cyclic,substituted and unsubstituted C₁₋₈ alkyl, wherein the said alkyl groupcan be single substituted by a homocyclic 6-membered aromatic group;homocyclic 6-membered aromatic group; —(CH₂—O—CH₂)_(x)CH₂— wherein x isan integer from 1 to 8; and L is a linker which can form a covalent bondwith a targeting agent;

c) R²³U, wherein R²³ is a single bond; or wherein R²³ is selected fromthe group: linear, non-cyclic, substituted and unsubstituted C₁₋₈ alkyl,wherein the said alkyl group can be single substituted by a homocyclic6-membered aromatic group; homocyclic 6-membered aromatic groups;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 6; and U is aphysiochemistry modifying group selected from the group consisting of:—(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂—(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integerfrom 0 to 6, and wherein R³², R³³, is an alkyl group having from 1-12,preferably 1-8, more preferably 1-4 C atoms, in particular methyl orethyl.

In the most general embodiment of the application, R¹⁷ and R¹⁸ areindependently H or selected from the group consisting of:

a) linear and branched, non-cyclic or cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- and7-membered aromatic rings which can be substituted by a linear orbranched C₁-C₆ alkyl group, wherein preferably one of R¹⁷ and R¹⁸ is notaromatic; and —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50

b) R²⁴L wherein R²⁴ is selected from the group: linear and branched,non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic or heterocyclic 5-, 6- or 7-membered aromatic group which canbe substituted by a linear or branched C₁-C₆ alkyl group; homocyclic andheterocyclic 5-, 6- or 7-membered aromatic groups which can besubstituted by a linear of branched C₁-C₆ alkyl group, whereinpreferably one of R¹⁷ and R²⁰ is not aromatic; —(CH₂—O—CH₂)_(x)CH₂—wherein x is an integer from 1 to 50; and L is a linker which can form acovalent bond with a targeting agent;

c) R²⁴U, wherein R²⁴ is a single bond; or wherein R²⁴ is selected fromthe group: linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear ofbranched C₁-C₆ alkyl group, wherein preferably one of R¹⁷ and R¹⁸ is notaromatic; —(CH₂O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; andU is a physiochemistry modifying group selected from the groupconsisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O—(CH₂)_(m)NH₂;—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl, wherein m is an integer from0 to 6.

In a preferred embodiment of the application, R¹⁷ and R¹⁸ areindependently H or selected from the group consisting of:

a) linear, non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic 6-membered aromatic group; homocyclic 6-membered aromaticgroups which can be substituted by a linear or branched C₁-C₄ alkylgroup, wherein preferably one of R¹⁷ and R¹⁸ is not aromatic;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; and

b) R²⁴L wherein R²⁴ is selected from the group: linear, non-cyclic,substituted and unsubstituted C₁₋₁₂ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic 6-memberedaromatic group which can be substituted by a linear or branched C₁-C₄alkyl group; homocyclic 6-membered aromatic group which can besubstituted by a linear or branched C₁-C₄ alkyl group, whereinpreferably one of R¹⁷ and R¹⁸ is not aromatic; —(CH₂—O—CH₂)_(x)CH₂—wherein x is an integer from 1 to 20; and L is a linker which can form acovalent bond with a targeting agent;

c) R²⁴U, wherein R²⁴ is a single bond; or wherein R²⁴ is selected fromthe group: linear, non-cyclic, substituted and unsubstituted C₁₋₁₂alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic 6-membered aromatic group which can besubstituted by a linear or branched C₁-C₄ alkyl group; homocyclic6-membered aromatic groups which can be substituted by a linear orbranched C₁-C₄ alkyl group, wherein preferably one of R¹⁷ and R¹⁸ is notaromatic; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; andU is a physiochemistry modifying group selected from the groupconsisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻—(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein mis an integer from 0 to 6, and wherein R³², R³³, is an alkyl grouphaving from 1-12, preferably 1-8, more preferably 1-4 C atoms, inparticular methyl or ethyl;

In a more preferred embodiment of the application, R¹⁷ and R¹⁸ areindependently H or selected from the group consisting of:

a) linear, non-cyclic, substituted and unsubstituted C₁₋₈ alkyl, whereinthe said alkyl group can be single substituted by a homocyclic6-membered aromatic group; homocyclic 6-membered aromatic groups,wherein preferably one of R¹⁷ and R¹⁸ is not aromatic; and—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 12;

b) R²⁴L wherein R²⁴ is selected from the group: linear and branched,non-cyclic and cyclic, substituted and unsubstituted C₁₋₈ alkyl, whereinthe said alkyl group can be single substituted by a homocyclic6-membered aromatic group; homocyclic 6-membered aromatic groups,wherein preferably one of R¹⁷ and R¹⁸ is not aromatic;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 12; and L is alinker which can form a covalent bond with a targeting agent;

c) R²⁴U, wherein R²⁴ is a single bond; or wherein R²⁴ is selected fromthe group: linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic groups; wherein preferably one of R¹⁷ and R¹⁸ is notaromatic; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 12; andU is a physiochemistry modifying group selected from the groupconsisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻—(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein mis an integer from 0 to 6, and wherein R³², R³³, is an alkyl grouphaving from 1-12, preferably 1-8, more preferably 1-4 C atoms, inparticular methyl or ethyl.

In a still more preferred embodiment of the application, R¹⁷ and R¹⁸ areindependently H or selected from the group consisting of:

a) linear, non-cyclic, substituted and unsubstituted C₁₋₈ alkyl, whereinthe said alkyl group can be single substituted by a homocyclic6-membered aromatic group; homocyclic 6-membered aromatic groups,wherein preferably one of R¹⁷ and R¹⁸ is not aromatic; and—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 6;

b) R²⁴L wherein R²⁴ is selected from the group: linear and branched,non-cyclic and cyclic, substituted and unsubstituted C₁₋₈ alkyl, whereinthe said alkyl group can be single substituted by a homocyclic6-membered aromatic group; homocyclic 6-membered aromatic groups,wherein preferably one of R¹⁷ and R¹⁸ is not aromatic;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 6; and L is alinker which can form a covalent bond with a targeting agent;

c) R²⁴U, wherein R²⁴ is a single bond; or wherein R²⁴ is selected fromthe group: linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic groups; wherein preferably one of R¹⁷ and R¹⁸ is notaromatic; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 6; andU is a physiochemistry modifying group selected from the groupconsisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻—(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein mis an integer from 0 to 6, and wherein R³², R³³, is an alkyl grouphaving from 1-12, preferably 1-8, more preferably 1-4 C atoms, inparticular methyl or ethyl.

In the most general embodiment of the application, A⁶, A⁷, A⁸, A⁹, andA¹⁰, A¹¹, A¹², A¹³ are C, N or ⁺N, and either

A)

form a 6-membered aromatic ring which together with the pyrrolin derivedring to which they are attached form an indol or an azaindol system,which indol system can comprise a total of 1 N atoms, and which azaindolsystem can comprise a total of 2 N atoms;

R³, R⁴, R⁵, R⁶, R⁷, R⁸ R⁹ R¹⁰ are independently H or selected from thegroup consisting of:

a) halide selected from Cl, Br, I; R²⁵H and OR²⁵H, wherein R²⁵ isselected from the group: linear and branched, non-cyclic and cyclic,substituted and unsubstituted C₁₋₂₀ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic or heterocyclic5-, 6- or 7-membered aromatic group which can be substituted by a linearor branched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear ofbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50;

b) R²⁵L and OR²⁵L, wherein R²⁵ is selected from the group: linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic 5-, 6- or 7-memberedaromatic group which can be substituted by a linear or branched C₁-C₆alkyl group; homocyclic and heterocyclic 5-, 6- or 7-membered aromaticgroups which can be substituted by a linear of branched C₁-C₆ alkylgroup; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; and Lis a linker which can form a covalent bond with a targeting agent; and

c) R²⁵U and OR²⁵U wherein R²⁵ is a single bond; or wherein R²⁵ isselected from the group: linear and branched, non-cyclic and cyclic,substituted and unsubstituted C₁₋₂₀ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic or heterocyclic5-, 6- or 7-membered aromatic group which can be substituted by a linearor branched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear orbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl, wherein m in an integer from0 to 6; and wherein OR²⁵H, OR²⁵L and OR²⁵U are present only when 0 isattached to a C atom;

or

B)

A⁶, A⁷, A⁸, A⁹, and A¹⁰, A¹¹, A¹², A¹³ are C, N, or ⁺N and form a6-membered aromatic ring which together with the pyrrolin derived ringto which they are attached form an indol or an azaindol system, and towhich indol or azaindol system a further 6-membered ring is annulatedwhich is formed by at least two of the substituents R³, R⁴, R⁵, R⁶, orR⁷, R⁸ R⁹ R¹⁰, resulting in a trinuclear ring in which 1, 2 or 3 C atomsmay be replaced by N or ⁺N and which are substituted by R, R¹², R¹³,R¹⁴, and R¹⁵, R¹⁶, R¹⁷; R¹⁸;

R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, R¹⁶, R¹⁷, R¹⁸ are independently H orselected from the group consisting of:

a) halide selected from Cl, Br, I; R²⁶H and OR²⁶H, wherein R²⁶ isselected from the group: linear and branched, non-cyclic and cyclic,substituted and unsubstituted C₁₋₂₀ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic or heterocyclic5-, 6- or 7-membered aromatic group which can be substituted by a linearor branched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear ofbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50; and

b) R²⁶L and OR²⁶L, wherein R²⁶ is selected from the group: linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic C₅-, C₆- or C₇-aryl groupwhich can be substituted by a linear or branched C₁-C₆ alkyl group;homocyclic and heterocyclic C₅-, C₆- or C₇-aromatic groups which can besubstituted by a linear or branched C₁-C₆ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; and L is alinker which can form a covalent bond with a targeting agent;

c) R²⁶U and OR²⁶U, wherein R²⁶ is a single bond; or wherein R²⁶ isselected from the group: linear and branched, non-cyclic and cyclic,substituted and unsubstituted C₁₋₂₀ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic or heterocyclic5-, 6- or 7-membered aromatic group which can be substituted by a linearor branched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear ofbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl.

In a preferred embodiment of the application, A⁶, A⁷, A⁸, A⁹, and A¹⁰,A¹¹, A¹², A¹³ are C, N, ⁺N and either

A)

form a 6-membered aromatic ring which together with the pyrrolin derivedring to which they are attached form an indol or an azaindol system,which indol system can comprise a total of 1 N atoms and which azaindolsystem can comprise a total of 2 N atoms;

R³, R⁴, R⁵, R⁶, R⁷, R⁸ R⁹ R¹⁰ are independently H or selected from thegroup consisting of:

a) Halide selected from Cl, Br, I; R²⁵H and OR²⁵H, wherein R²⁵ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₁₂ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic 6-membered aromatic group which canbe substituted by a linear or branched C₁-C₄ alkyl group; homocyclic6-membered aromatic groups which can be substituted by a linear orbranched C₁-C₄ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 20;

b) R²⁵L and OR²⁵L wherein R²⁵ is selected from the group: linear,non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl, wherein the saidalkyl group can be single or multiple substituted by a homocyclic6-membered aromatic group which can be substituted by a linear orbranched C₁-C₄ alkyl group; homocyclic 6-membered aromatic groups whichcan be substituted by a linear or branched C₁-C₄ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; and L is alinker which can form a covalent bond with a targeting agent; and

c) R²⁵U and OR²⁵U, wherein R²⁵ is a single bond; or wherein R²⁵ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₁₂ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic 6-membered aromatic group which canbe substituted by a linear or branched C₁-C₄ alkyl group; homocyclic6-membered aromatic groups which can be substituted by a linear orbranched C₁-C₄ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 20; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻,—(CH₂)_(m)C(O)O—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂;—(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6,and wherein R³², R³³, is an alkyl group having from 1-12, preferably1-8, more preferably 1-4 C atoms, in particular methyl or ethyl; andwherein OR²⁵H, OR²⁵L and OR²⁵U are present only when O is attached to aC atom;

or

B)

form a 6-membered aromatic ring which together with the pyrrolin derivedring to which they are attached form an indol or an azaindol system, andto which indol or azaindol system a further 6-membered ring is annulatedwhich is formed by at least two of the substituents R³, R⁴, R⁵, R⁶, orR⁷, R⁸ R⁹ R¹⁰, resulting in a trinuclear ring in which 1 or 2 C atomsmay be replaced by N, and which are substituted by R¹¹, R¹², R¹³, R¹⁴,and R¹⁵, R¹⁶, R¹⁷;

R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, R¹⁶, R¹⁷ are independently H or selectedfrom the group consisting of:

a) Halide selected from Cl, Br, I; R²⁶H and OR²⁶H, wherein R²⁶ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₁₂ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic 6-membered aromatic group which canbe substituted by a linear or branched C₁-C₄ alkyl group; homocyclic6-membered aromatic groups which can be substituted by a linear orbranched C₁-C₄ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 20;

b) R²⁶L and OR²⁶L wherein R²⁶ is selected from the group: linear,non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl, wherein the saidalkyl group can be single or multiple substituted by a homocyclic6-membered aromatic group which can be substituted by a linear orbranched C₁-C₄ alkyl group; homocyclic C₆ aromatic rings which can besubstituted by a linear or branched C₁-C₄ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; and L is alinker which can form a covalent bond with a targeting agent; and

c) R²⁶U and OR²⁶U, wherein R²⁶ is a single bond; or wherein R²⁶ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₁₂ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic 6-membered aromatic group which canbe substituted by a linear or branched C₁-C₄ alkyl group; homocyclic C₆aromatic rings which can be substituted by a linear or branched C₁-C₄alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20;and U is a physiochemistry modifying group selected from the groupconsisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻—(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein mis an integer from 0 to 6, and wherein R³², R³³, is an alkyl grouphaving from 1-12, preferably 1-8, more preferably 1-4 C atoms, inparticular methyl or ethyl; and wherein OR²⁶H, OR²⁶L and OR²⁶U arepresent only when O is attached to a C atom;

In a more preferred embodiment of the application, A₆, A₇, A₈, A₉, andA₁₀, A₁₁, A₁₂, A₁₃ are C, N, or ⁺N, and either

A)

form a 6-membered aromatic ring which together with the pyrrolin derivedring to which they are attached form an indol or an azaindol system,which indol system can comprise a total of 1 N atoms and which azaindolsystem can comprise a total of 2 N atoms;

R³, R⁴, R⁵, R⁶, R⁷, R⁸ R⁹ R¹⁰ are independently H or selected from thegroup consisting of:

a) Halide selected from Cl, Br, I; R²⁵H and OR²⁵H, wherein R²⁵ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic groups; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 12;

b) R²⁵L and —OR²⁵L, wherein R²⁵ is selected from the group: linear,non-cyclic, substituted and unsubstituted C₁₋₈ alkyl, wherein the saidalkyl group can be single substituted by a homocyclic 6-memberedaromatic group; homocyclic 6-membered aromatic groups;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 12; and L is alinker which can form a covalent bond with a targeting agent; and

c) R²⁵U and —OR²⁵U, wherein R²⁵ is a single bond; or wherein R²⁵ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 12; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl; and wherein OR²⁵H, —OR²⁵Land —OR²⁵U are present only when O is attached to a C atom;

or

B)

A₆, A₇, A₈, A₉, and A₁₀, A₁₁, A₁₂, A₁₃ are C, N, or ⁺N and form a6-membered aromatic ring which together with the pyrrolin derived ringto which they are attached form an indol or an azaindol system, and towhich indol or azaindol system a further 6-membered ring is annulatedwhich is formed by at least two of the substituents R³, R⁴, R⁵, R⁶, orR⁷, R⁸ R⁹ R¹⁰, resulting in a trinuclear ring in which 1 or 2 C atomsmay be replaced by N, and which are substituted by R, R¹², R¹³, R¹⁴, andR¹⁵, R¹⁶, R¹⁷;

R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, R¹⁶, R¹⁷ are independently H or selectedfrom the group consisting of:

a) Halide selected from Cl, Br, I; R²⁶H and OR²⁶H, wherein R²⁶ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic groups; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 12;

b) R²⁶L and OR²⁶L, wherein R²⁶ is selected from the group: linear,non-cyclic, substituted and unsubstituted C₁₋₈ alkyl, wherein the saidalkyl group can be single substituted by a homocyclic 6-memberedaromatic group; homocyclic 6-membered aromatic groups;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 12; and L is alinker which can form a covalent bond with a targeting agent; and

c) R²⁶U, and OR²⁶U, wherein R²⁶ is a single bond; or wherein R²⁶ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic groups; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 12; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻, —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl and wherein OR²⁶H, OR²⁵L andOR²⁵U are present only when O is attached to a C atom;

In a still more preferred embodiment of the application, A₆, A₇, A, A₉,and A₁₀, A₁₁, A₁₂, A₁₃ are C, N, or ⁺N, and either:

A)

form a 6-membered aromatic ring which together with the pyrrolin derivedring to which they are attached form an indol or an azaindol system,which indol system can comprise a total of 1 N atoms and which azaindolsystem can comprise a total of 2 N atoms;

R³, R⁴, R⁵, R⁶, R⁷, R⁸ R⁹ R¹⁰ are independently H or selected from thegroup consisting of:

a) Halide selected from Cl, Br, I; R²H and OR²⁵H, wherein R²⁵ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic groups; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 6;

b) R²⁵L and —OR²⁵L, wherein R²⁵ is selected from the group: linear,non-cyclic, substituted and unsubstituted C₁₋₈ alkyl, wherein the saidalkyl group can be single substituted by a homocyclic 6-memberedaromatic group; homocyclic 6-membered aromatic groups;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 6; and L is alinker which can form a covalent bond with a targeting agent; and

c) R²⁵U and —OR²⁵U, wherein R²⁵ is a single bond; or wherein R²⁵ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 6; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl; and wherein OR²⁵H, —OR²⁵Land —OR²⁵U are present only when O is attached to a C atom;

or

B)

A₆, A₇, A₈, A₉, and A₁₀, A₁₁, A₁₂, A₁₃ are C, N, or ⁺N and form a6-membered aromatic ring which together with the pyrrolin derived ringto which they are attached form an indol or an azaindol system, and towhich indol or azaindol system a further 6-membered ring is annulatedwhich is formed by at least two of the substituents R³, R⁴, R⁵, R⁶, orR⁷, R⁸ R⁹ R¹⁰, resulting in a trinuclear ring in which 1 or 2 C atomsmay be replaced by N, and which are substituted by R, R¹², R¹³, R¹⁴, andR¹⁵, R¹⁶, R¹⁷;

R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, R¹⁶, R¹⁷ are independently H or selectedfrom the group consisting of:

a) Halide selected from Cl, Br, I; R²⁶H and OR²⁶H, wherein R²⁶ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic groups; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 6;

b) R²⁶L and OR²⁶L, wherein R²⁶ is selected from the group: linear,non-cyclic, substituted and unsubstituted C₁₋₈ alkyl, wherein the saidalkyl group can be single substituted by a homocyclic 6-memberedaromatic group; homocyclic 6-membered aromatic groups;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 6; and L is alinker which can form a covalent bond with a targeting agent; and

c) R²⁶U, and OR²⁶U, wherein R²⁶ is a single bond; or wherein R²⁶ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic groups; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 6; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, is an alkyl group having from 1-12, preferably 1-8, more preferably1-4 C atoms, in particular methyl or ethyl and wherein OR²⁶H, OR²⁵L andOR²⁵U are present only when O is attached to a C atom;

In the most general embodiment of the present application, X and Y areselected from the group consisting of: CR²⁹R³⁰, where R²⁹ and R³⁰ areeach independently selected from H, unsubstituted and substituted linearor branched, cyclic or non-cyclic C₁-C₆ alkyl.

In a preferred embodiment of the application, X and Y are CR²⁹R³⁰, whereR²⁹ and R³⁰ are each independently selected from H, unsubstituted andsubstituted non-cyclic linear and branched C₁-C₄ alkyl.

In a more preferred embodiment of the application, X and Y are CR²⁹R³⁰,where R²⁹ and R³⁰ are each independently selected from H, unsubstitutedand substituted C₁-C₂ alkyl,

In the most general embodiment of the present application, E and E′ areindependently selected from H, unsubstituted and substituted linear orbranched, cyclic or non-cyclic C₁-C₆ alkyl.

In a preferred embodiment of the application, E and E′ are independentlyselected from H and unsubstituted and substituted linear or branched,cyclic or non-cyclic C₁-C₄ alkyl.

In a more preferred embodiment of the application, E and E′ areindependently selected from H and methyl and ethyl, preferably methyl.

The alkyleneoxy group —(CH₂—O—CH₂)_(x)CH₂— which is cited in the contextwith R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅,R₁₆, R₁₇, R₁₈, R₁₉, R₂₀, R₂₁, R₂₂, R₂₃, R₂₃, R₂₄, R₂₅, R₂₆, has a lengthdefined by x wherein x is an integer from 1 to 50, preferably from 1 to20, more preferably from 1 to 12, still more preferably from 1 to 8,i.e. 1, 2, 3, 4, 5, 6, 7 or 8, or x may be an integer from 1 to 6.

In an embodiment, it is conceivable that in any alkyleneoxy group—(CH₂—O—CH₂)_(x)CH₂— which is cited in the context with R₁, R₂, R₃, R₄,R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, R₁₇, R₁₈, R₁₉,R₂₀, R₂₁, R₂₂, R₂₃, R₂₃, R₂₄, R₂₅, R₂₆, x is an integer from 1 to 2500.

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ R⁹ R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶,R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, have the meanings asdefined for the general, the preferred, the more preferred and the stillmore preferred embodiments for the formula A. In a further embodiment,and the case where the above residues can be H, an alkyl group, anaromatic group, an alkyleneoxy group, any of the above residues can haveany of the following preferred meanings: H; a linear, non-cyclic,substituted and unsubstituted C₁₆ alkyl (methyl, ethyl, propyl, butyl,pentyl or hexyl) wherein the said alkyl group can be single substitutedby a homocyclic 6-membered aromatic group, preferably phenyl; andhomocyclic 6-membered aromatic groups, preferably phenyl, whereinpreferably one of R¹⁹ and R²⁰ is not aromatic in case of —NR²¹R²²;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 8, i.e. 1, 2, 3,4, 5, 6, 7 or 8, or an integer from 1 to 6. For R¹⁹ and R²⁰, and thecase wherein R¹⁹ and R²⁰, together with the N atom to which they areattached form a 5- or 6-membered heterocycle, this heterocycle cancontain one further heteroatom selected from O and N, wherein theheterocycle can be substituted by a linear or branched, cyclic or noncyclic C₁-C₆ alkyl group, in particular 4-cyclohexylpiperazinyl Each ofthe above residues R¹-R²⁶ can have the above meanings in combinationwith any of the general, preferred, more preferred, still more preferredand most preferred meanings of any of the other substituents, i.e. that,for example, R¹⁹ can have the above meaning, and any of the othersubstituents R¹-R¹⁸ and R²⁰-R²⁶ can have the general, preferred, morepreferred, still more preferred and most preferred meanings. Thisincludes the cases that R¹⁹ in —OR¹⁹ is not H, in particular if thecompound according to formula A does not contain at least 1 linkerand/or 1 physiochemistry modifying group as defined in the context ofthe present application.

In the most general embodiment of the present application, linkers L areselected from the group consisting of: —NH₂, —OH, —SH, —C(O)O⁻, —C(O)Cl,—(CO)O(CO)R²⁷, —C(O)NHNH₂, —C(O), —C(O)OR²⁸, wherein R²⁷ is selectedfrom the group consisting of H, alkyl and aryl; wherein R²⁸ is derivedfrom substituted and unsubstituted N-hydroxysuccinimide, substituted andunsubstituted N-hydroxysulfosuccinimide, nitrophenol, fluorophenol eachbound via —O—; azide N₃ ⁻, —NCO, —NCS, —CHO, —COCH₂I, phosphoramidityl,phthalamidyl, maleimide, an alkyne group in particular —C≡CR³¹ whereinR³¹ is H or a C₁-C₈ alkyl group, sulfonate esters, alkyl halides, acylhalides. propargylglycine, a pentanoyl group, in particular pentanoylchloride, pentynoic acid, propargylic acid,6-aminobenzo[d]thiazole-2-carbonitrile,6-hydroxybenzo[d]thiazole-2-carbonitrile, a 1,2-aminothiol group, inparticular L-cysteine or D-cysteine.

In the most general embodiment of the present application, L has thefollowing meaning:

L is selected from the group consisting of: —NH₂, —OH, —SH, —C(O)O⁻,—C(O)Cl, —(CO)O(CO)R²⁷, —C(O)NHNH₂, —C(O) —C(O)OR²⁸, wherein R²⁷ isselected from the group consisting of H, alkyl and aryl; wherein R²⁸ isderived from substituted and unsubstituted N-hydroxysuccinimide,substituted and unsubstituted N-hydroxysulfosuccinimide, nitrophenol,fluorophenol each bound via —O—; azide N₃ ⁻, —NCO, —NCS, —CHO, —COCH₂I,phosphoramidityl, phthalamidyl, maleimide, an alkyne group in particular—C≡CR³¹ wherein R³¹ is H or a C₁-C₈ alkyl group, preferably H or a C₁-C₄alkyl group, sulfonate esters, alkyl halides, acyl halides.propargylglycine, a pentanoyl group, in particular pentanoyl chloride,pentynoic acid, propargylic acid,6-aminobenzo[d]thiazole-2-carbonitrile,6-hydroxybenzo[d]thiazole-2-carbonitrile, a 1,2-aminothiol group, inparticular L-cysteine or D-cysteine, and the substituents Q, Z, E′, E,X, Y, R¹-R²⁶ and R²⁹-R³³ and A⁶-A¹³ have the general, the preferred, themore preferred, the still more preferred or the most preferredembodiments as defined above. This includes the cases that R¹⁹ in —OR¹⁹is not H, in particular if the compound according to formula A does notcontain at least 1 linker and/or 1 physiochemistry modifying group asdefined in the context of the present application.

In a preferred embodiment of the present application, L has thefollowing meaning:

L is selected from the group consisting of: —NH₂, —OH, —SH, —C(O)O⁻,—C(O)Cl, —C(O)OR²⁸, wherein R²⁸ is derived from substituted andunsubstituted N-hydroxysuccinimide, substituted and unsubstitutedN-hydroxysulfosuccinimide, nitrophenol, fluorophenol each bound via —O—;azide N₃ ⁻, —NCO, —NCS, —CHO, phosphoramidityl, phthalamidyl, maleimide,an alkyne group in particular —C≡CR³¹ wherein R³¹ is H or a C₁-C₈ alkylgroup, preferably H or a C₁-C₄ alkyl group, sulfonate esters, alkylhalides, acyl halides, pentynoic acid, propargylic acid,6-aminobenzo[d]thiazole-2-carbonitrile,6-hydroxybenzo[d]thiazole-2-carbonitrile, a 1,2-aminothiol group, inparticular L-cysteine or D-cysteine, and the substituents Q, Z, E′, E,X, Y, R¹-R²⁶ and R²⁹-R³³ and A⁶-A¹³ have the general, the preferred, themore preferred, the still more preferred or the most preferredembodiments as defined above. This includes the cases that R¹⁹ in —OR¹⁹is not H, in particular if the compound according to formula A does notcontain at least 1 linker and/or 1 physiochemistry modifying group asdefined in the context of the present application.

In a more preferred embodiment of the present application, L has thefollowing meaning:

L is selected from the group consisting of: —OH, —SH, —C(O)O⁻,—C(O)OR²⁸, wherein R²⁸ is derived from substituted and unsubstitutedN-hydroxysuccinimide, substituted and unsubstitutedN-hydroxysulfosuccinimide, nitrophenol, fluorophenol each bound via —O—;azide N₃ ⁻, —NCS, —CHO, phosphoramidityl, phthalamidyl, maleimide, analkyne group in particular —C≡CR³¹ wherein R³¹ is H or a C₁-C₈ alkylgroup, preferably H or a C₁-C₄ alkyl group, sulfonate esters, alkylhalides, acyl halides, 6-aminobenzo[d]thiazole-2-carbonitrile,6-hydroxybenzo[d]thiazole-2-carbonitrile, a 1,2-aminothiol group,L-cysteine, and the substituents Q, Z, E′, E, X, Y, R¹-R²⁶ and R²⁹-R³³and A⁶-A¹³ have the general, the preferred, the more preferred, thestill more preferred or the most preferred embodiments as defined above.This includes the cases that R¹⁹ in —OR¹⁹ is not H, in particular if thecompound according to formula A does not contain at least 1 linkerand/or 1 physiochemistry modifying group as defined in the context ofthe present application.

With respect to the dyes of the application according to formula A, anyof substituents Q, Z, E′, E, X, Y, R¹-R³³, A⁶-A¹³ and L can have thegeneral, the preferred, the more preferred or the still more preferredmeaning, whereas any other of the substituents Q, Z, E′, E, X, Y,R¹-R³³, A⁶-A¹³ and L as defined above can have any of the meanings asdefined for the general, the preferred, the more preferred or the stillmore preferred embodiments. This includes the cases that R¹⁹ in —OR¹⁹ isnot H, in particular if the compound according to formula A does notcontain at least 1 linker and/or 1 physiochemistry modifying group asdefined in the context of the present application. As an example, Q canhave the still more preferred meaning, and any of the substituents Q, Z,E′, E, X, Y, R¹-R³³, A⁶-A¹³ and L can have the general, the preferred,the more preferred, the still more preferred or the most preferredmeaning. As another example, L can have the more preferred meaning, andany of the substituents Q, Z, E′, E, X, Y, R¹-R³³, A⁶-A¹³ and L can havethe general, the preferred, the more preferred, the still more preferredor the most preferred meaning.

In a more preferred embodiment of the application, A⁶, A⁷, A⁸, A⁹, andA¹⁰, A¹¹, A¹², A¹³ are such that they form together with the pyrrolinderived ring to which they are attached an aromatic system selected from

In the most general embodiment, X and Y are selected from the groupconsisting of: CR²⁹R³⁰, where R²⁹ and R³⁰ are each independentlyselected from H, unsubstituted and substituted linear or branched,cyclic or non-cyclic C₁-C₆ alkyl, and the substituents Q, Z, E′, E, X,Y, R¹-R³³ and A⁶-A¹³ and L have the general, the preferred, the morepreferred or the still more preferred meanings as defined above. Thisincludes the cases that R¹⁹ in —OR¹⁹ is not H, in particular if thecompound according to formula A does not contain at least 1 linkerand/or 1 physiochemistry modifying group as defined in the context ofthe present application.

In a preferred embodiment, X and Y are selected from the groupconsisting of: CR²⁹R³⁰, where R²⁹ and R³⁰ are each independentlyselected from H, unsubstituted and substituted non-cyclic linear andbranched C₁-C₄ alkyl, and the substituents Q, Z, E′, E, X, Y, R¹-R³³ andA⁶-A¹³ and L have the general, the preferred, the more preferred or thestill more preferred meanings as defined above. This includes the casesthat R¹⁹ in —OR¹⁹ is not H, in particular if the compound according toformula A does not contain at least 1 linker and/or 1 physiochemistrymodifying group as defined in the context of the present application.

In a more preferred embodiment, X and Y are CR²⁹R³⁰, where R²⁹ and R³⁰are each independently selected from H, unsubstituted and substitutednon-cyclic linear and branched C₁-C₄ alkyl, and the substituents Q, Z,E′, E, X, Y, R¹-R³³ and A⁶-A¹³ and L have the general, the preferred,the more preferred or the still more preferred meanings as definedabove. This includes the cases that R¹⁹ in —OR¹⁹ is not H, in particularif the compound according to formula A does not contain at least 1linker and/or 1 physiochemistry modifying group as defined in thecontext of the present application.

In a still more preferred embodiment, X and Y are CR²⁹R³⁰, where R²⁹ andR³⁰ are each independently selected from H and methyl and ethyl,preferably methyl, and the substituents Q, Z, E′, E, X, Y, R¹-R³³ andA⁶-A¹³ and L have the general, the preferred, the more preferred or thestill more preferred meanings as defined above. This includes the casesthat R¹⁹ in —OR¹⁹ is not H, in particular if the compound according toformula A does not contain at least 1 linker and/or 1 physiochemistrymodifying group as defined in the context of the present application.

In the most preferred embodiment, X and Y are CR²⁹R³⁰, where R²⁹ and R³⁰are each methyl, and the substituents Q, Z, E′, E, X, Y, R¹-R³³ andA⁶-A¹³ and L have the general, the preferred the more preferred or thestill more preferred meanings as defined above. This includes the casesthat R¹⁹ in —OR¹⁹ is not H, in particular if the compound according toformula A does not contain at least 1 linker and/or 1 physiochemistrymodifying group as defined in the context of the present application.

In the most general embodiment, E and E′ are independently selected fromH, unsubstituted and substituted linear or branched, cyclic ornon-cyclic C₁-C₆ alkyl, and the substituents Q, Z, E′, E, X, Y, R¹-R³³and A⁶-A¹³ and L have the general, the preferred the more preferred orthe still more preferred meanings as defined above. This includes thecases that R¹⁹ in —OR¹⁹ is not H, in particular if the compoundaccording to formula A does not contain at least 1 linker and/or 1physiochemistry modifying group as defined in the context of the presentapplication.

In a preferred embodiment, E and E′ are independently selected from Hand linear and branched C₁-C₆ alkyl and the substituents Q, Z, E′, E, X,Y, R¹-R³³ and A⁶-A¹³ and L have the general, the preferred, the morepreferred or the still more preferred meanings as defined above. Thisincludes the cases that R¹⁹ in —OR¹⁹ is not H, in particular if thecompound according to formula A does not contain at least 1 linkerand/or 1 physiochemistry modifying group as defined in the context ofthe present application.

In a more preferred embodiment, E and E′ are independently selected fromH and methyl and ethyl. In the most preferred embodiment, E and E′ areboth methyl, and the substituents Q, Z, E′, E, X, Y, R¹-R³³ and A⁶-A¹³and L have the general, the preferred, the more preferred or the stillmore preferred meanings as defined above. This includes the cases thatR¹⁹ in —OR¹⁹ is not H, in particular if the compound according toformula A does not contain at least 1 linker and/or 1 physiochemistrymodifying group as defined in the context of the present application.

Preferable points of attachment for the linkers are the nitrogen on (i)the heterocycles of the dyes according to formula A, through for exampleR¹⁷ and/or R¹⁸, R¹ and/or R²; (ii) through any of the A6-A19 atoms whenat least one of them is N; Preferably, the dyes and the targeting agentsare linked through the N of the heterocycles, most preferably throughR¹⁷ and/or R¹⁸, R¹ and/or R² or R³ and/or R⁷ if A₆ and/or A₁₀ arenitrogen.

In a preferred embodiment, the dyes of the application have 1, 2, 3 or 4linkers, preferably 1, 2 or 3 linkers, more preferably 1 or 2 linkers,in particular 2 linkers. In general, the linkers are attached to thebasic structure of the dye via a spacer group, which is thus preferred.It is also preferred to attach the linkers in the following positions:position R¹, R², or R¹ and R²; in position R¹⁷, R¹⁸, or R¹⁷ and R¹⁸; or,if the ring annulated to the pyrrol structure contains a N atom, to thisN atom, e.g., in positions R³, R⁴, R⁷ and/or R⁶, preferably R³ and/orR⁷.

The above-cited general, preferred, preferred, more preferred and stillmore preferred preferred embodiments for the respective substituentsalso apply with respect to the below formulae B and C showing abioconjugate imaging agent, respectively the precursor of a bioconjugateimaging agent, of the application.

The optical properties modulating group will in general be incorporatedin the substituent Q.

The physiochemical properties modulating group can be attached to anyposition in the dye basic structure, in principle. However, thepositions laid out above will often be occupied by linkers or theoptical properties modulating group. As a consequence, thephysiochemical properties modulating group will often be attached inposition R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆,R₁₇, R₁₈ and/or R₁₇. The number of physiochemical properties modulatorsis preferably 1, 2 or 3, more preferably 1 or 2. A physiochemicalproperties modulator can be attached with or without a spacer group,often without a spacer group.

Formula B and formula C each depict one embodiment of the variantdenoted B in the definition of formula A. In formula B, Q, Z, E, E′, X,Y, and A⁶-A¹⁵ have the meanings as set forth for formula A, includingthe general, the preferred, the more preferred and the still morepreferred preferred embodiments, including the cases that R¹⁹ in —OR¹⁹is not H, in particular if the compound according to formula A does notcontain at least 1 linker and/or 1 physiochemistry modifying group asdefined in the context of the present application; R¹-R¹⁴ and R¹-R¹⁶,respectively, have the meanings as set forth for formula B, includingthe general, the preferred, the more preferred and the still morepreferred embodiments, including the cases that R¹⁹ in —OR¹⁹ is not H,in particular if the compound according to formula A does not contain atleast 1 linker and/or 1 physiochemistry modifying group as defined inthe context of the present application, except that a further 6-memberedring which is formed by at least two of the substituents R³, R⁴, R⁵, R⁶,or R⁷, R⁸ R⁹ R¹⁰, resulting in a trinuclear ring which cannot beannulated. In formula C, Q, Z, E, E′, X, Y, and A¹-A¹⁹ have the meaningsas set forth for formula A, including the general, the preferred, themore preferred and the still more preferred embodiments, including thecases that R¹⁹ in —OR¹⁹ is not H, in particular if the compoundaccording to formula A does not contain at least 1 linker and/or 1physiochemistry modifying group as defined in the context of the presentapplication; R¹-R¹⁷ have the meanings as set forth for formula A,including the general, the preferred, the more preferred and the stillmore preferred embodiments, including the cases that R¹⁹ in —OR¹⁹ is notH, in particular if the compound according to formula A does not containat least 1 linker and/or 1 physiochemistry modifying group as defined inthe context of the present application, except that a further 6-memberedring which is formed by at least two of the substituents R³, R⁴, R⁵, R⁶,or R⁷, R⁸ R⁹ R¹⁰, resulting in a trinuclear ring which cannot beannulated.

In a further aspect of the present application, the dyes according tothe application are asymmetrical in the sense that they do not have a C2symmetry. One example for a group of such asymmetric molecules is B.Asymmetry can also be caused by one or more substituents (linkers,optical properties modulating groups and physiochemistry propertiesmodulating groups) which are present only on one side of the molecule(i.e. on one side of the axe/defined by Q and Z).

In another aspect, the application provides a bioconjugate imaging agentcomprising a fluorescent dye of the application linked to at least onetargeting agent, see for example formula D below. The targeting agentis, in general, attached to the dye via a linking group, i.e. a groupthat is formed in a reaction with a complementary reactive group on thetargeting agent. In an embodiment of the application, the targetingagent may comprise an “anchor group” (having been attached to it priorto the reaction with the dye), which anchor group comprises functionalgroups capable of reacting with the linker functional group, or of moreeasily reacting with the linker functional group than the functionalgroups present on the targeting agent. Non-limiting examples of anchorgroups comprise amino acids and bifunctional polyethylene glycols. Inthe bioconjugate imaging agents of the invention, the case that R¹⁹ in—OR¹⁹ is not H does not apply. Precise examples will be cited later on.

A skilled artisan would understand that the net charge of a compoundshould be zero. So when a compound is depicted to have one or morenegative or positive ions, counter-ions, even if not shown, exist tomake the net charge of the compound zero.

In another aspect, the subject matter of the present applicationprovides a use of the fluorescent dyes of the application as pH sensors.

In another aspect, the fluorescent dyes can be used as a contrastreagents for optical acoustic/optoacoustic and for “shortwave infraredII (SWIR-II)” range (wavelengths from 0.9 to 1.7 microns) that has onlyrecently been made practical by the development of Indium GalliumArsenide (InGaAs) detectors.

In another aspect, the application provides a compound that can be usedas both fluorescent probe (novel aza-cyanine dye) linked to targetedmoiety such as fatty acid and a probe that can be detected with anotherimaging modality such as 19F-MRI. This can be accomplished by obtaininga compound as disclosed herein which comprises both a fatty acid moietyand a fluorine moiety.

In another aspect, the application provides an in vitro imaging method,the method comprising

(a) contacting a sample with the bioconjugate imaging agent of thepresent subject matter;

(b) allowing the agent to bind to a biological target;

(c) optionally removing unbound agent; and

(d) detecting signal emitted from the agent thereby to determine whetherthe agent has been activated by or bound to the biological target.

In another aspect, the application provides the bioconjugate imagingagent of the application for use in a method of in vivo imaging, themethod comprising:

(a) administering to a subject the bioconjugate imaging agent of theapplication;

(b) allowing the agent to distribute within the subject; and

(c) detecting a signal emitted by the bioconjugate imaging agent.

In another aspect, the application provides the bioconjugate imagingagent of the application for use in a method of in vivo optical imaging,the method comprising:

(a) administering to a subject a bioconjugate imaging agent of theapplication;

(b) allowing the agent to distribute within the subject;

(c) exposing the subject to light of a wavelength absorbable by thefluorescent dye; and

(d) detecting a signal emitted by the agent.

As used herein, the term “effective amount” refers to the amount of acompound sufficient to effect beneficial or desired results. Unlessstated otherwise, an effective amount can be administered in one or moreadministrations, applications or dosages and is not intended to belimited to a particular formulation or administration route. As usedherein, the term “treating” includes any effect, e.g., lessening,reducing, modulating, ameliorating or eliminating, that results in theimprovement of the condition, disease, disorder, and the like, orameliorating a symptom thereof.

“Animal” as used herein typically refers to a non-human mammal,including, without limitation, farm animals such as cattle, sheep, pigs,goats and horses; domestic mammals such as dogs and cats; laboratoryanimals including rodents such as mice, rats and guinea pigs; birds,including domestic, wild and game birds such as chickens, turkeys andother gallinaceous birds, ducks, geese, and the like. The term does notdenote a particular age. Thus, both adult and new born individuals areintended to be covered. The term ‘preclinical’ usually is used todescribe tests carried out on such laboratory animals predominantly onrodents.

As used herein, the terms “patient” and “subject” refer to organisms tobe subjected to, or treated by, the methods of the subject matter of thepresent application. Such organisms preferably include, but are notlimited to, mammals (e.g., murines, simians, equines, bovines, porcines,canines, felines, and the like), and most preferably includes humans.The term ‘clinical’ is usually tests carried out on larger vertebratemammals and predominantly on humans.

“Alkyne” refers to straight chain or branched hydrocarbon groups havingfrom 2 to 10 carbon atoms, e.g., from 2 to 4 carbon atoms; and having atleast 1, e.g., from 1 to 2, sites of double or triple bond unsaturation.This term includes, by way of example, bi-vinyl, allyl, andbut-3-en-1-yl. Included within this term are the cis and trans isomersor mixtures of these isomers.

“Haloalkyl” or “alkyl halide” refers to a substituted alkyl group,wherein one or more hydrogen atoms on the alkyl group have beensubstituted with a halo group. Examples of such groups include, withoutlimitation, fluoroalkyl groups, such as trifluoromethyl, difluoromethyl,trifluoroethyl and the like.

“Acyl” refers to the groups H C(O)—, alkyl-C(O)—, substitutedalkyl-C(O),

“Carboxyl,” “carboxy” or “carboxylate” refers to CO₂H or salts thereofderived from CO₂ ⁻

“Heteroaryl” refers to an aromatic group of from 2 to 15 carbon atoms,such as from 3 to 10 carbon atoms and 1 to 10 heteroatoms selected fromthe group consisting of oxygen, nitrogen (referred to as aza in theapplication) and sulfur within the ring. Such heteroaryl groups can havea single ring (such as, pyrrole, pyridyl, imidazolyl or furyl) ormultiple condensed rings in a ring system (for example as in groups suchas, indolizinyl, quinolinyl, benzofuran, benzimidazolyl orbenzothienyl), wherein at least one ring within the ring system isaromatic and at least one ring within the ring system is aromatic,provided that the point of attachment is through an atom of an aromaticring.

“Heterocycle,” “heterocyclic,” “heterocycloalkyl,” and “heterocyclyl”refer to a saturated or unsaturated group having a single ring ormultiple condensed rings, including fused bridged and spiro ringsystems, and having from 3 to 20 ring atoms, including 1 to 10 heteroatoms. These ring atoms are selected from the group consisting ofnitrogen (referred to as aza in application), sulfur, or oxygen,

The term “amino acid” as used herein is understood to mean an organiccompound containing both a basic amino group and an acidic carboxylgroup. Included within this term are natural amino acids (e.g., L-aminoacids), modified and unusual amino acids (e.g., D-amino acids), as wellas amino acids which are known to occur biologically in free or combinedform but usually do not occur in proteins. Natural amino acids include,but are not limited to, alanine, arginine, asparagine, aspartic acid,cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine,leucine, lysine, methionine, phenylalanine, serine, threonine, tyrosine,tyrosine, tryptophan, proline, and valine. Other amino acids include,but not limited to, arginosuccinic acid, citrulline, cysteine sulfinicacid, 3,4-dihydroxyphenylalanine, homocysteine, homoserine, ornithine,carnitine, selenocysteine, selenomethionine, 3-monoiodotyrosine,3,5-diiodotryosine, 3,5,5′-triiodothyronine, and 3,3′,5,5′-tetraiodothyronine. Modified or unusual amino acids which can beused to practice the subject matter of the application include, but arenot limited to, those derived from post translational modifications likephosphorylation and glycation, such as phosphoserine, phosphothreonine,phosphotyrosine, and others such as hydroxyproline,gamma-carboxyglutamate; hippuric acid, indole acetic acid, statine,penicillamine, ornithine, citruline and selenocysteine, D-amino acids,hydroxylysine, dehydroalanine, pyrrolysine, 2-aminoisobutyric acid,gamma aminobutyric acid, 5-hydroxytryptophan, S-adenosyl methionine,S-adenosyl homocysteine, 4-hydroxyproline, an N-Cbz-protected aminoacid, 2,4-diaminobutyric acid, homoarginine, norleucine,N-methylaminobutyric acid, naphthylalanine, phenylglycine,β-phenylproline, tert-leucine, 4-aminocyclohexylalanine,N-methyl-norleucine, 3,4-dehydroproline, N,N-dimethylaminoglycine,N-methylaminoglycine, 4-aminopiperidine-4-carboxylic acid,6-aminocaproic acid, trans-4-(aminomethyl)-cyclohexanecarboxylic acid,2-, 3-, and 4-(aminomethyl)-benzoic acid, 1-aminocyclopentanecarboxylicacid, 1-aminocyclopropanecarboxylic acid, and 2-benzyl-5-aminopentanoicacid. Protected amino acids are also covered and representativeprotecting groups such as carbobenzyloxy, (CbZ) at the amino terminusand others can be found and are known to those skilled in the art (Seefor example, Greene, T. W.; Wuts, P. G. M., Protecting Groups In OrganicSynthesis, 3rd edition, John Wiley & Sons, Inc., New York (1999)

The term “peptide” describes a sequence of 2 to 50 amino acids,preferably 3 to 20 amino acids or peptidyl residues. The sequence may belinear, branched, cyclic such as resulting from intramolecular disulfidebonds from cysteinyl residues. Peptide sequences specifically recitedherein are written or drawn out with the amino terminus on the left andthe carboxy terminus on the right. D and L amino acids are both coveredas well as protective groups like acetyl, acetoxymethyl, carbobenzyloxy,tert butyloxy and post translational modifications like methylation ofarginine and lysine, phosphorylation and glycation of serine, threonineand tyrosine “OH” groups are also covered.

As used herein, a “pseudopeptide” or “peptidomimetic” is a compoundwhich mimics the structure of an amino acid residue or a peptide, forexample, by using linkers other than via amide linkages (pseudopeptidebonds) and/or by using non-amino acid substituents and/or a modifiedamino acid residue. A “pseudopeptide residue” means that portion of apseudopeptide or peptidomimetic that is present in a peptide. The term“pseudopeptide bonds” includes peptide bond isosteres which may be usedin place of or as substitutes for the normal amide linkage. Thesesubstitute or amide “equivalent” linkages are formed from combinationsof atoms not normally found in peptides or proteins which mimic thespatial requirements of the amide bond and which should stabilize themolecule to enzymatic degradation. The following conventionalthree-letter amino acid abbreviations are used herein: Ala=alanine;Aca=aminocaproic acid, Ahx=6-aminohexanoic acid, Arg=arginine;Asn=asparagines; Asp=aspartic acid; Cha=cyclohexylalanine;Cit=citrulline; Cys=cysteine; Dap=diaminopropionic acid; Gln=glutamine;Glu=glutamic acid; Gly=glycine; H is =histidine; Ile=isoleucine;Leu=leucine; Lys=lysine; Met=methionine; NaI=naphthylalanine;Nle=norleucine; Orn=ornithine; Phe=phenylalanine; Phg=phenylglycine;Pro=praline; Sar=sarcosine; Ser=serine; Thi=Thienylalanine;Thr=threonine; Trp=tryptophan; Tyr=tyrosine; and Val=valine. Use of theprefix D- indicates the D-isomer of that amino acid; for exampleD-lysine is represented as D-Lys.

The term “saccharide” refers to a sugar or other carbohydrate that couldbe derived or can be the result from the reduction and/or oxidation of asimple sugar. The saccharide can be a C6-polyhydroxy compound, with 2-6hydroxy groups per unit, which could by cyclic or acyclic. Saccharidesinclude inositols and their phosphorylated derivatives, Saccharidesinclude simple sugars, i.e. C6 units (monomeric sugars) and theirderivatives, as well as polysaccharides with two or more monosaccharideresidues. The saccharide can include protecting groups on the hydroxylgroups, as described above in the definition of amino acids. Thehydroxyl groups of the saccharide can be replaced with one or more haloor amino groups. Additionally, one or more of the carbon atoms can beoxidized, e.g., to keto or carboxyl groups. The term glycation andglycosylation refer to the addition of saccharide molecules toappropriate residues such as hydroxyl and amino groups in peptides andproteins.

As is known to those of skill in the art, “salts” of the compounds ofthe present application may be derived from inorganic or organic acidsand bases. Examples of acids include, but are not limited to,hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric,maleic, phosphoric, glycolic, lactic, salicylic, succinic,toluene-p-sulfonic, tartaric, acetic, citric, formic, benzoic, malonic,naphthalene-2-sulfonic, benzenesulfonic acid, and the like. Examples ofbases include, but are not limited to, alkali metals (e.g., sodium)hydroxides, alkaline earth metals (e.g., magnesium), hydroxides,ammonia, and compounds of formula NW₄ ⁺, wherein W is C₁₋₄ alkyl, andthe like.

Throughout the description, where compositions and kits are described ashaving, including, or comprising specific components, or where processesand methods are described as having, including, or comprising specificsteps, it is contemplated that, additionally, there are compositions andkits of the present application that consist essentially of, or consistof, the recited components, and that there are processes and methodsaccording to the present application that consist essentially of, orconsist of, the recited processing steps.

Certain compounds described herein may exist in particular geometric orstereoisomeric forms. The present application contemplates all suchcompounds, including cis- and trans-isomers, R- and S-enantiomers,diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof,and other mixtures thereof, as falling within the scope of theapplication. Additional asymmetric carbon atoms may be present in asubstituent such as an alkyl group. All such isomers, as well asmixtures thereof, are intended to be included in this application.

The cyanine dyes derived from polymethine linked heterocycles such asIndocyanine Green (ICG) imaging agents are suitable chemicals which areused to provide the contrast or signal in fluorescence and that isdetectable by optical imaging techniques. The use of NIR fluorescentcyanine dyes for in vivo imaging started with the dye indocyanine green(ICG) because of its ready availability with good purity plus it haddesirable NIR optical properties. Importantly, this is the only knownNIR fluorescent dye approved by the US Food and Drug Administration(FDA) for monitoring cardiac output, hepatic function, and retinalangiography in humans. For optical imaging, various studies have shownthat ICG accumulates in tumors through enhanced permeability andretention effects and it has also successfully been used to image tumorsand lymph nodes. Many ICG derivatives or analogues have been designedand synthesized for different purposes, such as improving aqueoussolubility or adding reactive functions for further bio-conjugation. Forexample, a hydrophilic glucamide-derivatized indocyanine exhibitedincreased hydrophilicity and showed improved tumor-to-normal tissuecontrast relative to ICG. A new class of fluorophores that incorporatemultiple nitrogens exemplified by PPCy dyes has been synthesized via thereaction of diketopyrrolpyrrole with heteroarylacetonitriles. Althoughclassified as cyanine dyes they are structurally different from thecyanine dyes. However they exhibit features for optical imaging, such ashigh quantum yields (>0.50), low photobleaching, and long fluorescencelifetimes (2.5 to 3.8 ns).

The application provides cyanine compounds that incorporate additionalnitrogen atoms, also referred to as aza, in the heterocycles bridgingthe polymethine as well as the polymethine linkage for appendingadditional charges and linkers as modifications that are used tomodulate photochemical, biological, solubility as well as amenable toother modes of interrogation such as optoaccoustic methods. Theincorporation of aza moiety (nitrogen) in the additional benzene ringsbesides the indole nitrogen also enables under appropriate substitutionpH sensitive compounds. A ratiometric measurement of the spectroscopicbehavior of dyes that are differentially sensitive to acidic or basicenvironments can be exploited to indicate pH values. Advantages ofratiometric methods are accrued because several parameters such as pathlength, local probe concentration, photobleaching and leakage from thecells are not important. For these reasons, stable cyanine dyes areneeded for use in labeling biomolecules as well as in vivo imaging forthe diagnosis and prognosis of diseases such as cancer, infectiousdisease imaging and metabolic activity. Such compositions and methodswould aid in the analysis of responses to various therapies. The presentsubject matter satisfies these and other needs.

The application provides novel class of fluorescent dyes belonging tothe cyanine family (aza cyanine dyes), their derivatives forbioconjugation and imaging agents derived there from. The fluorescentdyes serve as labels and comprise aza substitution in the heterocyclesas well as the bridging polymethine linkage.

Synthesis

The fluorescent dyes of the application generally comprise two to eightnitrogen atoms in the heterocycles as well as the polymethine linkageconnecting the heterocycles. The nitrogen substitution instead of the CHmoiety provides a heteroatom that improves aqueous solubility, enableseasier appending of groups through alkylation of the said nitrogen,reduces the 7 stacking that lowers the quantum yield in thecorresponding CH analogues. The nitrogen henceforth referred to as azaprovide charge based derivatives that can be tuned to the biologicalspecificity. Prior art with azabenzolium cyanines developed as nucleicacid intercalating agents has also shown a concomitant shift inwavelength to the red compared to their CH analogues (Scheme 1).

Optical techniques that need designer molecular probes for detecting andtracking molecular processes or biomarkers of interest are facilitatedby the availability of the aza moiety for appending different chemicalmodifiers. The development of new molecular probes has attracted theattention of researchers for many decades because of their diverseapplications in chemistry, biology, and medicine. In recent years,optical imaging of molecular processes in living organisms hasstimulated interest in the development of numerous molecular probes foruse in the near-infrared (NIR) region (700-900 nm) and there are about6100 and more in the MICAD database.

NIR molecular probes offer two major advantages over those that emit atvisible wavelengths. First, biological tissues have lower absorption ofNIR light than visible light. This allows NIR light to penetrate deeperinto tissue than light at visible wavelengths, thus enabling theassessment of information from deeper structures. Second, lessautofluorescence is present at the NIR compared to visible wavelengths,enabling higher signal-to-background ratios. Molecular probes that emitlight in the NIR region are expected to be suitable for in vivo imagingand with the substitution of the CH moiety with N provides structurallysimilar dyes with different photophysical, photochemical andbiocompatibility that are superior to the carbon analogues. Prior artderivatives are usually derived from benzindolelinium andnaphthindolelinium derivatives with the bridging methine linkagesusually all carbon (Scheme 1), the current application is frompyridoindolelinium and quinolinoindolinium derivatives that containwithin the bridge a hetero atom preferably nitrogen (Scheme 2).

In general, the compounds as described herein can be synthesized asfollows. First, a quaternized heterocycle (per examplepyridoindolelinium and quinolinoindolinium) is prepared by attaching asolubilizing groups or linkers. The quaternized heterocylic species isthen coupled with a bisimine (bridge), which is an electrophilicreagent, obtained from Vilsmeier-Haack-Arnold formylation of apiperidone derivative. A substituent is then attached to the nitrogenatom in the central heterocycle (bridge), the resulting centralheterocycle formed is then quaternized. The bisimine is reacted with adifferent quaternary heterocycle with the final result of a symmetric orasymmetric compound.

Bisimines are displayed in the formula below and can also be describedas PhNH-PMB-CH═NHPh.HCl.

In some embodiments, a salt of the fluorescent dyes of the applicationcan be formed by any suitable counter ion. In some preferredembodiments, the counter ion selected from the group comprising but arenot limited to chloride, bromide, iodide, triflate, tosylate, formate,acetate, trifluoro acetate, benzoate, oxalate, cyanide, cyanate,thiocyanate, hydrogen carbonate, carbonate, arsenate, arsenite,phosphate, hydrogen phosphate, dihydrogen phosphate, nitrite, nitrate,sulfate, hydrogen sulfate, thiosulfate, sulphite, perchlorate, chlorate,bromate, iodate, chlorite, hypochlorite, hypobromite, chromate,dichromate, permanganate, hexafluorophophate, tetraphenylborate,tetrafluoroborate.

In some preferred embodiments, the fluorescent dyes of the applicationabsorb in the region of 530 nm to 880 nm and have fluorescence emissionin the region of 540-900 nm when excited in between 530-880 nm.

In further embodiments, Q is Cl.

When the indolelinium heterocycle, with a 6,5 fused system, is not fusedto additional rings and with one double bond, the resulting“indocarbocyanine” dye typically exhibits an absorption maximum near 550nm. Where two double bonds are present, the “indodicarbocyanines”typically absorb maximally near 650 nm. The “indotricarbocyanine” dyes,where three double bonds are present, typically absorbs maximally near750 nm. The addition of an extra ring as in 6,6,5 or benzindoleniumheterocycle adds about 15-20 nm to the absorption of the base indoleniumdescribed previously. Azindocyanine green derivatives the preferred dyeof the application have three double bonds and two benzindoleniumheterocycles bridging the polymethine chain, typically absorption rangesfrom 750-850 nm depending on additional substituents referred to aschemical modifiers (CM), solvent polarity and pH.

The azacyanine dyes have a high solubility in PBS buffer pH 7.4. This ismore than 20 mM greater than commercial dyes such as ICG, 1.2 mM (1mg/mL) in water, but it is not readily soluble in saline.

In some embodiments, the fluorescent dye of the application is acompound of formula E:

wherein

Q′ is Cl, Br, I, —OR^(19′), —SR^(19′), or —NR^(19′)R^(20′), R^(19′) andR^(20′) are independently H or phenyl, wherein the phenyl can besubstituted by C₁₋₆ alkyl, C₁₋₆ fluroalkyl, —(CH₂)₀₋₃SO₃ ⁻,—(CH₂)₀₋₃SO₃-alkali metal, —(CH₂)₀₋₃COOH, —(CH₂)₀₋₃COO-alkali metal,—NCO, —NCS, —(CH₂)₀₋₃NH₂, or —(CH₂)₀₋₃N⁺H₃, or R^(19′) and R^(20′)together with the nitrogen to which they are attached form a 5- or6-membered heterocycle optionally containing one further heteroatomselected from O and N, wherein the heterocycle can be substituted by alinear or branched, cyclic or non-cyclic C₁₋₆ alkyl group;

R_(1″), R_(2″), R_(3′), and R_(7′) are independently absent, H, C₁₋₆alkyl, or —(CH₂)₁₋₆ L′, wherein L′ is —COOH, —COO—C₁₋₆alkyl, —NH₂, —OH,—SH, —COO⁻, SO₃ ⁻, SO₃-alkali metal, —COO-succinimide,—COO-sulfosuccininide, —NCO, —NCS, —COO-nitrophenyl, or—COO-fluorophenyl;

A₆, and A₁₀, are independently C, N, or N⁺;

R_(5′), R_(6′), R_(9′), and R_(10′), are independently H, or R_(5′) andR_(6′) together with the carbons to which they are attached form abenzene, or R_(9′) and R₁₀, together with the carbons to which they areattached form a benzene, wherein the benzene can be substituted by—(CH₂)₀₋₃ SO₃ ⁻, —(CH₂)₀₋₃ SO₃-alkali metal, —(CH₂)₀₋₃COOH, or—(CH₂)₀₋₃COO-alkali metal;

Z′ is NR^(17′) or ⁺NR^(17′)R^(18′), wherein R^(17′) and R^(18′) areindependently C₁₋₆ alkyl, —(CH₂)₁₋₃ ethynyl, —(CH₂)₁₋₆ L′, wherein L′ is—COOH, —COO—C₁₋₆alkyl, —NH₂, —OH, —SH, —COO⁻, SO₃ ⁻, SO₃-alkali metal,—COO-succinimide, —COO-sulfosuccininide, —COO-nitrophenyl, or—COO-fluorophenyl.

In some embodiments, a probe for multimodality imaging has a structureof the following formula F:

Wherein R_(1″), R_(2″), R_(3″), R_(5′), R_(6′), R_(7′), R_(9′), R_(10′),A_(6′), A_(10′), and Z′ are defined as for formula E, Q′ is —OR^(19′) or—SR^(19′), wherein R^(19′) is phenyl substituted by —NHCSNH—R′″ or—NHCONH—R′″, wherein R′″ is a phenyl or heterocyclic 5-, 6-, or7-membered aromatic substituted by —(CH₂)₁₀₋₃₀ COOH and at least onegroup selected from F and C₁₋₆ fluoroalkyl.

In some embodiments, the fluorescent dyes of the application areselected from the group comprising

wherein

X₁ is selected from H, SO₃R, or CO₂R,

Z is selected from CH₂, N—C₁₋₆ alkyl (such as NMe), N⁺(C₁₋₆ alkyl)₂(such as N⁺Me₂), N-ML, N⁺Me-ML,

ML is selected from (CH₂)₁₋₆COOR (such as (CH₂)₅COOR) and (CH₂)₁₋₅SO₃R(such as (CH₂)₄SO₃R),

R is H, metal cation, ammonium, substituted or unsubstitutedN-succinimide.

Examples for preferred dyes according to the application include thefollowing compounds I-XIX, XXIII and XXV-XXVIII,

Another aspect of the application provides a bioconjugate imaging agentcomprising the fluorescent dyes of the application. In an embodiment, abioconjugate imaging agent comprises a fluorescent dye of theapplication linked to at least one targeting agent (optionally by ananchor group or various anchor groups, i.e. 2, 3, 4 or 5 anchor groups).

The term “linked” or “chemically linked”—in general via a linkinggroup—is understood to mean a chemical bond between atoms. Chemicalbonds are known to the skilled artisan. In the context of the presentapplication, the chemical bond is preferably an ionic bond or a covalentbond, most preferably a covalent bond.

Properties of a bioconjugate imaging agent can be adjusted by modifyingthe charge and molecular weight of the fluorescent dye (fluorophore),targeting agents and, in some cases, the anchor group. In addition,properties of the bioconjugate imaging agent can be adjusted by thevarious substituents as defined above in the specification(physiochemistry properties modulators and optical propertiesmodulators).

A targeting agent is a moiety that specifically recognizes a target,typically an in-vivo or an in-vitro biological target, such as areceptor or another cellular recognition moiety. In some embodiments, atargeting agent is selected from the group comprising peptides (e.g.,RGD peptide, which specifically binds to αvβ₃ integrin), smallmolecules, aptamers including peptide aptamers and DNA and RNA aptamers,antibodies, carbohydrates, saccharides, and nucleic acids. A furtherdefinition of targeting agents and preferred embodiments thereof isgiven below.

Frequently modification of the targeting agents compromises the bindingavidity of the targeting moiety to its putative receptor on the targetsample or disease causing organism or aberrant signalling cells.

In certain embodiments, the targeting agents comprise fluorophores ofthe current application linked to moieties that recognize cell surfacereceptors or report on the environment of the cell such as pH.

In certain embodiments, a targeting agent is a peptide that is anenzymatic substrate such that when conjugated to the fluorescent dye ofthe application provides substantially no fluorescence. Cleavage of thepeptide by a particular enzyme dissociates the fluorescent dye causingan increase in fluorescence. The increase in fluorescence reports on thepresence of the activating enzyme.

In some embodiments, targeting agents either all from the same groupingor combinations thereof are linked to the fluorescent dye eitherdirectly or through linking groups. Preferable points of attachment forthe linking groups are the nitrogen on (i) the heterocycles of the dyesof the application, through for example R¹⁷ and/or R¹⁸ and/or R²⁰, R¹and/or R²; (ii) through any of the A6-A19 atoms when at least one ofthem is N. Preferred compounds are linked through the N of theheterocycles (most preferably through R¹⁷ and/or R¹⁸ or R²⁰, R¹ and/orR²), or if the ring annulated to the pyrrol structure contains a N atom,to this N atom, e.g., in positions R³, R⁴, R⁷ and/or R⁶, preferably R³and/or R⁷.

An anchor group is any functional group that can be used to link atleast one targeting agent to the fluorescent dye of the application, ingeneral via a linker. The anchor group will be attached to the targetinggroup, prior to linking it to the dye of the application.

Useful anchor groups include both natural and non-natural amino acids,oligopeptides, for example linear or cyclic oligopeptides, nucleicacids, peptides or peptides moieties, such as glycine, β-alanine,γ-aminobutyric acid or aminocaproic acid, as well as synthetic linkermolecules such as aminoethyl maleimide or aminomethyl benzoic acid. Inother embodiments, the anchor group is a polymer such ashomobifunctional or heterobifunctional polyethylene glycol (PEG).Several PEG derivatives are commercially available available fromseveral suppliers (e.g., Quanta Biodesign, Merck). When the anchor groupis a peptide, the peptide optionally may include proteolytic cleavagesite that can be cleaved with a variety of agents, for example, anenzyme. It is understood that there is no particular structural, size orcontent limitation for a given linker. Anchor groups can include, forexample, a variety of functional groups such as maleimide,dithiopyridyl, thiol, azide, alkene, or alkyne that permit the assemblyof molecules of diverse architecture. Anchor groups can behomofunctional linkers or heterofunctional linkers. For example, amine(NH₂)-functionalized moieties can be reacted with bifunctionalcross-linkers designed to react with amino groups. Particularly usefulconjugation reagents that can facilitate covalent linkage between, forexample, a fluorescent dye (a fluorophore), and an enzymaticallycleavable oligopeptide can include a N-hydroxysuccinimide (NHS) esterand/or a maleimide. The NHS ester can react with the amine group of, forexample, a peptide or fluorophore. The maleimide can react with thesulfhydryl group of another molecule. Other particularly useful anchorgroups are bifunctional crosslinkers such as N-succinimidyl3-(2-pyridyldithio)propionate (SPDP), long chain-SPDP, maleimidobenzoicacid-N-hydroxysuccinimide ester (MBS), succinimidyltrans-4-(maleimidylmethyl)cyclohexane-1-carboxylate (SMCC), succinimidyliodoacetate (SIA).

In certain embodiments, an anchor group can be branched, for exampleglutamic acid or 5-(aminomethyl) isophthalic acid, or a dendrimer, suchas a lysine or glutamic acid dendrimer, with multiple M groups linked toa single site on the fluorescent dye (fluorophore).

In certain embodiments, the biological modifier or physiochemistrymodifier may be a PEG moiety that has a molecular weight, for example,from about 0.1 kDa to about 50 kDa, about 5 kDa to about 35 kDa, orabout 10 kDa to about 30 kDa. Alternatively, the PEG may be dPEG,functionalized at a discrete molecular weight, for example, of about1100 daltons. In certain embodiments, the PEG ismethoxyPEG(5000)-succinimidylpropionate (mPEG-SPA),methoxyPEG(50000)-succinimidylsuccinate (mPEG-SS). Such PEGS arecommercially available from Nektar Therapeutics SunBiowest or LaysanBioor NOF. The PEG moiety can be conjugated to reactive amines on thefluorescent dyes via a carboxyl functionality. Alternatively, the PEGmodifier or physiochemistry modifier can be conjugated to thefluorescent dyes by using a thiol reactive cross linker and thenreacting with a thiol group on the PEG. In one embodiment, the PEG maybe branched, or Y-shaped, as available from Nektar Therapeutics Ca,JenKem USA, or Quanta Biodesign or comb-shaped, or synthesized bycoupling two or more PEGs to a small molecule such as glutamic acid.

In another embodiment the chemical modifier or physiochemistry modifiermay be dendrimers of various generations to provide multiple attachmentpoints, such as those derived from polyamido(amine) PAMAM andcharacterized generationally by the number of functional groups andmultiplicative radiating chains. The dendrimers are available fromMerck, Dendritech and Polymer factory (Sweden).

In other embodiments, the biological chemical modifier orphysiochemistry modifier can be polyvinylpyrrolidone (PVP)-typepolymers. The biological or chemical modifier or physiochemistrymodifier can be a functionalized polyvinylpyrrolidone, for example,carboxy or amine functionalized on one (or both) ends of the polymer (asavailable from Polymersource) or within the polymer chain.Alternatively, the biological chemical modifier or physiochemistrymodifier can include Poly N-(2-hydroxypropyl)methacrylamide (HPMA), orfunctionalized HPMA (amine, carboxy, etc.), Poly(N-isopropyl acrylamide)or functionalized poly(N-isopropylacrylamide).

Accordingly, a further aspect of the present application is abioconjugate imaging agent comprising a targeting agent as describedabove linked to a dye of the basic structure as depicted in formula A.The bioconjugate imaging agent has the formula D.

in which R³-R¹⁰, A⁶-A¹³, X, Y, Q, Z, E and E′ have the general,preferred, more preferred, still more preferred and most preferredmeanings as defined in connection with formula A,

R^(1′) and R^(2′) independently of each other have the meaning of R²³ asdefined in connection with R²³L for formula A, in the general,preferred, more preferred, still more preferred and most preferredmeanings as defined in connection with formula A; and wherein both ofR^(1′) and R^(2′) are present; or only one of R^(1′) and R^(2′) ispresent as attached to T via LG, in which case the other substituentR^(1′) or R^(2′) is absent, H or has the meaning of R¹ or R² as definedin connection with formula A, in the general, preferred, more preferred,still more preferred and most preferred meanings as defined inconnection with formula A.

The bioconjugate imaging agent may also have the formula G which has thesame formula as formula A except that Q is R²¹-LG-T, —O—R²¹-LG-T,—SR²¹-LG-T, or —NR²¹R²²-LG-T, R²¹ and R²² has the same meaning of R²¹and R²² as defined in connection with R²¹L, —OR²¹L, —SR²¹L, and—NR²¹R²²L for formula A.

LG in both formula D and G is a linking group formed in the reaction ofa linker as defined in the general, preferred, preferred, morepreferred, still more preferred and most preferred meanings for formulaA, with a complementary group on the targeting agent as defined in thegeneral, preferred, more preferred and still more preferred meanings asdefined in connection with formula A;

T in both formula D and G is a targeting agent independently selectedfrom receptors, ligands, antibodies, in particular monoclonal andpolyclonal antibodies and fragments of these antibodies, antigens,peptides, (e.g., RGD peptide, which specifically binds to vP³ integrin),enzyme substrates, enzymes, (specific) proteins and protein fragments,biotin, avidin, streptavidin, anti-biotin, carbohydrates, saccharides,lectin, DNA and fragments thereof, RNA and fragments thereof, aDNA andfragments thereof, aRNA and fragments thereof, hormones, folate,aptamers including peptide aptamers and DNA and RNA aptamers, enzymesubstrates, and small molecules such as a moiety comprising fatty acid(e.g., an amino substituted fatty acid) or a moiety comprising amino(e.g., an aniline substituted or unsubstituted). The targeting agent asshown in formula D is formed in the reaction of the respective linker asdefined in the general, preferred, preferred, more preferred, still morepreferred and most preferred meanings for formula A, with acomplementary group on the targeting agent as defined in the general,preferred, more preferred and still more preferred meanings as definedin connection with formula A.

In the context of the present application, a targeting agent is, in apreferred embodiment of the invention, a ligand that is able tospecifically interact with cell specific molecules via coordinativebonds in such a manner that results in a site-specific complex formingwith the cell specific molecule. In the context of the presentapplication, a coordinative bond is an intermolecular force, such asionic bonds, hydrogen bonds and Van der Waals forces. Underphysiological conditions the targeting agent typically acts as aninhibitor or an activator after it coordinatively bonds to the cellspecific molecule.

Targeting agents that form those site-specific complexes with cellspecific molecules are known to a person skilled in the art or may beavailable from recent articles. For example, these targeting agents arewell described in “CourseSmart International E-Book for Principles ofBiochemistry” (D. L. Nelson and M. M. Cox, Eds. Palgrave Macmillan, 13Feb. 2013) and “Illustrated Dictionary of Immunology. Third Edition” (J.M. Cruse and R. E. Lewis, Eds. CRC Press, 20 Apr. 2009).

Depending on cell type and accessibility of the targeted cell specificmolecule the targeting agent T is independently selected from the groupcited above.

A small molecule is a low molecular weight <900 daltons organic compoundthat may help regulate a biological process, with a size on the order of10⁻⁹ m. In a preferred embodiment, a small molecule is a molecule thatbinds to a specific biological target—such as a specific protein ornucleic acid—and acts as an effector, altering the activity or functionof the target.

In the context of the present application, a receptor is a molecule, ingeneral a protein, that receives chemical signals from a ligand bindingto it. Classically, receptors are molecules which are embedded in themembrane of a cell and are known to the person skilled in the art. Theycan also be used without the transmembrane part. The term receptor herealso includes other proteins which are drug-targets, in particularenzymes, transporters and ion-channels

In the context of the present application, a ligand is a substance thatforms a complex with a receptor, in general a protein, by binding to asite thereof by intermolecular forces, such as ionic bonds, hydrogenbonds and Van der Waals forces. The ligand can be a small molecule, ion,or protein, a substrate, an inhibitor, an activator, a neurotransmitter.

In the context of the present application, an antigen is a molecule thatbinds to Ag-specific receptors including antigens and is any molecule ormolecule fragment that can be recognized by highly variable antigenreceptors. Antigens are usually peptides, polysaccharides or lipids.

In the context of the present application, the term “antibody” refers toimmunoglobulins which are a class of soluble proteins found in bodyfluids of humans and other vertebrates. They are also termed“antibodies” and play a key role in the processes of recognition,binding and adhesion of cells. Antibodies are oligomeric glycoproteinswhich have a paramount role in the immune system by the recognition andelimination of antigens, in general bacteriae and viruses.

The polymeric chain of antibodies is constructed such that they compriseso-called heavy and light chains. The basic immunoglobulin unit consistsof two identical heavy and two identical light chains connected bydisulfide bridges. There are five types of heavy chains (α, γ, δ, ε, μ),which determine the immunoglobulin classes (IgA, IgG, IgD, IgE, IgM).The light chain group comprises two subtypes, λ and κ IgGs are solubleantibodies, that can be found in blood and other body fluids. They arebuilt by B-cell derived plasma cells as response to and to neutralizebacterial or other pathogens. The two carboxy terminal domains of theheavy chains are forming the Fc fragment (“constant fragment”), theamino terminal domains of the heavy and light chains are recognizing theantigen and are named Fab fragment (“antigen-binding fragment”). Fcfusion proteins are created through a combination of an antibody Fcfragment and a protein or protein domain that provides the specificityfor a given drug target. Other Fc fusion proteins are combinations ofthe Fc fragment with any type of therapeutic proteins or proteindomains. The Fc part is considered to add stability and deliverabilityto the protein drug. Therapeutic antibodies and Fc fusion proteins areused to treat various diseases, prominent examples include rheumatoidarthritis, psoriasis, multiple sclerosis and many forms of cancer.Therapeutic antibodies can be monoclonal or polyclonal antibodies.

In the subject matter of the present application, all immunoglobulin(antibody) types IgA, IgG, IgD, IgE, IgM can be used. IgM is preferred,and this term comprises natural, monoclonal and polyclonal antibodies,Fc fusion proteins and therapeutic antibodies (polyclonal andmonoclonal).

The general, preferred, more preferred and still more preferredembodiments cited in connection with formula A also apply with respectto the above formula (D). In the bioconjugate imaging agents of theinvention according to (D), however, the case that R¹⁹ in —OR¹⁹ is not Hdoes not apply.

With respect to the above formula D, the respective bioconjugate maycontain two targeting groups attached to the dye skeleton via LG, R^(1′)and R^(2′), or only one of R^(1′) and R^(2′) is present to attach T viaLG, meaning that the bioconjugate targeting agent contains only onetargeting group. In this latter case, the other substituent R^(1′) orR^(2′) is absent, is H or has the meaning of R¹ or R² as defined inconnection with formula A, in the general, preferred, more preferredstill more preferred and most preferred meanings as defined inconnection with formula A; or one of R^(1′) and R^(2′) has the meaningof R²³L as defined in connection with formula A, in the general,preferred, more preferred, still more preferred and most preferredmeanings, which means that a linker L is connected to the dye skeletonvia R²³; or one of R^(1′) and R^(2′) has the meaning of R²³U as definedin connection with formula A, in the general, preferred, more preferredand still more preferred meanings, which means that a physiochemistrymodifying group U is connected to the dye skeleton via R²³.

Targeting agents are ligands that bind to receptors that areoverexpressed on cancer cells, in a preferred embodiment. However,receptors overexpressed on cancer cells are also expressed onnon-malignant cells in lower numbers. Therefore, ligand should have theaffinity and specificity for overexpressed cell surfaced receptor. Thereare several targeting agents known biological targets. These targetsinclude for example transferrin, monoclonal antibodies (MAbs),polyclonal antibodies, peptides, EGF (epidermal growth factor), folateand aptamers.

The targeting agents T can be the same or different. If T are different,the linking groups LG will preferably be different from each other, butmay also be the same.

Irrespective of the fact if the targeting agents are different or not,the biomolecule imaging agents according to the above formula can besymmetrical, or asymmetrical in the sense that they do not have a C2symmetry.

Examples of bioconjugate imaging agents of the application are compoundsXX, XXI, XXII, and XXVIII as shown in Examples. Another example ofimage-rendering bioconjugates of the application is the followingcompound:

where the IgG molecule is

activated esters* amines/anilines carboxamides acyl azides**amines/anilines Carboxamides acyl halides amines/anilines Carboxamidesacyl halides alcohols/phenols Esters acyl nitriles alcohols/phenolsEsters acyl nitriles amines/anilines carboxamides aldehydesamines/anilines imines aldehydes or ketones hydrazines hydrazonesaldehydes or ketones hydroxylamines oximes alkyl halides amines/anilinesalkyl amines alkyl halides carboxylic acids Esters alkyl halides thiolsthioethers alkyl halides alcohols/phenols Ethers alkyl sulfonates thiolsthioethers alkyl sulfonates carboxylic acids Esters alkyl sulfonatesalcohols/phenols Ethers anhydrides alcohols/phenols Esters anhydridesamines/anilines carboxamides aryl halides thiols thiophenols arylhalides mines ryl amines aziridines thiols thioethers boronates glycolsboronate esters carboxylic acids amines/anilines carboxamides carboxylicacids alcohols Esters carboxylic acids hydrazines hydrazidescarbodiimides carboxylic acids N-acylureas or anhydrides diazoalkanescarboxylic acids Esters epoxides thiols thioethers haloacetamides thiolsthioethers halotriazines amines/anilines aminotriazines halotriazinesalcohols/phenols triazinyl ethers imido esters amines/anilines amidinesisocyanates amines/anilines Ureas isocyanates alcohols/phenols urethanesisothiocyanates amines/anilines thioureas maleimides thiols thioethersphosphoramidites alcohols phosphite esters silyl halides alcohols silylethers sulfonate esters amines/anilines alkyl amines sulfonate estersthiols thioethers sulfonate esters carboxylic acids Esters sulfonateesters alcohols ethers sulfonyl halides amines/anilines sulfonamidessulfonyl halides phenols/alcohols sulfonate esters

Examples for preferred bioconjugate imaging agents according to theapplication include the following compound XX, XXI, XXII, and XXVIII. Inbioconjugate XXVIII, the “dye” is XXVII.

Another aspect of the subject matter of the application is the pHsensitivity of the fluorescent dyes of application when the nitrogenatom in the heterocycle is substituted and another N atom is availablefor protonation or deprotonation. The excitation and emissionwavelengths are pH dependent, a feature that enables lysosomal trackingas the environment is acidic. At low pH the indole nitrogen isprotonated and the dyes of the application shift to longer wavelengthsupon deprotonation as the conjugation is extended. Such dyes are pHsensors as their absorbance and consequently fluorescence changes as aconsequence of the pH of the environment. The fluorescent dyes of theapplication are pH sensors and are defined by their ability to changethe fluorescence absorption and emission properties as a consequence ofprotonation of the non quaternized nitrogen in the system. Thus, theapplication provides a use of the fluorescent dyes of the application aspH sensors. The application also provides a method for measuring a pH ofa solution, wherein the fluorescent dyes of the application are used.

In a further embodiment of the application, the bioconjugate imagingagent according to the application binds to a biological target. In thisembodiment, the bioconjugate imaging agent permits detection of thepresence of the biological target, preferably by visualisation, and ofthe disease or the diseased tissue expressing or presenting thebiological target.

The resulting bioconjugate imaging agent can have a high bindingaffinity to a target, for example, due to an interaction between thebiomolecule and the target, for example, via receptor-ligandinteraction, an antibody-antigen interaction, peptide-peptide receptorinteraction, enzyme substrate-enzyme interaction, protein-proteinreceptor interaction, biotin-avidin (or streptavidin or anti-biotin)interaction, carbohydrate-lectin (or carbohydrate receptor) interaction,DNA(RNA)-aDNA(aRNA) interaction, hormone-hormone receptor interaction.

T is a targeting agent independently selected from receptors, ligands,monoclonal and polyclonal antibodies and fragments of these antibodies,antigens, peptides, enzyme substrates, enzymes, (specific) proteins andprotein fragments, biotin, avidin, streptavidin, anti-biotin,carbohydrates, saccharides, lectin, DNA and fragments thereof, RNA andfragments thereof, aDNA (antisense DNA) and fragments thereof, aRNA(antisense RNA) and fragments thereof, hormones, folate, aptamers, andenzyme substrates.

In an embodiment of the application, the targeting agent binds totargets that are overexpressed on cancer cells. However, targetsoverexpressed on cancer cells are also expressed on non-malignant cellsin lower numbers. Therefore, the targeting agent used according to theapplication has affinity and specificity for overexpressed cell surfacetargets. Non-limiting examples include folate, transferrin, monoclonalantibodies (MAbs), peptides, EGF (epidermal growth factor) and aptamers.

Accordingly, the targeting agent can be a receptor, a ligand, anantibody, preferably a monoclonal antibody, an antigen, a peptide, anenzyme substrate, an enzyme, a protein, biotin, avidin, streptavidin,anti-biotin, a carbohydrate, a saccharide, lectin, a carbohydrate, DNA,RNA, aDNA, aRNA, a hormone.

One advantage of the bioconjugate imaging agents of the invention isthat they do not demonstrate any binding to or uptake by live cells andselectively only binds to necrotic cells. This is shown by the examples.

In a further embodiment of the present invention, the fluorescent dyesand the bioconjugate imaging agents of the invention are modified suchthat they carry a chelating agent (hereinafter denoted as “CA”). Thechelating agent lends itself for various purposes, e.g. for binding to ametal, preferably a radioactive metal. The binding of the metal to thechelate in general occurs via coordinate bonds (chelate effect), inwhich 2 or more atoms in the chelating agent bind to a single atom, ingeneral a metal atom, Coordinative bonds are generally formed in areaction between the metal atom (ion) and a free electron pair on anatom in the chelating agent.

Chelating agents are well known to the person skilled in the art. In thecontext of the present invention, the use of chelating agents which bindto metals, preferably radioactive metals and/or known radioactiveisotopes of known metals, in particular radioactive metals orradioactive isotopes of metals which lend themselves as tumor imagingagent and/or as MRI contrast agent, is preferred.

The present invention preferably makes use of in particular1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA),1,4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA),Triethylenetetramine (TETA), Ethylenediaminetetraacetic acid (EDTA),1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA), andDiethylenetriaminepentaacetic acid (DTPA).

Chelating agents used in the present invention, in particular the abovechelating agents, can be used to bind radioactive metals or radioactiveisotopes metals, preferably as ⁶⁸Gallium (68Ga), ⁶⁴Copper (64Cu) fortumor imaging using PET or ¹¹¹Indium (111In), or any other metal,preferablyGd³⁺ for gadolinium-based MRI contrast agent, making thisconjugate useful for various types of imaging modalities such as PET,SPECT, and MRI.

Chelating agents, preferably the chelating agents cited above, can beattached to any appropriate position in the dye molecules of theinvention, i.e. the chelating agent can be in the position of any of thesubstituents Q, E, E′ and R¹-R¹⁶. “Being in the position of any” in thepresent context means that the chelating agent can replace therespective substituent, or it can be attached to the respectivesubstituent. “Attached to” here means that chelating agent is attachedto the chemical entity as defined relative to the respectivesubstituent, in the preferred, the more preferred, the still morepreferred or the most preferred embodiments as defined above. Forexample, this means that in case the chelating agent CA is in theposition of Q, R¹ and/or, R², CA can be attached (in the most generalembodiment) to a group selected from a linear and branched, non-cyclicand cyclic, substituted and unsubstituted C₁₋₂₀ alkyl, wherein the saidalkyl group can be single or multiple substituted by a homocyclic orheterocyclic 5-, 6- or 7-membered aromatic group which can besubstituted by a linear or branched C₁-C₆ alkyl group; homocyclic andheterocyclic 5-, 6- and 7-membered aromatic rings which can besubstituted by a linear of branched C₁-C₆ alkyl group; and—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50. “Attached to”here also refers to the embodiment that CA is attached to a group U or Lor even an optical properties modifying group. Here, CA may be attachedto the respective group in a reaction transforming the reactive entitiesinto different functionalities. In this embodiment, it may be necessaryto provide a further group U, L or an optical properties modifying groupin the fluorescent dye or the bioconjugate imaging agent, inorder toreach the desired properties of the resulting dye and the bioconjugateimaging agent according to the invention.

In case the chelating agent replaces the respective substituent in therespective position, then the chelating agent can be attached to therespective atom directly. In the first embodiment, CA is attached to therespective atom on the dye via an atom previously present in thechelating agent, or via an atom in a functional group which haspreviously been attached to the CA. This is shown in the examples.

In the second embodiment, CA is attached to a chemical entity linking itto the respective atom in the respective site of the fluorescent dye. Ingeneral, these chemical entities are those defined for Q, alternative b)in connection with Formula A, in the general, preferred, more preferred,still more preferred and most preferred meanings as defined throughoutthe present application. The said chemical entities can, before thechelating agent is attached, be connected to the chelating agent or tothe fluorescent dye, before linking the chelating agent to the dye.

Accordingly, in the general meaning, and in case CA is attached to achemical entity linking it to the respective atom being part of thefluorescent dyes of the invention, the entity comprising CA is, in themost general meaning, defined as: R³⁵CA, —OR³⁵CA, —SR³⁵CA and —NR³⁵R³⁶CAwherein R³⁵ and R³⁶ d are independently selected from the groupconsisting of: H, linear and branched, non-cyclic and cyclic,substituted and unsubstituted C₁₋₂₀ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic or heterocyclic5-, 6- or 7-membered aromatic group which can be substituted by a linearor branched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic rings which can be substituted by a linear orbranched C₁-C₆ alkyl group, wherein preferably one of R³⁵ and R³⁶ is notaromatic in case of —NR³⁵R³⁶; —(CH₂—O—CH₂)_(x)CH₂-L wherein x is aninteger from 1 to 50; and CA is a chelating agent as defined therein.

The above groups having R³⁵ and R³⁶ may each be an optical propertiesmodifying group.

The preferred, more preferred, still more preferred and most preferredmeanings for CA attached to a chemical entity are, accordingly, thosedefined for Q b) in each of the preferred, more preferred, still morepreferred and most preferred embodiments, with R²¹ and R²² beingreplaced by R³⁵ and R³⁶.

The chelating agent can be in any position Q, E, E′ and R¹-R¹⁶, asstated above. Preferably, the chelating agent is in position Q, R¹and/or R². Most preferably, CA is in position Q.

The number of chelating groups attached to the fluorescent dyes (and,therefore, also to the bioconjugate imaging agents) of the invention mayvary from 1 to 4, preferably from 1 to 3, more preferably from 1 to 2.In one particular preferred embodiment, this number is 1. In anotherpreferred embodiment, this number is 2.

Table 1 below cites various preferred chelating agents and therespective radioactive metals/isotopes which are bound by the agent. Thetable below is not meant to be limiting

Chelation agent Metals chelated 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Indium-111, gallium-67/68, tetraacetic acid (DOTA) Copper-64, Yttrium-861,4,7-Triazacyclononane-1,4,7-triacetic acid Indium-111, gallium-67/68(NOTA) Triethylenetetramine (TETA) Copper-64 Ethylenediaminetetraaceticacid (EDTA) gallium-68, Copper-64 1,4,7-triazacyclononane-1-glutaricacid-4,7- gallium-68, Indium-111, diacetic acid (NODAGA) Copper-64Diethylenetriaminepentaacetic acid (DTPA) Indium-111, gallium-67/68,Copper-64, Yttrium-86, Zirconium-89

Below is shown the synthesis of a fluorescent dye of the invention towhich a chelating agent (here: DOTA) is attached in a chemical reaction.The reaction starts from Compound VIII

The amine-functionalized Compound VIII can then be coupled to a varietyof chelating agents such as1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) thathave been modified to contain a N-Hydroxysuccinimide functional group asshown in reaction diagram 2. This reaction is completed by using thefunctionalized Compound VIII and the N-hydroxysuccinimide ester form ofDOTA, which is commercially available, in the presence of 4 equivalentsof N,N-Diisopropylethylamine (DIPEA) at room temperature in a nitrogenatmosphere.

Radiolabeling of the DOTA-Compound VIII conjugate is accomplished usinga 0.25M ammonium acetate buffer with a pH of 7.0 at 37° C. forIndium-111, which is added to the solution in 0.4N hydrochloric acid andstirred for 45 minutes. Other metal chelates behave in a similar fashionfor chelation procedures. The reaction with Indium-111 is shown inreaction diagram 3.

In the reaction diagram 4 is shown an alternative starting structure forconjugation and chelation of compound VIII

In reaction diagram 5 is shown an alternative starting structure(carboxylic) for conjugation and chelation of compound VIII

In reaction diagram 6 is shown an alternative structure of compound VIIIwith a functional group of isothiocyanat for a conjugation with amodified DOTA compound

In reaction diagram 7 is shown a further structure of compound VIII withthe isothiocyanat group as the starting compound for conjugation with amodified DOTA compound.

DOTA (and other chelating agents) are known to bind radioactive isotopessuch as ⁶⁸Gallium (68Ga), ⁶⁴Copper (64Cu) for tumor imaging using PET or¹¹¹Indium (111In) or any other metal such as Gd³⁺ for gadolinium-basedMRI contrast agent, making this conjugate useful for various types ofimaging modalities such as PET, SPECT, and MRI. Corresponding compoundsare also efficient fluorescent reagents, the conjugates can be used foroptoacoustic, near-infrared imaging (600-900 nm) and shortwave infrared(SWIR II) range of wavelengths from 0.9 to 1.7 microns (see more detailsbelow). The molecule could also be envisioned for radiotherapyapplications for local tumor irradiation when chelated to radioisotopessuch as Lutetium or Yttrium (¹⁷⁷Lu, ⁹⁰Y).

The carboxylic acid moiety on this molecule can also be used to coupleto any other targeting ligand such as folic acid, cyclic RGD peptides(for alpha-v beta-3 receptor targeting) or antibody of choice (ex.Trastuzumab or TEM-1) or any other types of antibodies such as probodies(“masked” antibodies), nano-bodies, etc.

In reaction diagram 8 is shown an aza-fatty acid probe which can be usedfor image-guided surgery as some tumors show preferential uptake offatty acids by comparison to normal tissue:

In reaction diagram 9 is shown a probe for multimodality imaging:

The final compound in reaction diagram 9 can be both a fluorescent probeand an imaging probe via imaging modality such as 19F-MRI.

The above-described embodiment of the invention in which the fluorescentdyes and the bioconjugate imaging agents of the invention are modifiedsuch that they carry a chelating agent, and in which the said chelatingagent binds to a metal ion, preferably a radioactive metal/isotope canbe used in all embodiments of the invention as disclosed hereinbeforeand hereinafter, which are directed toward the fluorescent dyes and/orthe bioconjugate imaging agents, including the respective kits.

Another aspect of the present invention is drawn towards a kit forfluorescence labelling of a biological sample, comprising a dye asdescribed above or a salt thereof, preferably a solution of the dye orthe salt, or a bioconjugate imaging agent according to any of claims7-9, and optionally a suitable buffer.

Another aspect of the application provides methods for in vitro and invivo imaging using the fluorescent dyes of the application including thedyes functionalized with a chelating agent including the embodiment withchelated metals in bioconjugate imaging agents. Optical imaging includesall methods from direct visualization without use of any device and useof devices such as various scopes, catheters and optical imagingequipment, for example computer based hardware for tomographicpresentations. The imaging agents are useful with optical imagingmodalities. Measurement techniques are known to the person skilled inthe art and include, for example, endoscopy fluorescence endoscopy andfurther techniques which are known to the person skilled in the art; Animaging system useful in the practice of the application typicallyincludes three basic components: (1) an appropriate light source forinducing excitation of the imaging agent, (2) a system for separating ordistinguishing emissions from light used for fluorophore (fluorescentdye) excitation, and (3) a detection system. Exemplary detection systemsinclude an endoscope, catheter, tomographic system, hand-held imagingsystem, an intraoperative microscope or a fluorescent microscope.

Another aspect of the application provides a method of in vivo imaging,the method comprising: (a) administering to a subject a bioconjugateimaging agent of the application comprising the fluorescent dye of theapplication; (b) allowing the agent to distribute within the subject;

and (c) detecting a signal emitted by the bioconjugate imaging agent.

Another aspect of the application provides a method of in vivo opticalimaging, the method comprising: (a) administering to a subject abioconjugate imaging agent of the application comprising the fluorescentdye of the application; (b) allowing the agent to distribute within thesubject; (c) exposing the subject to light of a wavelength absorbable bythe fluorescent dye and (d) detecting a signal emitted by the agent.

Another aspect of the application provides a method of in vivo imaging,wherein the signal emitted by the bioconjugate imaging agent is used toconstruct an image. In other embodiments, the image is a tomographicimage. In certain embodiments, the subject matter of the presentapplication is a method of in vivo optical imaging, wherein steps(a)-(c) are repeated at predetermined time intervals thereby to permitevaluation of the emitted signals of the targeting agent in the subjectover time. In certain embodiments, the subject matter of the presentapplication is a method of in vivo optical imaging, wherein steps(a)-(d) are repeated at predetermined time intervals thereby to permitevaluation of the emitted signals of the bioconjugate imaging agents inthe subject over time. In certain embodiments, the subject matter of thepresent application is a method of in vivo imaging, wherein the subjectis an animal or a human. In certain embodiments, the subject matter ofthe present application is a method of in vivo imaging, wherein in step(a) two or more bioconjugate imaging agents whose signal properties aredistinguishable from one another are administered to a subject, whereinat least one of the bioconjugate imaging agents has a targeting agent.In certain embodiments, the subject matter of the present application isa method of in vivo optical imaging, wherein the illuminating anddetecting steps are performed using an endoscope, catheter, tomographicsystem, hand-held optical imaging system, or an intraoperativemicroscope.

Another aspect of the application provides a method of in vivo imaging,wherein the presence, absence, or level of emitted signal is indicativeof a disease state. In certain embodiments, the subject matter of thepresent application is a method of in vivo imaging, wherein the methodis used to detect and/or monitor a disease. In certain embodiments, thedisease is selected from the group consisting of bone disease, cancer,cardiovascular disease, a neurogenerative disease, environmentaldisease, dermatological disease, a bone disease, trauma (e.g., injury),cell death, an autoimmune disease, immunologic disease, inheriteddisease, infectious disease, inflammatory disease, metabolic disease,and ophthalmic disease. Any cell type, tissue or organ can be monitoredincluding for example, liver, kidney, pancreas, heart, blood, urine,plasma, eyes, CNS (brain), PNS, skin, solid tumours, etc

In all the above aspects/embodiments of the invention, the terms“fluorescent dyes of the application” and “bioconjugate imaging agents”include dyes and bioconjugate imaging systems functionalized with achelating agent including the embodiment in which metalas are chelatedby chemically attached. chelating agent. The above also applies withrespect to any of the following embodiments.

In a preferred embodiment of the application, the above method of theapplication can be uses to detect the degree of cell death. In thisembodiment, it is even more preferred if the cell death results from amechanism selected from apoptosis, necrosis, and necroptosis.

In the methods of the application, the subject is a human or an animal.In case of an animal, the animal is preferably a mammal.

In a further preferred embodiment of the above methods of theapplication, a compound, a dye according to the application is coupledto one or more of:

a) a radio-active tracer,

b) an MRI contrast agent,

c) nanoparticle and,

d) a biologically active compound

Another aspect of the application provides a method of in vivo imaging,wherein, in step (a), cells labelled by a bioconjugate imaging agent areadministered to the subject. In other embodiments, the signal emitted bythe agent is used to monitor trafficking and localization of the cells.

With respect to optical in vivo imaging, such a method typicallycomprises (a) administering to a subject one or more of the bioconjugateimaging agents described herein, (b) allowing sufficient time to permitthe agent to distribute with the subject, and (c) detecting a signalemitted by the bioconjugate imaging agents. The signal emitted by theagent can be used to construct an image, for example, a tomographicimage. The foregoing steps can be repeated at predetermined timeintervals thereby to permit evaluation of the emitted signals of thetargeting agents in the subject over time. The subject may be avertebrate, for example, a mammal, for example, a human. The subject mayalso be a non-vertebrate.

Information provided by such in vivo imaging approaches, for example,the presence, absence, or level of emitted signal can be used to detectand/or monitor a disease in the subject. Exemplary diseases include,without limitation, autoimmune disease, bone disease, cancer,cardiovascular disease, environmental disease, dermatological disease,immunologic disease, inherited disease, infectious disease, metabolicdisease, neurodegenerative disease, and ophthalmic disease.

In addition, in vivo imaging can be used to assess the effect of acompound or therapy by using the bioconjugate imaging agents, whereinthe subject is imaged prior to and after treatment with the compound ortherapy, and the corresponding signal/images are compared.

In an embodiment of the application, the dyes and the conjugates withthe targeting agent and the conjugates with the target molecules may beused in optoacoustic imaging application.

The dyes of the application may also be used as quenchers.

The methods and compositions (fluorescent dyes and/or bioconjugateimaging agents) of the application can also be used in the detection,characterization and/or determination of the localization of a disease,including early disease, the severity of a disease or adisease-associated condition, the staging of a disease, and/ormonitoring a disease. The presence, absence, or level of an emittedsignal can be indicative of a disease state. With respect to each of theforegoing, examples of such disease or disease conditions that can bedetected or monitored (before, during or after therapy) includeinflammation (for example, inflammation caused by arthritis, forexample, rheumatoid arthritis), cancer (for example, colorectal,ovarian, lung, breast, prostate, cervical, testicular, skin, brain,gastrointestinal, pancreatic, liver, kidney, bladder, stomach, leukemia,mouth, esophageal, bone), cardiovascular disease (for example,atherosclerosis and inflammatory conditions of blood vessels, ischemia,stroke, thrombosis, disseminated intravascular coagulation),dermatologic disease (for example, Kaposi's Sarcoma, psoriasis, allergicdermatitis), ophthalmic disease (for example, macular degeneration,diabetic retinopathy), infectious disease (for example, 1, viral, fungaland parasitic infections, including Acquired Immunodeficiency Syndrome,Malaria, Chagas Disease, Schistosomiasis), immunologic disease (forexample, an autoimmune disorder, lymphoma, multiple sclerosis,rheumatoid arthritis, diabetes mellitus, lupus erythematosis, myastheniagravis, Graves disease), central nervous system disease (for example, aneurodegenerative disease, such as Parkinson's disease or Alzheimer'sdisease, Huntington's Disease, amyotrophic lateral sclerosis, priondisease), inherited diseases, metabolic diseases, environmental diseases(for example, lead, mercury and radioactive poisoning, skin cancer,bone-related disease (for example, osteoporosis, primary and metastaticbone tumors, osteoarthritis), neurodegenerative disease, andsurgery-related complications (such as graft rejection, organ rejection,alterations in wound healing, fibrosis or other complications related tosurgical implants).

The methods and compositions described herein can, therefore, be used,for example, to detect and/or quantify the presence and/or localizationof elevated positively charged cell surfaces in a subject, includinghumans, for instance in infectious or apoptotic cells, and to detectand/or quantify the presence and/or localization of infection and celldeath, including the presence of infectious or apoptotic areas within anorgan. The methods and compositions described herein can also be used todetect and/or quantify apoptosis associated with diseases, disorders andconditions, including but not limited to preneoplastic/neoplasticdisease including areas at risk for acute occlusion (i.e. vulnerableplaques) in coronary and peripheral arteries, regions of expandinganeurysms, unstable plaque in carotid arteries, and ischemic areas. Themethods and compositions of the application can also be used inidentification and evaluation of cell death, injury, apoptosis,necrosis, and hypoxia. The methods and compositions can also be used fordrug delivery and to monitor drug delivery, especially when drugs ordrug-like molecules are chemically attached to the fluorescent probes.Exemplary drug molecules include chemotherapeutic and cytostatic agentsand photodynamic agents including but not limited to Photofrin, Lutrin,Antrin, aminolevulinic acid, hypericin, benzoporphyrin derivative, andporphyrins.

In addition, the methods and compositions described herein can be usedto image an infection in a subject. The method comprises administeringto a subject (for example, a human or animal) an amount of one or moreof the bioconjugate imaging agents described herein sufficient tofacilitate in vivo and ex vivo imaging. After sufficient time to permitthe agent to distribute within the animal or distribute within the areato be imaged, the presence and/or amount of the agent is determined. Thepresence and/or amount of the agent can then be used to create an image,for example, a tomographic image, representative of elevated positivelycharged cell surfaces within the tissues of the subject.

In addition, the methods and compositions described herein can be usedto image infections in a subject such as tuberculosis, Lyme disease,brucellosis, whooping cough, pneumonia, tetanus, diphtheria, typhoidfever, meningitis, cellulitis, impetigo, botulism, psittacosis,urethritis, enteritis, colitis, anthrax, Legionnaire's Disease,syphilis, tularemia, bronchitis, ulcers, boils, leptospirosis,listeriosis, gonorrhea, shigellosis, salmonellosis, cholera, cystitis,septicemia, txinoses, endocarditis, toxic shock syndrome, scarlet fever,rheumatic fever, and Rocky Mountain Spotted Fever.

Another aspect of the application provides an in vitro imaging method,the method comprising: (a) contacting a sample with the bioconjugateimaging agent of the subject matter of the present application; (b)allowing the agent to bind to a biological target; (c) optionallyremoving unbound agent; and (d) detecting signal emitted from the agentthereby to determine whether the agent has been activated by or bound tothe biological target. In other embodiments, the sample is a biologicalsample.

With respect to in vitro imaging, the imaging agents can be used in avariety of in vitro assays. After an imaging agent has been designed,synthesized, and optionally formulated, it can be tested in vitro by oneskilled in the art to assess its biological and performancecharacteristics. For instance, different types of cells grown in culturecan be used to assess the biological and performance characteristics ofthe agent. Cellular uptake, binding or cellular localization of theagent can be assessed using techniques known in the art, including, forexample, fluorescent microscopy, FACS analysis, immunohistochemistry,immunoprecipitation, in situ hybridization and Forster resonance energytransfer (FRET) or fluorescence resonance energy transfer. By way ofexample, the agents can be contacted with a sample for a period of timeand then washed to remove any free agents. The sample can then be viewedusing an appropriate detection device such as a fluorescent microscopeequipped with appropriate filters matched to the optical properties of afluorescent agent. Fluorescence microscopy of cells in culture orscintillation counting is also a convenient means for determiningwhether uptake and binding has occurred. Tissues, tissue sections andother types of samples such as cytospin samples can also be used in asimilar manner to assess the biological and performance characteristicsof the agents. Other detection methods including, but not limited toflow cytometry, immunoassays, hybridization assays, and microarrayanalysis can also be used.

Another aspect of the application provides clinical applications of thecompounds (fluorescent dyes and bioconjugate imaging agents) of theapplication. Certain of the bioconjugate imaging agents describedherein, for example, agents containing the optical or radiolabel anddrug molecule, can be used to ameliorate a symptom of, or treat, aparticular disease or disorder. The method comprises (a) administeringan amount of one or more the agents described herein sufficient toimpart a therapeutic effect in the subject; and (b) permittingsufficient time for the agent to distribute within the subject orotherwise localize in a region of the subject to be treated and then,(c) depending on the therapeutic agent, optionally activating the agentto impart a therapeutic effect. For example, when the therapeutic agentis a radiolabel, no subsequent activation is required. However, when thetherapeutic agent is a photoreactive agent, for example, a dye used inphotodynamic therapy, exposing the agent to light having a wavelengththat activates the agent may activate the agent. As a result, the agentscan be used to treat a condition of interest, for example, a cancer,immune disorder, inflammatory disorder, vascular disorder and the like.Furthermore the agents can be used to reduce tumor burden, to inhibitinfection in an organ, or other region of interest in the subject, orreduce apoptotic cell proliferation within a subject.

Another aspect of the application provides probes that are molecularimaging agents, the molecular agents could be the fluorescent dyes ofthe application themselves in a particular environment such as solventor vehicle in which it is administered or bioconjugates defined agentsconsisting of a fluorochrome (fluorescent dye) of the applicationconjugated through the linking group to a targeting agent as definedearlier. The molecular imaging agents are usually administered ordelivered to a subject wherein the signal emitted by the agent is usedto construct an image as described below.

Bioconjugate imaging agents described herein may be formulated with oneor more pharmaceutically acceptable carriers (additives) and/or diluentsto provide a pharmaceutical composition. Exemplary pharmaceuticalcompositions comprise one or more agents and one or morepharmaceutically acceptable carriers. As described in detail below, thepharmaceutical compositions may be specially formulated foradministration in solid or liquid form. Examples for administrationinclude oral administration, parenteral administration, topicalapplication, and transdermal administration.

The term “pharmaceutically acceptable” is employed herein to refer tothose compounds, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

Pharmaceutically-acceptable carriers include a liquid or solid filler,diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium,calcium or zinc stearate, or steric acid), or solvent encapsulatingmaterial, involved in carrying or transporting the subject compound fromone organ, or portion of the body, to another organ, or portion of thebody. Each carrier must be “acceptable” in the sense of being compatiblewith the other ingredients of the formulation and not injurious to thepatient. Wetting agents, emulsifiers and lubricants, as well as coloringagents, release agents, coating agents, sweetening, flavoring andperfuming agents, preservatives and antioxidants may also be present.Materials which can serve as pharmaceutically-acceptable carriers areknown to the skilled artisan and include the typical materials.

In certain embodiments, the application provides a pharmaceuticallyacceptable composition suitable for administration to a subjectcomprising a bioconjugate imaging agent and a pharmaceuticallyacceptable excipient.

In some embodiments of the application, the fluorescent dyes of theapplication can be prepared as follows:

The bioconjugate imaging agents comprising fluorescent dyes of theapplication are derived according to the following scheme

This application relates to new azacyanine dyes derived frompyridoindolelinium containing a heteroatom bridge preferably nitrogen.Incorporation of pyridoindolelinium into these cyanine dyes results insignificantly increased solubility in both phosphate-buffered saline andwater solutions over existing commercially available cyanine dyes ICGand IRDye800. The new azacyanine dyes XIII, XIV, XV, and II have c Log Pvalues of −2.423, −3.545, −6.518, and −13.277 respectively, showing muchgreater hydophilicity than the commercially available ICG and IRDye800dyes with c Log P values of 5.74 and −1.86.

Several cyanine dyes including probe XXI, RGD-ICG conjugate andInegriSense™750 (Perkin Elmer) were evaluated for targeting subcutaneoustumors in mice. Probe XXI exhibits faster and more specific tumor uptakewith the optimal background to noise ratio achieved in 2 hours postinjection. In comparison IntegriSense™750, a successful commerciallyavailable small molecule integrin Q v Q 3 antagonist NIR probe showsoptimal background to noise ratio in 24 hours. RGD-ICG conjugateexhibited tumor uptake kinetics similar to probe XXI, but it alsogenerated a lot of nonspecific binding to various animal tissues,possible due to random precipitation of the hydrophobic ICG dye. Fastertumor binding kinetics of probe XXI was also observed in bigger animalslike dogs where highest accumulation in the tumor tissue was detectedwithin 6 hours post injection compared with 36 hours forIntegriSense™750 (See FIG. 11 and FIGS. 12A and 12B).

Those skilled in the art will appreciate that the subject matterdescribed herein is susceptible to variations and modifications otherthan those specifically described. It is to be understood that theapplication includes all such variations and modifications withoutdeparting from the spirit or essential characteristics thereof. Theapplication also includes all of the steps, features, compositions andcompounds referred to or indicated in this specification, individuallyor collectively, and any and all combinations or any two or more of saidsteps or features. The present disclosure is therefore to be consideredas in all aspects illustrated and not restrictive, the scope of thesubject matter being indicated by the appended Claims, and all changeswhich, come within the meaning and range of equivalency are intended tobe embraced therein.

The foregoing description will be more fully understood with referenceto the following Examples. Such Examples, are, however, exemplary ofmethods of practising the present subject matter and are not intended tolimit the scope of the application.

Examples

Synthesis of Compound 3

2-Hydrazinopyridine (1) (10.0 g.), isopropyl methyl ketone (10 ml.),were placed at 80° C. and stirred for 2 h. Excess of isopropyl methylketone was evaporated along with water under reduced pressure. Thehydrazone 2 was heated at 250° C. with anhydrous zinc chloride (250 mg.)until ammonia evolution ceased (1 hr.). The dark brown product wasfractionated under reduced pressure to give 3. Repeatedrecrystallisation from cyclohexane gave 3 as colourless needles. Yieldover 2 steps: 19% HRMS calc: 161.1079; found 161.1085.

Synthesis of Compound 5

Compound 3 (130 mg) and 4 (500 uL), were placed in a sealed tube at 70°C. and stirred for 36 h. The reaction mixture was cooled down and ethylacetate was added to give rise to a precipitate. The solid was separatedby centrifugation. The solid was resuspended by means of sonication andcentrifuged to isolated the solid. The procedure was repeated 3 times toobtain a pale pink solid. Yield 77%. HRMS calc: 297.1273; found297.1281.

Synthesis of Compound 6

Compound 3 (180 mg) and methyl iodide (210 uL), were placed in acetonein a two necks flask under reflux and stirred for 2 h. The reactionmixture was cooled down and ethyl acetate was added to give rise to aprecipitate. The solid was separated by centrifugation. The solid wasresuspended by means of sonication and centrifuged to separate thesolid. The procedure was repeated 3 times to obtain a pale yellow solid6. Yield 93%. HRMS calc: 175.1235; found 175.1236.

Synthesis of Compound 7

Compound 3 (200 mg) and 6-bromo hexanoic acid (731 mg), were dissolvedin DMF (1 ml) in a sealed tube and warmed up to 120° C. for 2 h. Thereaction mixture was cooled down and ethyl acetate was added to giverise to a precipitate. The solid was separated by centrifugation. Thesolid was resuspended by means of sonication and centrifuged to isolatethe solid. The procedure was repeated 3 times to obtain a red solid.Yield 95%. HRMS calc: 275.1760; found 275.1766.

Synthesis of Compound 10

Hydrazin derivative (8) (1.0 g.), isopropyl methyl ketone (540 mg.),were placed at 130° C. and stirred for 4 h under nitrogen. Dilute themixture with water and decant. Add NaOH 1M until ph 8 and formation of abrownish precipitate. Extract the solid with ethyl acetate 3 times.Yield 37%, HRMS calc: 211.1235; found 211.1236.

Synthesis of Compound 11

Compound 10 (130 mg) and 4 (500 uL), were placed in a sealed tube at 70°C. and stirred for 36 h. The reaction mixture was cooled down and ethylacetate was added to give rise to a precipitate. The solid was separatedby centrifugation. The solid was resuspended by means of sonication andcentrifuged to isolated the solid. The procedure was repeated 3 times toobtain a pale grey solid. Yield 55%. HRMS calc: 347.1431; found347.1431.

Synthesis of Compound 12

Compound 10 (180 mg) and methyl iodide (210 uL), were placed in acetonein a two necks flask under reflux and stirred for 4 h. The reactionmixture was cooled down and ethyl acetate was added to give rise to aprecipitate. The solid was separated by centrifugation. The solid wasresuspended by means of sonication and centrifuged to separate thesolid. The procedure was repeated 3 times to obtain the red solid 12.Yield 71%. HRMS calc: 225.1392; found 225.1394.

Synthesis of Compound 15

A solution of DMF (1.8 ml, 23.39 mmol) and dichloromethane (1.8 ml) wascooled in ice with stirring under nitrogen. Phosphorous oxychloride(2.68 g, 17.50 mmol) in dichloromethane (1.8 ml) was added dropwise over10 min. 1-Methylpiperidin-4-one 13 (0.5 g, 4.41 mmol) was added dropwiseover 10 min. The solution turned yellow. The mixture was heated at 70°C. for 3 h and become orange. The reaction mixture was cooled down andpoured over cold water (10 ml). Solution was concentrated under vacuumand the yellow residue was washed twice with ether and air dried toobtain compound 14. Yield: 0.52 g, (62%). ¹H NMR (400 MHz, DeuteriumOxide) 8.89 (s, 1H), 5.38 (s, 1H), 4.30 (d, J=14.9 Hz, 2H), 3.83 (d,J=14.9 Hz, 2H), 2.94 (s, 3H).

An ethanol solution (2.8 ml) of aniline (0.56 ml, 6.11 mmol) was slowlyadded into a solution of 14 (0.5 g, 2.66 mmol) in DMF (1.84 ml) and HCl(0.69 ml). The reaction temperature was maintained around 10-15° C. withan ice-water bath during the addition of aniline. After the reactionmixture was stirred for an additional 20 minutes, it was poured, withstirring, into 75 ml of diethyl ether. The deep-purple solid wascollected by filtration and washed twice with cold water, washed twicewith ether and then dried under vacuum at ambient temperature overnight.Product 15 was obtained as purple solid in 75% yield (0.79 g). ¹H NMR(400 MHz, Deuterium Oxide) δ: 8.08 (s, 1H), 7.77-6.87 (m, 10H), 4.42 (d,J=13.7 Hz, 1H), 4.23 (d, J=15.0 Hz, 1H), 3.98 (d, J=13.8 Hz, 1H), 3.80(d, J=14.9 Hz, 1H), 2.98 (s, 3H). ESI-QTOF MS m/z (C20H21Cl₂N3)calculated: 373.1113, found: [M-Cl]⁻=338.1424. HRMS calc: 338.1424;found 338.1422.

Synthesis of Compound 16

15 (0.075 g, 0.20 mmOI) and methyl iodide (0.433 g, 3.05 mmol) wereplaced into a seal tube in dry methanol (6 ml) under N₂. The reactionmixture was heated at 40° C. for 28 h. The solvent was removed undervacuum and the product was washed twice with ether, and precipitatedfrom methanol/ether. Product 16 was obtained as a red burgundy solid in84% yield (0.086 g). ESI-QTOF MS m/z (C21H24Cl₂IN3) calculated:515.0392, found C₂₁H₂₂N₃Cl [M]+=352.1581.

Synthesis of Compound 18

Compound 17 (1g) and 6-bromo-hexanoic acid (1g), were placed undernitrogen in a microwave flask and dissolved in nitromethane (2 ml). Thereaction mixture was microwave for 2 hours at 110° C., 300 W. Ethylacetate was added to give rise to a precipitate. The solid was separatedby centrifugation. The solid was resuspended by means of sonication andcentrifuged to separate the solid. The procedure was repeated 3 times toobtain a grey solid 18. Yield 95%. ¹H NMR (400 MHz, Methanol-d₄) δ: 8.35(d, J=8.5 Hz, 1H), 8.27 (d, J=9.0 Hz, 1H), 8.19 (d, J=8.3 Hz, 1H), 8.03(d, J=8.9 Hz, 1H), 7.79 (dt, J=34.2, 7.5 Hz, 2H), 4.66 (t, J=7.8 Hz,2H), 2.38 (t, J=7.1 Hz, 2H), 2.19-1.96 (m, 2H), 1.87 (s, 6H), 1.75 (p,J=7.3 Hz, 2H), 1.60 (tt, J=9.7, 6.1 Hz, 2H). HRMS calc: 324.1985; found324.1983.

Synthesis of Compound 20

Compound 19 (0.5 g, 1.72 mmol) was dissolved in methanol (45 ml), then asolution of KOH (0.145 g, 2.59 mmol) in 2-propanol was added to themixture. The reaction mixture was stirred for 2 hours at r.t. under N₂.Solvent was evaporated under reduced pressure without dryness and thesolid was filtered off and dried under vacuum providing a pinkish solid(0.5 g, 90%). Product was used to the next step without furtherpurification.

1,1,2-Trimethyl-1H-benzo[e]indole-7-sulfonate potassium salt (0.5 g,1.52 mmol) and 6-bromohexanoic acid (0.38 g, 1.98 mmol) in1,2-dichlorobenzene (5 ml) were heated at 110° C. under nitrogenatmosphere for 48 h. After the mixture was cooled down, solvent wasdecanted and the solid was triturated with 2-isopropanol (50 ml). Thesolid was collected through filtration, washed with EtOAc (3×25 ml) anddried under vacuum overnight to give 0.48 g of a grey solid (78%) ofcompound 20. ¹H NMR (400 MHz, DMSO-d₆) δ: 8.54-8.25 (m, 3H), 8.13 (d,J=8.8 Hz, 1H), 7.96 (d, J=8.8 Hz, 1H), 4.57 (t, J=7.6 Hz, 2H), 2.93 (s,3H), 2.24 (t, J=7.2 Hz, 2H), 1.91 (p, J=7.8 Hz, 2H), 1.75 (s, 6H),1.66-1.36 (m, 4H).

Synthesis of Compound 22

Thionyl chloride (2.8 ml, 38.45 mmol) was slowly added to methanol in anice bath. A solution of bromohexanoic acid (1.5 g, 7.69 mmol) inmethanol was added to the solution of thionyl chloride. The reactionmixture was stirred at 40° C. for 6 h. The solvent was evaporated givingthe methyl-6-bromohexanoate (1.5 g, 94%) as yellow oil. Product was usedwithout further purification to the next step. ¹H NMR (400 MHz,Chloroform-d) δ: 3.69 (s, 3H), 3.42 (t, J=6.7 Hz, 2H), 2.35 (t, J=7.4Hz, 2H), 1.89 (p, J=7.0 Hz, 2H), 1.68 (p, J=7.5 Hz, 2H), 1.58-1.39 (m,2H).

To a solution of 4-piperidone (0.125 g, 1.26 mmol) in anhydrous DMF (2ml), K₂CO₃ (0.2 g, 1.51 mmol), 21 (0.52 g, 2.48 mmol) and KI (0.015 g,0.090 mmol) were added to the mixture. The reaction mixture was stirredat r.t. for 36 hours under N₂. The reaction mixture was filtered off andfiltrate was concentrated and dried under vacuum providing a white solid(0.29 g, 98%) of compound 22. Product was used without furtherpurification to the next step. ¹H NMR (400 MHz, Chloroform-d) δ: 3.64(d, J=2.0 Hz, 3H), 3.38 (t, J=6.7 Hz, 2H), 2.70 (t, J=6.2 Hz, 2H), 2.42(t, J=6.8 Hz, 4H), 2.30 (t, J=7.4 Hz, 4H), 1.85 (p, J=7.0 Hz, 2H),1.70-1.56 (m, 4H).

Synthesis of Compound 24

Phosphorus oxychloride (0.1 ml) was added to cooledN,N-dimethylformamide (0.12 ml) at 0° C. The temperature was maintainedat 0° C. Stirring was continued for another 30 minutes before theaddition of 22 (0.12 g, 0.52 mmol). The mixture was then stirred at roomtemperature for 4 hours before it was poured into water (5 ml),concentrated and washed twice with ether affording a yellow oil (0.16 g,88%). After dried under vacuum overnight the crude product was useddirectly in the next reaction without further purification.

A solution containing aniline (0.062 g, 0.66 mmol) was dissolved inethanol (0.32 ml) was slowly added into a solution containing 23 (0.09g, 0.29 mmol) in DMF (0.2 ml) and concentrated hydrochloric acid (0.075ml). The reaction temperature was maintained around 10-15° C. with anice-water bath during the addition of aniline. After the reactionmixture was stirred for an additional 30 minutes, it was poured, withstirring, into 75 ml of ether. The deep-brown solid was collected byfiltration and washed twice with cold water, and then dried under vacuumat ambient temperature overnight. Yield: 0.12 g, 80%. ESI-QTOF MS m/z(C₂₆H₃₁Cl₂N₃O₂) calculated: 487.1793 found: [M−Cl]+=452.2104.

Synthesis of Compound 25

Compound 24 was (0.07 g, 0.137 mmol) dissolved in water, and HCl wasadded to the mixture. Reaction was stirred at room temperature for 18hours. The solution was concentrated to dryness, and residue was washedseveral times with acetone to provide a red solid of compound 25.ESI-QTOF MS m/z (C25H29Cl2N3O2) calculated: 473.1637, found[M−Cl]−=438.1956. Yield: 0.045 g.

Synthesis of Dye I

Compound 6 (10 mg) and 15 (2.8 mg), were placed in a sealed tube anddissolved in ethanol. Sodium acetate (5.4 mg) was added and the reactionstirred for 4 h at 70° C. The solvent was removed by rotavap and thecrude separate by C4 column HPLC Agilent semi-prep. A dark blue-greenprecipitate was isolated. Compound I obtained in 91% yield. HRMS calc:500.2579; found 500.2576.

Synthesis of Dye II

Compound 5 (10 mg) and 15 (2.8 mg), were placed in a sealed tube anddissolved in ethanol. Sodium acetate (5.4 mg) was added and the reactionstirred for 4 h at 70° C. The solvent was removed by rotavap and thecrude separate by C18 HPLC Agilent semi-prep. A dark blue-greenprecipitate was isolated. Compound II obtained in 83% yield. HRMS calc:742.2500; found 742.2515.

Synthesis of Dye III

Compound 7 (16.7 mg) and 15 (5 mg), were placed in a sealed tube anddissolved in ethanol. Sodium acetate (9.8 mg) was added and the reactionstirred for 4 h at 70° C. The solvent was removed by rotavap and thecrude separate by C4 HPLC Waters semi-prep. A dark blue solid wasisolated. Compound III obtained in 75% yield. HRMS calc: 700.3641; found700.3624.

Synthesis of Dye IV

A mixture of 18 (43 mg, 0.10 mmol), 15 (20 mg, 0.053 mmol) and sodiumacetate (15 mg, 0.19 mmol) was dissolved in 6 ml of ethanol. Afterstirring at room temperature for 4 hours under N₂, the solvent wasremoved under reduced pressure. The residue was dissolved indichloromethane and filtered to remove the excess of sodium acetateaffording a dark green solid. Crude product was purified by HPLC (WatersRP-C18) to afford the corresponding compound IV as green solid (10 mg,25%). ESI-QTOF MS m/z (C50H57ClN3O4) calculated: 798.4032, found:[M]+=798.4037.

Synthesis of Dye V

A mixture 20 (40 mg, 0.09 mmol), 15 (17 mg, 0.045 mmol) and sodiumacetate (18 mg, 0.22 mmol) was dissolved in 6 ml of ethanol. Afterstirring at room temperature for 9 hours under N₂, the solvent wasremoved under reduced pressure. Crude product was purified by HPLC(Waters RP-C18) to afford the corresponding compound V as green solid (9mg, 25%). ESI-QTOF MS m/z (C50H55ClN3O10S2) calculated: 956.3023, found:[M]+=956.2997.

Synthesis of Dye VI

A mixture of 7 (40 mg, 0.11 mmol), 16 (15 mg, 0.029 mmol) and sodiumacetate (24 mg, 0.28 mmol) was dissolved in ethanol (5 ml). Reactionmixture was stirred at 70° C. for 7 hours under N₂, the solvent wasremoved under reduced pressure. Crude product was purified by HPLC(Waters RP-C18) to afford the corresponding compound VI as green solid(6 mg, 25%). ESI-QTOF MS m/z (C41H54ClN5O4) calculated: 842.2904, found:[M−I/2]⁺=357.6933.

Synthesis of Dye VII

7 (42 mg, 0.12 mmol), and 5 (35 mg, 0.12 mmol) were first dissolved inethanol (5 ml) under N₂ and stirred for 5 min, then 15 (20 mg, 0.048mmol) and sodium acetate (39 mg, 0.48 mmol) were added into thesolution. Reaction mixture was stirred at 70° C. for 7 hours under N₂,the solvent was removed under reduced pressure. Crude product waspurified by HPLC (Waters RP-C18) to afford the corresponding compoundVII as green solid (8 mg, 24%). Formation of symmetric dyes was observedbut they were not isolated. ESI-QTOF MS m/z (C₃₈H₄₈ClN₅O₅S) calculated:721.3065, found: [M]⁺=722.3134.

Synthesis of Dye VIII

Dye I (20 mg, 0.038 mmol) and methyl iodide (0.22 g, 1.6 mmol) wereplaced into a seal tube in dry methanol (4 ml) under N₂. The reactionmixture was heated at 40° C. for 3 h. The solvent was removed undervacuum and the product was washed twice with ether. Crude product waspurified by HPLC (Waters RP-C18) to afford the corresponding compound asgreen solid (6.5 mg, 29%). ESI-QTOF MS m/z (C31H38ClN5) calculated:642.1855, found: [M−I/2]⁺=257.6408.

Synthesis of Dye IX

Dye V (5 mg, 0.005 mmol) and 1-cyclohexylpiperazine (4.5 mg, 0.026 mmol)were dissolved in dry DMF (0.5 mL) and the solution was stirred at roomtemperature for 16 h. The solution color gradually changed from green todeep blue. The solvent was removed under vacuum and the product waswashed twice with diethyl ether, and precipitated from methanol/ether.Purification was carried out by C8 HPLC (Agilent) to afford compound IXas dark blue solid (2.2 mg, 39%). ESI-QTOF MS m/z (C₆₀H₇₄N₅O₁₀S₂)calculated: 1088.4883 915.5783, found: [M]⁺=1088.5243.

Synthesis of Dye X

A mixture of 18 (40 mg, 0.099 mmol), 16 (20 mg, 0.048 mmol) and sodiumacetate (20 mg, 0.24 mmol) were dissolved in 6 ml of ethanol. Afterstirring at room temperature for 2 hours under N₂, the solvent wasremoved under reduced pressure. The residue was dissolved indichloromethane and filtered to remove the excess of sodium acetateaffording a dark green solid. Crude product was purified by HPLC (WatersRP-C18) to afford the corresponding compound as green solid (8 mg, 21%).ESI-QTOF MS m/z (C57H66IN4O4) calculated: 997.4123, found:[M−I]+=871.1780.

Synthesis of Dye XI

Compound 26 (365 mg, 1.33 mmol) and 15 (100 mg, 0.2.65 mmol) and sodiumacetate (209 mg, 2.65 mmol) were placed into a sealed tube in dryethanol (8 mL) under N₂. The reaction mixture was heated at 110° C.during 30 min. Solvent was removed under reduced pressure and the crudeproduct was separated by HPLC (Waters 2998, Photodiode Array Detector,column: XTerra® Prep MS C₁₈OBD™ Column, 5 μm, 19×50 mm). Compound XI,was obtained in 20% yield (26 mg). HRMS calc: 714.3781; found 357.185.

Synthesis of Dye XII

Dye XI (13 mg, 0.018 mmol) and methyl iodide (0.1 mL, 1.6 mmol) wereplaced into a seal tube in dry methanol (2 ml) under N₂. The reactionmixture was stirred at rt. for 2 h. The solvent was removed under vacuumand the product was washed twice with ether affording a green solid.LCMS confirm the purity and formation of compound XII. Crude product wasused to the next step without further purification. LRMS m/z(C₄₂H₅₆ClN₅O₄) calculated: 856.306, found: [M−I/2]⁺=364.70.

Synthesis of Dye XIII

In a dry 25 mL flask under N₂ was added 4-hydroxybenzene sulfonate (17.2mg, 0.087 mmol) and sodium hydride (4.2 mg, 0.175 mmol) in anhydrous DMF(0.8 mL). The reaction mixture was stirred at room temperature for 1.5 hunder N₂. Chloro dye XII (15.0 mg, 0.017 mmol) dissolved in anhydrousDMF (1.0 mL) was then added to the reaction mixture, and stirredovernight under N₂. Reaction progress was monitored by LC-MS. Solventwas removed under reduced pressure. The crude product was purified byHPLC (Waters 2998, Photodiode Array Detector, column: XTerra® Prep MSC₁₈OBD™ Column, 5 μm, 19×50 mm) to obtain dye 5.09 mg of the pure dyeXIII (32% yield). FTMS m/z (C48H60IN5NaO8S) calculated: 1016.3099,found: [M−I/2]⁺=444.7026.

Synthesis of Compound XIV

In a dry 25 mL flask under N₂ was added 4-hydroxybenzene sulfonate (18mg, 0.094 mmol) and sodium hydride (4.5 mg, 0.188 mmol) in anhydrous DMF(1 mL). The reaction mixture was stirred at room temperature for 1.5 hunder N₂. Chloro dye VI (16.0 mg, 0.018 mmol) dissolved in anhydrous DMF(1.5 mL) was then added to the reaction mixture, and stirred for 3 daysunder N₂. Reaction progress was monitored by LC-MS. Solvent was removedunder reduced pressure. The crude product was purified by HPLC (Waters2998, Photodiode Array Detector, column: XTerra® Prep MS C₁₈OBD™ Column,5 μm, 19×50 mm) to obtain dye 6.5 mg of the pure dye XIV (32% yield).ESI-QTOF-MS m/z (C47H58IN5NaO8S) calculated: 1002.29, found:[M−I−Na/2]+=426.7054.

Synthesis of Dye XV

Dye V (8 mg, 0.0083 mmol) and methyl iodide (0.05 mL) were placed into aseal tube in dry methanol (2 ml) under N₂. The reaction mixture wasstirred at rt. for 4 h. The solvent was removed under vacuum and theproduct was washed twice with ether affording a green solid. LCMSconfirm the purity and formation of compound XV. Crude product was usedto the next step without further purification. LRMS m/z(C₅₀H₅₈ClIN₃O₁₀S₂) calculated: 1098.230, found: [M−I/2]+=971.33.

Synthesis of Dye XVI

In a dry 25 mL flask under N₂ was added 4-hydroxybenzene sulfonate (30mg, 0.152 mmol) and sodium hydride (7.4 mg, 0.308 mmol) in anhydrous DMF(1 mL). The reaction mixture was stirred at room temperature for 1.5 hunder N₂. Chloro dye XV (17.0 mg, 0.015 mmol) dissolved in anhydrous DMF(1.5 mL) was then added to the reaction mixture, and stirred overnightunder N₂. Reaction progress was monitored by LC-MS. Solvent was removedunder reduced pressure. The crude product was purified by HPLC (Waters2998, column: XTerra® Prep MS C18OBD™ Column, 5 μm, 19×50 mm) to obtaindye 5.8 mg of the pure dye XVI (30% yield). LRMS m/z (C₅₇H₆₂IN₃NaO₁₄S₃)calculated: 1258.23, found: [M−I−Na]=1109.33.

Synthesis of Dye XVII

To a solution of tyramine (15 mg, 0.1 mmol) in DMF (1 mL) under N₂, wasadded TEA (22 mL, 0.159 mmol) followed by Boc anhydride (35 mg, 0.159mmol), and the reaction mixture was stirred for 2 h. To the abovesolution under N₂, was then added NaH (2.4 mg, 0.1 mmol) and the mixturewas stirred for 1 h. Finally the chloro dye VI was added to the reactionmixture under N₂, and the mixture was stirred for 48 h. Reaction wasmonitored by LCMS until disappearance of the chloro dye. The solventswere evaporated from the reaction mixture at 60° C., and the residue wasredissolved in a mixture of DCM/TFA (0.6 mL, 1:1). The reaction mixturewas stirred for 2.5 h, and then concentrated under reduced pressure.Crude sample was purified by HPLC (Waters RP-C18) to obtain 3 mg of XVIIas green solid (44% yield). LRMS m/z (C₄₉H₆₅IN₆O₅) calculated: 944.4050,found: [M−I/2]=408.70.

Synthesis of Dye XVIII

5 (46 mg, 0.158 mmol) was dissolved in ethanol (3 ml) under N₂ andstirred for 5 min, then 25 (15 mg, 0.031 mmol) and sodium acetate (25mg, 0.31 mmol) were added into the solution. Reaction mixture wasstirred at 70° C. for 7 hours under N₂, the solvent was removed underreduced pressure. Crude product was purified by HPLC (Waters RP-C18) toafford the corresponding compound as dark green solid (6 mg, 25%).ESI-QTOF MS m/z (C₄₁H₅₃ClN₅O₈S₂) calculated: 842.3030, found:[M]⁺=843.3156.

Synthesis of Dye XIX

Dye XVIII (3 mg, 0.0035 mmol), dry DMF (1 mL), and DIPEA (1.5 μl, 0.0070mmol) were added and mixture stirred at room temperature under N₂, thenTSTU (1.6 mg, 0.0053 mmol) was added, and the resulting mixture wasprotected from light and stirred at room temperature for 3 h. Thereaction was checked for completion by RP-HPLC (Waters), and theresulting succinimidyl ester XIX. LRMS=(C₄₅H₅₆ClN₆OS₂) calculated:939.3193, found MS: 939.4.

Synthesis of Dye XX

Dye XIII (3.0 mg, 0.0029 mmol) was dissolved in dry DMF (1 mL) under N₂,and DIPEA (2.52 μL, 0.014 mmol) was added to the solution. The mixturewas stirred at room temperature for 30 min. To the above solution underN₂ was then added TsTU (2.27 mg, 0.0074 mmol). The reaction mixture wasstirred for 3 h and monitored by LC-MS to confirm formation of NH-ester.After 3 h, peptide c(RGDfK) (6.24 mg, 0.01 mmol) in DMF (0.4 mL) andDIPEA were added to the reaction mixture. The reaction was stirred for18 h, while monitoring by LC-MS. Solvent was removed by reduced pressureand the product was purified by HPLC (Waters 2998, Photodiode ArrayDetector, column: XTerra® Prep MS C₁₈OBD™ Column, 5 μm, 19×50 mm) toobtain a pure target product XX in 60% yield (2.48 mg). FTMS m/z(C₇₅H₉₉IN₁₄NaO₁₄S) calculated: 1601.6123, found: [M−I−Na+H/2]+=726.3640.

Synthesis of Dye XXI

Dye XIV (3.0 mg, 0.003 mmol) was dissolved in dry DMF (1 mL) under N₂,and DIPEA (2.55 μL 3.5 equiv) was added to the solution. The mixture wasstirred at room temperature for 30 min. To the above solution under N₂was then added TsTU (3.1 mg, 0.01 mmol). The reaction mixture wasstirred for 3 h and monitored by LC-MS to confirm formation of NH-ester.After 4.5 h, peptide derivative c(RGDfK) (9 mg, 0.015 mmol) in DMF (1mL) were added to the reaction mixture. The reaction was stirred for 24h, while monitoring by LC-MS. Solvent was removed by reduced pressureand the product was purified by HPLC (Waters 2998, Photodiode ArrayDetector, column: XTerra® Prep MS C₁₈OBD™ Column, 5 μm, 19×50 mm) toobtain a pure target product XXI in 62% yield (4 mg). FTMS m/z(C₁₀₁H₁₃₆IN₂₃NaO₂S) calculated: 2172.8990, found: [M−I−Na/2]+=1012.5097.

Synthesis of Dye XXII

Dye III (2 mg, 0.0028 mmol) in dry DMF (1 mL), and DIPEA (3 μl. 0.014mmol) were added and mixture stirred at room temperature under N₂, thenTSTU (1.9 mg, 0.0063 mmol) was added, and the resulting mixture wasprotected from light and stirred at room temperature for 3 h. Thereaction was checked for completion by HPLC-MS (Agilent). 2RGDderivative (7.8 mg, 0.00589 mmol) and DIPEA (3 μl, 0.014 mmol) wereadded and mixture stirred at room temperature under N₂. The reaction waschecked for completion by HPLC-MS (Agilent). The solvent was removedunder reduced pressure. Crude product was purified by HPLC (WatersRP-C18) to afford the corresponding compound XXII as dark green solid (5mg, 53%).

Synthesis of Compound XXIII

Compounds 11 and 7 are dissolved in ethanol under N₂, then compound 15and sodium acetate are added into the solution. Reaction mixture isheated at 70° C. under N₂, The solvent is removed under reducedpressure, and crude product is purified by HPLC to afford thecorresponding asymmetrical compound XXIII.

Synthesis of Compound XXIV

Compounds 20 and 5 are dissolved in ethanol under N₂, then compound 15and sodium acetate are added into the solution. Reaction mixture isheated at 70° C. under N₂, The solvent is removed under reducedpressure, and crude product is purified by HPLC to afford thecorresponding asymmetrical compound XXIV.

Synthesis of Compound XXV

Dye II and 4-iodobut-1-yne are placed into a seal tube in dry methanolunder N₂. The reaction is stirred at r.t. The solvent is removed undervacuum and crude product is purified by HPLC to afford the correspondingcompound XXV.

Synthesis of Compound XXVI

Compounds 11 and 20 are dissolved in ethanol under N₂, and then compound15 and sodium acetate are added into the solution. Reaction mixture isheated at 70° C. under N₂, The solvent is removed under reducedpressure, and crude product is purified by HPLC to afford thecorresponding asymmetrical compound XXVI.

Preparation of IgG Bioconjugate XXVIII

The corresponding antibody was diluted with 2× volume of 0.1 M NaHCO₃(pH 8.5). 25 equivalents of fluorescent NHS dye XXVII (from 10 mM stocksolution in DMSO) was added to the antibody solution and gently shackedin dark at room temperature for 2 hours. After incubation, antibody waspurified by centrifuge filtration using desalting Zeba spin column 7Kand stored in PBS at 4° C. affording bioconjugate XXVIII. The number offluorophores per antibody was determined by spectrophotometric analysisand determined to be approximately 2-3 fluorescent dyes per antibody.

Synthesis of Compound XXVIX

DOTA is attached in a chemical reaction to compound VIII shown againbelow. The reaction starts from Compound VIII shown below.

Compound VIII can be functionalized with a group containing a benzenethiol, such as 4-aminobenzenthiol, or 2-(4-mercaptophenyl)acetic acid,shown below.

These compounds react readily in Dimethylformamide (DMF) at roomtemperature under a nitrogen atmosphere, as shown in the reactiondiagram below. Dye A was dissolved in dry DMF and placed under nitrogenwhile stirring. The appropriate thiol was 20 added to a dry vial, anddissolved in dry DMF before being added to the solution.¹ The resultingcompounds were seen on an HPLC-MS to have m/z values of 302 and 324,corresponding to the values of [M⁺/2] for the amine-functionalized andcarboxylate compounds respectively.

The amine-functionalized Compound VIII is coupled to1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) modifiedto contain a N-Hydroxysuccinimide functional group as shown in reactiondiagram 2. This reaction is completed by using the functionalizedCompound VIII and the N-hydroxysuccinimide ester form of DOTA, which iscommercially available, in the presence of 4 equivalents ofN,N-Diisopropylethylamine (DIPEA) at room temperature in a nitrogenatmosphere.

Radiolabeling of the DOTA-Compound VIII conjugate can be accomplishedaccording to literature,² using a 0.25M ammonium acetate buffer with apH of 7.0 at 37° C. for Indium-111, which is added to the solution in0.4N hydrochloric acid and stirred for 45 minutes. Other metal chelatesbehave in a similar fashion for chelation procedures. The example ofIndium-111 chelation is shown reaction diagram 3

Since Compound VIII is also an efficient fluorescent reagent, thisconjugate can be used for optoacoustic, near-infrared imaging (600-900nm) and shortwave infrared (SWIR II) range of wavelengths from 0.9 to1.7 microns (see more details below). This molecule could also beenvisioned for radiotherapy applications for local tumor irradiationwhen chelated to radioisotopes such as Lutetium or Yttrium (¹⁷⁷Lu, ⁹⁰Y)

Optical Property Analyses

All optical measurements were performed at 37° C. in methanol in 10 mmspectrofluorometric quartz cuvettes with C ˜10⁻⁶ M. Perkin Elmer Lambdaspectrophotometer was used to record UV/Vis/NIR spectra. Forfluorescence quantum yield (QY) measurements, ICG in methanol (QY 7.8%)was used as a calibration standard under conditions of matchedabsorbance at 770 nm. As shown in FIG. 1A-9B a range of compounds werefound to exhibit substantial absorbance at the 800 nm wavelength. Thesecompounds exhibited a variety of emission wavelengths ranging from about800 to about 900 nm. Especially

FIG. 1A and FIG. 1B show absorption and fluorescence spectra, andquantum yield QY of Compound I.

FIG. 2A and FIG. 2B show absorption and fluorescence spectra, and QY ofCompound II.

FIG. 3A and FIG. 3B show absorption and fluorescence spectra, and QY ofCompound III.

FIG. 4A and FIG. 4B show absorption and fluorescence spectra, and QY ofCompound IV.

FIG. 5A and FIG. 5B show absorption and fluorescence spectra, and QY ofCompound V.

FIG. 6A and FIG. 6B show absorption and fluorescence spectra, and QY ofCompound VI.

FIG. 7A and FIG. 7B show absorption and fluorescence spectra, and QY ofCompound VII.

FIG. 8A and FIG. 8B show absorption and fluorescence spectra, and QY ofCompound VIII.

FIG. 9A and FIG. 9B show absorption and fluorescence spectra, and QY ofCompound IX.

Evaluation of XXVIII for In Vivo Fluorescence Imaging

Female nude mice 6-8 weeks of age were injected with IM of 4T1 cells in100 ul of PBS subcutaneously into the right flank. Once the tumorsreached approximately 0.5 cm³ in size, animals were injected with 0.7nmol of antibody conjugate XXVIII intravenously in 100 ul of PBS. Micewere then imaged at different time points using IVIS Spectrum instrument(Perkin Elmer) at recommended settings 745/810 nm excitation/emission.Three representative mice bearing an established 4T1-luc2 tumoursimplanted subcutaneously into the right flank were injected with theindicated imaging agent. FIG. 10A: Mice were imaged by IVIS Spectrum toshow tumour localization and FIG. 10B: NTR fluorescence images to showspecific biomarker detection, after intravenously receiving 0.7 nmol ofantibody conjugate XXVIII.

Evaluation of XXI for In Vivo Fluorescence Imaging

Female nude mice 6-8 weeks of age were injected with 1M of 4T1 cells in100 ul of PBS subcutaneously into the right flank. Once the tumorsreached approximately 0.5 cm³ in size, animals were injected with 20nmol of the imaging probe XXI intravenously in 100 ul of PBS. Mice werethen imaged at different time points using IVIS Spectrum instrument(Perkin Elmer) at recommended settings 745/810 nm excitation/emission.FIG. 11 shows NIR fluorescence images of 4T1-luc2 tumour bearing mice atthe indicated time points after intravenous injection of probe XXI,IntegriSense™ 750, and RGD-ICG. FIGS. 12 A and 12 B show the optimalbackground/noise ratio calculated from the region of interest of 4T1tumour bearing mice at 2 h post injection of probe XXI (FIG. 12A) and 24h post injection of IntegriSense™ 750 (FIG. 12B).

Evaluation of XXI for Fluorescence Image-Guided Surgery

Example 1: A kuvasz dog (male, 30 kg) diagnosed with mastocytoma tumoron his right leg was used for image guided surgery study. All caninestudies were performed at Veterinair Verwijscentrum Gouda, Netherlands.Canine was injected intravenous catheterization into the cephalic veinwith fluorescence probe XXI (180 nmol/kg) 6 h prior to surgery. Canineunderwent to general anesthesia prior to surgery. Image guided cancersurgery was performed using Solaris Open-air Fluorescence Imaging System(Perkin Elmer), equipped with four fluorescent channels (470 nm, 660 nm,750 nm and 800 nm) to obtain real-time visualization of tumor imaging inambient light FIG. 13A shows I.V. catheter injection in a 30 kg dog 6 hbefore surgery with 180 nmol/kg of probe XXI, and FIG. 13B showslocalization of mastocytoma tumour in dog's right leg. FIG. 14A showsfluorescence image-guided surgical procedure of mastocytoma tumourresection. A mastocytoma tumour (solid arrow) is clearly identified by arim around the tumor in vivo, 6 h after injection of probe XXI. Normaltissue (dashed arrow) shows negligible background uptake of probe XXI.The enhanced ability to visualize tumor margins in fluorescenceimage-guided surgery led to more complete resection of the tumor (rounddot arrow), and FIG. 14B shows occult malignant lesion. FIG. 15A showsno apparent fluorescence from residual tumour could be observed afterthe operation, and FIG. 15B shows after resection carried out under theguidance of fluorescent light and slicing of the same specimen, the rimaround the tumor can be visualized ex vivo.

Example 2: A labrador dog (male, 33 kg) diagnosed with mastocytoma tumoron his nose was used for image guided surgery study. All canine studieswere performed at Veterinair Verwijscentrum Gouda, Netherlands. Caninewas injected intravenous catheterization into the cephalic vein withfluorescence probe XXI (92 nmol/kg) 10 h prior to surgery. Canineunderwent to general anesthesia prior to surgery. Image guided cancersurgery was performed using Solaris Open-air Fluorescence Imaging System(Perkin Elmer), equipped with four fluorescent channels (470 nm, 660 nm,750 nm and 800 nm) to obtain real-time visualization of tumor imaging inambient light FIG. 16A shows I.V. catheter injection in a 33 Kg dog 10 hbefore surgery with 92 nmol/kg of probe XXI, and FIG. 16B showslocalization of mastocytoma tumour in dog's nose FIG. 17A showsfluorescence image-guided surgical procedure of dog's mastocytoma tumourand FIG. 17B shows after resection carried out under the guidance offluorescent light and slicing of the same specimen, the rim around thetumor can be visualized ex vivo.

Imaging Necrosis

Ex vivo cell death assay for compounds, VI and XIV were studied using amethod of cryogenic tissue damage. Briefly, a bar of a dry ice wasapplied to sliced skin tissue of a nude mouse recently sacrificed in apetri dish for a period of 60 sec. Subsequently, the skin tissue sampleswere incubated with different concentrations of dye VI and XIV (1 uM, 5uM, and 10 uM) for 10 min at room temperature. After gentle washing withPBS, the samples were scanned for fluorescence using an IVIS Spectrumimaging system FIG. 18A shows cryogenic tissue damage with dye VI, thecells at the site of focal dry-ice treatment showed strong fluorescencesignal whereas no signal was obtained from the viable cells, and FIG.18B shows total photon flux of treated cells at differentconcentrations. FIG. 19A shows cryogenic tissue damage with dye XIV,fluorescence of the dye XIV showed strong accumulation of fluorescenceat the site of focal dry-ice treatment in the cryogenic tissue, and FIG.19B shows total photon flux of treated tissue at differentconcentrations.

Evaluation of VIII for Necrosis Imaging:

Compound VIII has been shown to selectively target necrotic tissue invivo. Cardiotoxin (10M in 50 μL of PBS) was injected into the rightthigh of the mouse and 50 μL of PBS was injected into the left thigh. 24hours post-injection of toxin, Compound VIII (40 μmoles in 100L PBS) wasinjected intravenously into the tail of the mouse. The results show thatthe dye selectively targets the necrotic area and clears through thekidneys instead of accumulating in the liver. The results are shownbelow in FIG. 20-22. The brightnesses of the images are not on scalewith one another. The quantification is shown on the same graph.Significant signal over-background ratios resulting from accumulation ofthe dye in necrosis areas observed as early as 10 min post-injection ofthe Compound VIII making it ideal for clinical translation.

Cell Uptake:

It is important that necrosis-targeting compound does not demonstrateany binding to or uptake by live cells and selectively only binds tonecrotic cells. This should significantly minimize unwanted side effectswhen used in patients.

Therefore, we performed such experiments in live cells with CompoundVIII compound. No uptake of Compound VIII was observed in live A431cells even at long incubation periods (30 min) at rather highconcentrations (25 uM). The following procedure was used:

Cells were grown in 96 well plates to confluent level. Media wasremoved, cells washed with PBS, incubated for a set time (5, 15, or 30minutes) at varying concentrations of the dye (5 μM, 10 uM, and 25 μM)in PBS. Dye was removed, cells washed twice with PBS, then PBS added forimaging.

The values for each well were consistent with that of the control groupof wells that were not exposed to the dye in wells A1-A3. The brightwell at F12 is a solution of Compound VIII at 5 μM in PBS to insureimaging of the dye is occurring. The wells from B1-C10 are cells thatwere incubated with the dye; these wells were individually selected, andthe radiance was compared to that of the control, with no significantdifference between the groups. The image taken on the IVIS Spectrum isdisplayed below in FIG. 7.

The values for each well are also shown in the Table below.

TABLE 1 Incubation of Compound VIII in A431 cells Avg Radiant AverageEfficiency [p/s/cm²/sr]/ values[p/s/cm²/sr]/ Image [μW/cm²] [μW/cm²]Control 1.40E+07 1.46E+07 1.57E+07 1.42E+07 5 μM, 5 1.64E+07 1.49E+07minutes 1.47E+07 1.36E+07 10 μM, 5 1.50E+07 1.39E+07 minutes 1.39E+071.28E+07 25 μM, 5 1.39E+07 1.33E+07 minutes 1.34E+07 1.27E+07 5 μM, 151.29E+07 1.24E+07 minutes 1.23E+07 1.19E+07 10 μM, 15 1.24E+07 1.20E+07minutes 1.18E+07 1.17E+07 25 μM, 15 1.22E+07 1.20E+07 minutes 1.20E+071.19E+07 5 μM, 30 1.18E+07 1.17E+07 minutes 1.16E+07 1.17E+07 10 μM, 301.16E+07 1.15E+07 minutes 1.15E+07 1.13E+07 25 μM, 30 1.20E+07 1.20E+07minutes 1.20E+07 1.20E+07 5 μM 3.33E+07 3.33E+07 solution of dye

Using Aza-Dyes as Fluorescent Probe for Shortwave Infrared/NIR II:

Aza-dyes also have shown the potential to be used in the short waveinfrared (SWIR) region located between 1000-2000 nm. This region is alsoknown as near infrared II (NIR-II), although this region is usuallydefined as between 1000-1700 nm. It is important for in vivo imagingbecause tissue scattering and autofluorescence are significantly lowerthan in the NIR I (700-1000 nm) region. This has led SWIR/NIR-II to becalled a “tissue transparent” zone.

Recently it has been shown that some cyanine dyes, including ICG andCW-800, also have emission in the SWIR region that is between 1000-1700nm using an InGaAs SWIR camera system³. It was already shown that in theNIR-II region there is less absorption and no scattering enabling 2times deeper imaging with much higher resolution respectively. Here wedemonstrate that the new NIRF AZA-cyanine compounds such as CompoundVIII and compound VI also absorbs in the NIR-II region and can be imagedwith a commercial SWIR camera system. The results are shown on FIG. 24.The camera used for obtaining the data has the following specs:“Princeton NIRvana detector, IsoPlane SCT320 spectrometer, Nikoninverted microscope, 658 nm, 785 nm and Xenon lamp/monochromatorillumination sources”

The other derivatives of aza-cyanine analogs covered in the currentinvention are currently being tested to find the optimal SWIR imagingdye.

1.-21. (canceled)
 22. A fluorescent dye of formula A, which is attachedto at least one chelating group:

or a salt thereof, wherein Z is selected from the group consisting ofNR¹⁷ and ⁺NR¹⁷R¹⁸; Q is independently H or selected from the groups a),b), and c) consisting of: a) halide selected from Cl, Br, I; R¹⁹U,—OR¹⁹U, —SR¹⁹U and —NR¹⁹R²⁰U, wherein R¹⁹ is a single bond; or whereinR¹⁹ and R²⁰ may independently be an optical properties modifying group,and are independently selected from the group consisting of: H, linearand branched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic C₅-, C₆- or C₇ aromatic ringwhich can be substituted by a linear or branched C₁-C₆ alkyl group; andhomocyclic and heterocyclic 5-, 6- and 7-membered aromatic rings whichcan be substituted by a linear or branched C₁-C₆ alkyl group, whereinpreferably one of R¹⁹ and R²⁰ is not aromatic in case of —NR¹⁹R²⁰U;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; and U is aphysiochemistry modifying group selected from the group consisting of:—(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻, —(CH₂)_(m)NH₂;—(CH₂)_(m)NHR³²; —(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6,and wherein R³² and R³³ are independently of each other an alkyl grouphaving from 1-12, preferably 1-8, more preferably 1-4 C atoms, inparticular methyl or ethyl; and wherein in case of —(CH₂)_(m)NH₂;—(CH₂)_(m)NHR³²; —(CH₂)_(m)NR³²R³³ the N atom may be bond to a furthersubstituent R³⁴ to form a quaternary N atom, and wherein R³⁴ is in allthe above cases independently selected from H, and an alkyl group havingfrom 1-12, preferably 1-8, more preferably 1-4 C atoms, in particularmethyl or ethyl, b) R²¹L, —OR²¹L, —SR²¹L and —NR²¹R²²L wherein R²¹ andR²² may independently be an optical properties modifying group and areindependently selected from the group consisting of: H, linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic 5-, 6- or 7-memberedaromatic group which can be substituted by a linear or branched C₁-C₆alkyl group; homocyclic and heterocyclic 5-, 6- or 7-membered aromaticrings which can be substituted by a linear or branched C₁-C₆ alkylgroup, wherein preferably one of R²¹ and R²² is not aromatic in case of—NR²¹R²²; —(CH₂—O—CH₂)_(x)CH₂-L wherein x is an integer from 1 to 50;and L is a linker which can form a covalent bond with a targeting agent,c) R¹⁹, —OR¹⁹, —SR¹⁹ and —NR¹⁹R²⁰ wherein R¹⁹ and R²⁰ wherein R¹⁹ andR²⁰ may independently be an optical properties modifying group and areindependently selected from the group consisting of: H, linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic 5-, 6- or 7-memberedaromatic ring which can be substituted by a linear or branched C₁-C₆alkyl group; and homocyclic and heterocyclic 5-, 6- and 7-memberedaromatic rings which can be substituted by a linear of branched C₁-C₆alkyl group, wherein preferably one of R¹⁹ and R²⁰ is not aromatic incase of —NR¹⁹R²⁰; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to50; or wherein R¹⁹ and R²⁰, together with the N atom to which they areattached, form a 5- or 6-membered heterocycle optionally containing onefurther heteroatom selected from O and N, wherein the heterocycle can besubstituted by a linear or branched, cyclic or non cyclic C₁-C₆ alkylgroup, in particular 4-cyclohexylpiperazinyl; L is selected from thegroup consisting of: —NH₂, —OH, —SH, —C(O)O⁻, —C(O)Cl, —(CO)O(CO)R²⁷,—C(O)NHNH₂, —C(O) —C(O)OR²⁸, wherein R²⁷ is selected from the groupconsisting of H, alkyl and aryl; wherein R²⁸ is derived from substitutedand unsubstituted N-hydroxysuccinimide, substituted and unsubstitutedN-hydroxysulfosuccinimide, nitrophenol, fluorophenol each bound via —O—;azide N₃ ⁻, —NCO, —NCS, —CHO, —COCH₂I, phosphoramidityl, phthalamidyl,maleimide, an alkyne group in particular —C≡CR³¹ wherein R³¹ is H or aC₁-C₈ alkyl group, sulfonate esters, alkyl halides, acyl halides,propargylglycine, a pentanoyl group, in particular pentanoyl chloride,pentynoic acid, propargylic acid,6-aminobenzo[d]thiazole-2-carbonitrile,6-hydroxybenzo[d]thiazole-2-carbonitrile, a 1,2-aminothiol group, inparticular L-cysteine or D-cysteine; R¹ and R² are absent, H orindependently selected from the group: a) linear and branched,non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic or heterocyclic 5-, 6- or 7-membered aromatic group which canbe substituted by a linear or branched C₁-C₆ alkyl group; homocyclic andheterocyclic 5-, 6- and 7-membered aromatic rings which can besubstituted by a linear of branched C₁-C₆ alkyl group; and—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50, b) R²³Lwherein R²³ is selected from the group consisting of linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the alkyl group can be single or multiple substituted bya homocyclic or heterocyclic C₅-, C₆- or C₇-aryl group which can besubstituted by a linear or branched C₁-C₆ alkyl group; homocyclic andheterocyclic 5-, 6- and 7-membered aromatic rings which can besubstituted by a linear or branched C₁-C₆ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; and L is alinker which can form a covalent bond with a targeting agent, c) R²³U,wherein R²³ is a single bond; or wherein R²³ is selected from the group:linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic rings which can be substituted by a linear orbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³ are independently of each other an alkyl group having from 1-12,preferably 1-8, more preferably 1-4 C atoms, in particular methyl orethyl, wherein m in an integer from 0 to 6; R¹⁷ and R²⁰ areindependently H or selected from the group consisting of: a) linear andbranched, non-cyclic or cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic 5-, 6- or 7-memberedaromatic group which can be substituted by a linear or branched C₁-C₆alkyl group; homocyclic and heterocyclic 5-, 6- and 7-membered aromaticrings which can be substituted by a linear or branched C₁-C₆ alkylgroup, wherein preferably one of R¹⁷ and R¹⁸ is not aromatic; and—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50, b) R²⁴Lwherein R²⁴ is selected from the group: linear and branched, non-cyclicand cyclic, substituted and unsubstituted C₁₋₂₀ alkyl, wherein the saidalkyl group can be single or multiple substituted by a homocyclic orheterocyclic 5-, 6- or 7-membered aromatic group which can besubstituted by a linear or branched C₁-C₆ alkyl group; homocyclic andheterocyclic 5-, 6- or 7-membered aromatic groups which can besubstituted by a linear of branched C₁-C₆ alkyl group, whereinpreferably one of R¹⁷ and R²⁰ is not aromatic; —(CH₂—O—CH₂)_(x)CH₂—wherein x is an integer from 1 to 50; and L is a linker which can form acovalent bond with a targeting agent, c) R²⁴U, wherein R²⁴ is a singlebond; or wherein R²⁴ is selected from the group: linear and branched,non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic or heterocyclic 5-, 6- or 7-membered aromatic group which canbe substituted by a linear or branched C₁-C₆ alkyl group; homocyclic andheterocyclic 5-, 6- or 7-membered aromatic groups which can besubstituted by a linear of branched C₁-C₆ alkyl group, whereinpreferably one of R¹⁷ and R¹⁸ is not aromatic; —(CH₂—O—CH₂)_(x)CH₂—wherein x is an integer from 1 to 50; and U is a physiochemistrymodifying group selected from the group consisting of: —(CH₂)_(m)SO₃ ⁻,—(CH₂)_(m)C(O)O—(CH₂)_(m)NH₂; —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂—(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is am integerfrom 0 to 6, and wherein R³², R³³, are independently of each other analkyl group having from 1-12, preferably 1-8, more preferably 1-4 Catoms, in particular methyl or ethyl, wherein m is an integer from 0 to6; A⁶, A⁷, A⁸, A⁹, and A¹⁰, A, A¹², A¹³ are C, N or ⁺N, and either A)form a 6-membered aromatic ring which together with the pyrrolin derivedring to which they are attached form an indol or an azaindol system,which indol system can comprise a total of 1 N atoms, and which azaindolsystem can comprise a total of 2 N atoms; R³, R⁴, R⁵, R⁶, R⁷, R⁸ R⁹ R¹⁰are independently H or selected from the group consisting of: a) halideselected from Cl, Br, I; R²⁵H and OR²⁵H, wherein R²⁵ is selected fromthe group: linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear ofbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50, b) R²⁵L and OR²⁵L, wherein R²⁵ is selected from the group:linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear ofbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50; and L is a linker which can form a covalent bond with atargeting agent, c) R²⁵U and OR²⁵U wherein R²⁵ is a single bond; orwherein R²⁵ is selected from the group: linear and branched, non-cyclicand cyclic, substituted and unsubstituted C₁₋₂₀ alkyl, wherein the saidalkyl group can be single or multiple substituted by a homocyclic orheterocyclic 5-, 6- or 7-membered aromatic group which can besubstituted by a linear or branched C₁-C₆ alkyl group; homocyclic andheterocyclic 5-, 6- or 7-membered aromatic groups which can besubstituted by a linear or branched C₁-C₆ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; and U is aphysiochemistry modifying group selected from the group consisting of:—(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂—(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integerfrom 0 to 6, and wherein R³², R³³, are independently of each other analkyl group having from 1-12, preferably 1-8, more preferably 1-4 Catoms, in particular methyl or ethyl, wherein m in an integer from 0 to6; and wherein OR²⁵H, OR²⁵L and OR²⁵U are present only when O isattached to a C atom; or B) A⁶, A⁷, A⁸, A⁹, and A¹⁰, A¹¹, A¹², A¹³ areC, N, or ⁺N and form a 6-membered aromatic ring which together with thepyrrolin derived ring to which they are attached form an indol or anazaindol system, and to which indol or azaindol system a further6-membered ring is annulated which is formed by at least two of thesubstitutents R³, R⁴, R⁵, R⁶, or R⁷, R⁸ R⁹ R¹⁰, resulting in atrinuclear ring in which 1, 2 or 3 C atoms may be replaced by N or ⁺Nand which are substituted by R, R¹²R¹³, R¹⁴, and R¹⁵, R¹⁶, R¹⁷; R¹⁸;R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, R¹⁶, R¹⁷, R¹⁸ are independently H orselected from the group consisting of: a) halide selected from Cl, Br,I; R²⁶H and OR²⁶H, wherein R²⁶ is selected from the group: linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic 5-, 6- or 7-memberedaromatic group which can be substituted by a linear or branched C₁-C₆alkyl group; homocyclic and heterocyclic 5-, 6- or 7-membered aromaticgroups which can be substituted by a linear of branched C₁-C₆ alkylgroup; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50, b)R²⁶L and OR²⁶L, wherein R²⁶ is selected from the group: linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₂₀alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic or heterocyclic C₅-, C₆- or C₇-aryl groupwhich can be substituted by a linear or branched C₁-C₆ alkyl group;homocyclic and heterocyclic C₅-, C₆- or C₇-aromatic groups which can besubstituted by a linear or branched C₁-C₆ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 50; and L is alinker which can form a covalent bond with a targeting agent, c) R²⁶Uand OR²⁶U, wherein R²⁶ is a single bond; or wherein R²⁶ is selected fromthe group: linear and branched, non-cyclic and cyclic, substituted andunsubstituted C₁₋₂₀ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic or heterocyclic 5-, 6- or7-membered aromatic group which can be substituted by a linear orbranched C₁-C₆ alkyl group; homocyclic and heterocyclic 5-, 6- or7-membered aromatic groups which can be substituted by a linear ofbranched C₁-C₆ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 50; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)S O₃ ⁻, —(CH₂)_(m)C(O)O⁻, and d)—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, are independently of each other an alkyl group having from 1-12,preferably 1-8, more preferably 1-4 C atoms, in particular methyl orethyl; X and Y are selected from the group consisting of CR²⁹R³⁰, whereR²⁹ and R³⁰ are each independently selected from H, unsubstituted andsubstituted linear or branched, cyclic or non-cyclic C₁-C₆ alkyl, E andE′ are independently selected from H, unsubstituted and substitutedlinear or branched, cyclic or non-cyclic C₁-C₆ alkyl, wherein the atleast one chelating agent is attached to a group U or L.
 23. Thefluorescent dye of claim 22, wherein the substituents have the followingmeanings: in the heterocycle being part of the conjugated double bondcarbon chain, Z is NR¹⁷, or ⁺NR¹⁷R¹⁸, Q is selected from the groups a),b), and c) consisting of: a) halide selected from Cl, Br, I; R¹⁹U,—OR¹⁹U, —SR¹⁹U and —NR¹⁹R²⁰U; wherein R¹⁹ is a single bond; or whereinR¹⁹ and R²⁰ may independently be an optical properties modifying group,and are independently selected from the group consisting of: H, linear,non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl, wherein the saidalkyl group can be single or multiple substituted by a homocyclic6-membered aromatic group which can be substituted by a linear orbranched C₁-C₄ alkyl group; and homocyclic 6-membered aromatic ringswhich can be substituted by a linear or branched C₁-C₄ alkyl group,wherein preferably one of R¹⁹ and R²⁰ is not aromatic in case of—NR¹⁹R²⁰U; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20;and U is a physiochemistry modifying group selected from the groupconsisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O—(CH₂)_(m)P(O)O₂ ²⁻—(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein mis an integer from 0 to 6, and wherein R³², R³³, are independently ofeach other an alkyl group having from 1-12, preferably 1-8, morepreferably 1-4 C atoms, in particular methyl or ethyl; and wherein incase of —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; —(CH₂)_(m)NR³²R³³ the N atom maybe bond to a further substituent R³⁴ to form a quaternary N atom, andwherein R³⁴ is in all the above cases independently selected from H, andan alkyl group having from 1-12, preferably 1-8, more preferably 1-4 Catoms, in particular methyl or ethyl, b) R²¹L, —OR²¹L, —SR²¹L and—NR²¹R²²L wherein R²¹ and R²² may independently be an optical propertiesmodifying group and are independently selected from the group consistingof: H; linear, non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl,wherein the said alkyl group can be single or multiple substituted by ahomocyclic C₆-aryl group which can be substituted by a linear orbranched C₁-C₄ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 20; and homocyclic 6-membered aromatic groups rings which canbe substituted by a linear or branched C₁-C₄ alkyl group, whereinpreferably one of R²¹ and R²² is not aromatic in case of —NR²¹R²²; and Lis a linker which can form a covalent bond with a targeting agent. andc) R¹⁹, —OR¹⁹, —SR¹⁹ and —NR¹⁹R²⁰ wherein R¹⁹ and R²⁰ may independentlybe an optical properties modifying group and are independently selectedfrom the group consisting of: H; linear, non-cyclic, substituted andunsubstituted C₁₋₁₂ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic C₆-aryl group which can besubstituted by a linear or branched C₁-C₄ alkyl group; and homocyclic6-membered aromatic groups which can be substituted by a linear orbranched C₁-C₄ alkyl group, wherein preferably one of R¹⁹ and R²⁰ is notaromatic in case of —NR¹⁹R²⁰U; —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 20; or wherein R¹⁹ and R²⁰, together with the N atomto which they are attached, form a 5- or 6-membered heterocycleoptionally containing one further heteroatom selected from O and N,wherein the heterocycle can be substituted by a linear or branched,cyclic or non cyclic C₁-C₆ alkyl group, in particular4-cyclohexylpiperazinyl; L is selected from the group consisting of:—NH₂, —OH, —SH, —C(O)O⁻, —C(O)Cl, —C(O)OR²⁸, wherein R²⁸ is derived fromsubstituted and unsubstituted N-hydroxysuccinimide, substituted andunsubstituted N-hydroxysulfosuccinimide, nitrophenol, fluorophenol eachbound via —O—; azide N₃ ⁻, —NCO, —NCS, —CHO, phosphoramidityl,phthalamidyl, maleimide, an alkyne group in particular —C≡CR³¹ whereinR³¹ is H or a C₁-C₈ alkyl group, preferably H or a C₁-C₄ alkyl group,sulfonate esters, alkyl halides, acyl halides, pentynoic acid,propargylic acid, 6-aminobenzo[d]thiazole-2-carbonitrile,6-hydroxybenzo[d]thiazole-2-carbonitrile, a 1,2-aminothiol group, inparticular L-cysteine or D-cysteine; R¹ and R² are absent, independentlyH or selected from the group: a) linear, non-cyclic, substituted andunsubstituted C₁₋₁₂ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic C₆-aromatic group which can besubstituted by a linear or branched C₁-C₄ alkyl group; homocyclic6-membered aromatic rings which can be substituted by a linear orbranched C₁-C₄ alkyl group; and —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 20; b) R²³L wherein R²³ is selected from the group:linear, non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl, whereinthe said alkyl group can be single or multiple substituted by ahomocyclic C₆-aromatic group which can be substituted by a linear orbranched C₁-C₄ alkyl group; homocyclic C₆aromatic rings which can besubstituted by a linear or branched C₁-C₄ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; and L is alinker which can form a covalent bond with a targeting agent; c) R²³U,wherein R²³ is a single bond; wherein R²³ is selected from the group:linear, non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl, whereinthe said alkyl group can be single or multiple substituted by ahomocyclic 6-membered aromatic group which can be substituted by alinear or branched C₁-C₄ alkyl group; homocyclic C₆ aromatic rings whichcan be substituted by a linear or branched C₁-C₄ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; and U is aphysiochemistry modifying group selected from the group consisting of:—(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂—(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integerfrom 0 to 6, and wherein R³², R³³, are independently of each other analkyl group having from 1-12, preferably 1-8, more preferably 1-4 Catoms, in particular methyl or ethyl; R¹⁷ and R¹⁸ are independently H orselected from the group consisting of: a) linear, non-cyclic,substituted and unsubstituted C₁₋₁₂ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic 6-memberedaromatic group; homocyclic 6-membered aromatic groups which can besubstituted by a linear or branched C₁-C₄ alkyl group, whereinpreferably one of R¹⁷ and R¹⁸ is not aromatic; —(CH₂—O—CH₂)_(x)CH₂—wherein x is an integer from 1 to 20, b) R²⁴L wherein R²⁴ is selectedfrom the group: linear, non-cyclic, substituted and unsubstituted C₁₋₁₂alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic 6-membered aromatic group which can besubstituted by a linear or branched C₁-C₄ alkyl group; homocyclic6-membered aromatic group which can be substituted by a linear orbranched C₁-C₄ alkyl group, wherein preferably one of R¹⁷ and R¹⁸ is notaromatic; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; andL is a linker which can form a covalent bond with a targeting agent, andc) R²⁴U, wherein R²⁴ is a single bond; or wherein R²⁴ is selected fromthe group: linear, non-cyclic, substituted and unsubstituted C₁₋₁₂alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic 6-membered aromatic group which can besubstituted by a linear or branched C₁-C₄ alkyl group; homocyclic6-membered aromatic groups which can be substituted by a linear orbranched C₁-C₄ alkyl group, wherein preferably one of R¹⁷ and R¹⁸ is notaromatic; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; andU is a physiochemistry modifying group selected from the groupconsisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻—(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein mis an integer from 0 to 6, and wherein R³², R³³, are independently ofeach other an alkyl group having from 1-12, preferably 1-8, morepreferably 1-4 C atoms, in particular methyl or ethyl; A⁶, A⁷, A⁸, A⁹,and A¹⁰, A¹¹, A¹², A¹³ are C, N, ⁺N and either A) form a 6-memberedaromatic ring which together with the pyrrolin derived ring to whichthey are attached form an indol or an azaindol system, which indolsystem can comprise a total of 1 N atoms and which azaindol system cancomprise a total of 2 N atoms; R³, R⁴, R⁵, R⁶, R⁷, R⁸ R⁹ R¹⁰ areindependently H or selected from the group consisting of: a) halideselected from Cl, Br, I; R²⁵H and OR²⁵H, wherein R²⁵ is selected fromthe group: linear, non-cyclic, substituted and unsubstituted C₁₋₁₂alkyl, wherein the said alkyl group can be single or multiplesubstituted by a homocyclic 6-membered aromatic group which can besubstituted by a linear or branched C₁-C₄ alkyl group; homocyclic6-membered aromatic groups which can be substituted by a linear orbranched C₁-C₄ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 20, b) R²⁵L and OR²⁵L wherein R²⁵ is selected from the group:linear, non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl, whereinthe said alkyl group can be single or multiple substituted by ahomocyclic 6-membered aromatic group which can be substituted by alinear or branched C₁-C₄ alkyl group; homocyclic 6-membered aromaticgroups which can be substituted by a linear or branched C₁-C₄ alkylgroup; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; and Lis a linker which can form a covalent bond with a targeting agent, andc) R²⁵U and OR²⁵U, wherein R²⁵ is a single bond; or wherein R²⁵ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₁₂ alkyl, wherein the said alkyl group can be single ormultiple substituted by a homocyclic 6-membered aromatic group which canbe substituted by a linear or branched C₁-C₄ alkyl group; homocyclic6-membered aromatic groups which can be substituted by a linear orbranched C₁-C₄ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 20; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻,—(CH₂)_(m)C(O)O—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂;—(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6,and wherein R³², R³³, are independently of each other an alkyl grouphaving from 1-12, preferably 1-8, more preferably 1-4 C atoms, inparticular methyl or ethyl; and wherein OR²⁵H, OR²⁵L and OR²⁵U arepresent only when O is attached to a C atom; or B) form a 6-memberedaromatic ring which together with the pyrrolin derived ring to whichthey are attached form an indol or an azaindol system, and to whichindol or azaindol system a further 6-membered ring is annulated which isformed by at least two of the substituents R³, R⁴, R⁵, R⁶, or R⁷, R⁸ R⁹R¹⁰, resulting in a trinuclear ring in which 1 or 2 C atoms may bereplaced by N, and which are substituted by R, R¹², R¹³, R¹⁴, and R,R¹⁶, R¹⁷; R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, R¹⁶, R¹⁷ are independently H orselected from the group consisting of: a) halide selected from Cl, Br,I; R²⁶H and OR²⁶H, wherein R²⁶ is selected from the group: linear,non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl, wherein the saidalkyl group can be single or multiple substituted by a homocyclic6-membered aromatic group which can be substituted by a linear orbranched C₁-C₄ alkyl group; homocyclic 6-membered aromatic groups whichcan be substituted by a linear or branched C₁-C₄ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; b) R²⁶L andOR²⁶L wherein R²⁶ is selected from the group: linear, non-cyclic,substituted and unsubstituted C₁₋₁₂ alkyl, wherein the said alkyl groupcan be single or multiple substituted by a homocyclic 6-memberedaromatic group which can be substituted by a linear or branched C₁-C₄alkyl group; homocyclic C₆ aromatic rings which can be substituted by alinear or branched C₁-C₄ alkyl group; —(CH₂—O—CH₂)_(x)CH₂— wherein x isan integer from 1 to 20; and L is a linker which can form a covalentbond with a targeting agent; and c) R²⁶U and OR²⁶U, wherein R²⁶ is asingle bond; or wherein R²⁶ is selected from the group: linear,non-cyclic, substituted and unsubstituted C₁₋₁₂ alkyl, wherein the saidalkyl group can be single or multiple substituted by a homocyclic6-membered aromatic group which can be substituted by a linear orbranched C₁-C₄ alkyl group; homocyclic C₆ aromatic rings which can besubstituted by a linear or branched C₁-C₄ alkyl group;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20; and U is aphysiochemistry modifying group selected from the group consisting of:—(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂—(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integerfrom 0 to 6, and wherein R³², R³³, are independently of each other analkyl group having from 1-12, preferably 1-8, more preferably 1-4 Catoms, in particular methyl or ethyl; and wherein OR²⁶H, OR²⁶L and OR²⁶Uare present only when 0 is attached to a C atom; X and Y are selectedfrom the group consisting of: CR²⁹R³⁰, where R²⁹ and R³⁰ are eachindependently selected from H, unsubstituted and substituted non-cycliclinear and branched C₁-C₄ alkyl; E and E′ are independently selectedfrom H and unsubstituted and substituted linear or branched, cyclic ornon-cyclic C₁-C₄ alkyl.
 24. The fluorescent dye according to claim 22,wherein the substituents have the following meanings: in the heterocyclebeing part of the conjugated carbon chain Z is NR¹⁷, or ⁺NR¹⁷R¹⁸, Q isselected from the groups a), b), and c) consisting of: a) Halideselected from Cl, Br, I; R¹⁹U, —OR¹⁹U, —SR¹⁹U and —NR¹⁹R²⁰U, wherein R¹⁹is a single bond; or wherein R¹⁹ and R²⁰ may independently be an opticalproperties modifying group, and are independently selected from thegroup consisting of: H; linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; and homocyclic6-membered aromatic groups wherein preferably one of R¹⁹ and R²⁰ is notaromatic in case of —NR¹⁹R²⁰U; —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 12; and U is a physiochemistry modifying groupselected from the group consisting of: —(CH₂)_(m)SO₃ ⁻,—(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂;—(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6,and wherein R³², R³³, are independently of each other an alkyl grouphaving from 1-12, preferably 1-8, more preferably 1-4 C atoms, inparticular methyl or ethyl; and wherein in case of —(CH₂)_(m)NH₂;—(CH₂)_(m)NHR³²; —(CH₂)_(m)NR³²R³³ the N atom may be bond to a furthersubstituent R³⁴ to form a quaternary N atom, and wherein R³⁴ is in allthe above cases independently selected from H, and an alkyl group havingfrom 1-12, preferably 1-8, more preferably 1-4 C atoms, in particularmethyl or ethyl; b) R²¹L, —OR²¹L, —SR²¹L and —NR²¹R²²L wherein R²¹ andR²² may independently be an optical properties modifying group and areindependently selected from the group consisting of: H; linear,non-cyclic, substituted and unsubstituted C₁₋₈ alkyl, wherein the saidalkyl group can be single substituted by a homocyclic 6-memberedaromatic group; homocyclic 6-membered aromatic groups, whereinpreferably one of R²¹ and R²² is not aromatic in case of —NR²¹R²²;—(CH₂—O—CH₂)_(x)CH₂-L wherein x is an integer from 1 to 12; and L is alinker which can form a covalent bond with a targeting agent; and L is alinker which can form a covalent bond with a targeting agent; c) R¹⁹,—OR¹⁹, —SR¹⁹ and —NR¹⁹R²⁰ wherein R¹⁹ and R²⁰ may independently be anoptical properties modifying group and are independently selected fromthe group consisting of: H; linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; and homocyclic6-membered aromatic groups, wherein preferably one of R¹⁹ and R²⁰ is notaromatic in case of —NR²¹R²²; —(CH₂—O—CH₂)_(x)CH₂— wherein x is aninteger from 1 to 12; or wherein R¹⁹ and R²⁰, together with the N atomto which they are attached, form a 6-membered heterocycle optionallycontaining one further heteroatom selected from O and N, wherein theheterocycle can be substituted by a linear or branched, cyclic or noncyclic C₁-C₆ alkyl group, in particular 4-cyclohexylpiperazinyl; L isselected from the group consisting of: —OH, —SH, —C(O)⁻, —C(O)OR²⁸,wherein R²⁸ is derived from substituted and unsubstitutedN-hydroxysuccinimide, substituted and unsubstitutedN-hydroxysulfosuccinimide, nitrophenol, fluorophenol each bound via —O—;azide N₃ ⁻, —NCS, —CHO, phosphoramidityl, phthalamidyl, maleimide, analkyne group in particular —C≡CR³¹ wherein R³¹ is H or a C₁-C₈ alkylgroup, preferably H or a C₁-C₄ alkyl group, sulfonate esters, alkylhalides, acyl halides, 6-aminobenzo[d]thiazole-2-carbonitrile,6-hydroxybenzo[d]thiazole-2-carbonitrile, a 1,2-aminothiol group,L-cysteine; R¹ and R² are absent, H or independently selected from thegroup: a) linear, non-cyclic, substituted and unsubstituted C₁₋₈ alkyl,wherein the said alkyl group can be single substituted by a homocyclic6-membered aromatic group; homocyclic 6-membered aromatic rings; and—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 20, b) R²³Lwherein R²³ is selected from the group: linear, non-cyclic, substitutedand unsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 12; and L is a linker which can form a covalent bond with atargeting agent, and c) R²³U, wherein R²³ is a single bond; or whereinR²³ is selected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic groups; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 12; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂ —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²;(CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6, and wherein R³²,R³³, are independently of each other an alkyl group having from 1-12,preferably 1-8, more preferably 1-4 C atoms, in particular methyl orethyl; R¹⁷ and R¹⁸ are independently H or selected from the groupconsisting of: a) linear, non-cyclic, substituted and unsubstituted C₁₋₈alkyl, wherein the said alkyl group can be single substituted by ahomocyclic 6-membered aromatic group; homocyclic 6-membered aromaticgroups, wherein preferably one of R¹⁷ and R¹⁸ is is not aromatic; and—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 12, b) R²⁴Lwherein R²⁴ is selected from the group: linear and branched, non-cyclicand cyclic, substituted and unsubstituted C₁₋₈ alkyl, wherein the saidalkyl group can be single substituted by a homocyclic 6-memberedaromatic group; homocyclic 6-membered aromatic groups, whereinpreferably one of R¹⁷ and R¹⁸ is is not aromatic; —(CH₂—O—CH₂)_(x)CH₂—wherein x is an integer from 1 to 12; and L is a linker which can form acovalent bond with a targeting agent, and c) R²⁴U, wherein R²⁴ is asingle bond; or wherein R²⁴ is selected from the group: linear andbranched, non-cyclic and cyclic, substituted and unsubstituted C₁₋₈alkyl, wherein the said alkyl group can be single substituted by ahomocyclic 6-membered aromatic group; homocyclic 6-membered aromaticgroups; wherein preferably one of R¹⁷ and R¹⁸ is not aromatic;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 12; and U is aphysiochemistry modifying group selected from the group consisting of:—(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻; —(CH₂)_(m)NH₂;—(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integer from 0 to 6,and wherein R³², R³³, are independently of each other an alkyl grouphaving from 1-12, preferably 1-8, more preferably 1-4 C atoms, inparticular methyl or ethyl; A₆, A₇, A₈, A₉, and A₁₀, A₁₁, A₁₂, A₁₃ areC, N, or ⁺N, and either A) form a 6-membered aromatic ring whichtogether with the pyrrolin derived ring to which they are attached forman indol or an azaindol system, which indol system can comprise a totalof 1 N atoms and which azaindol system can comprise a total of 2 Natoms; R³, R⁴, R⁵, R⁶, R⁷, R⁸ R⁹ R¹⁰ are independently H or selectedfrom the group consisting of: a) Halide selected from Cl, Br, I; R²⁵Hand OR²⁵H, wherein R²⁵ is selected from the group: linear, non-cyclic,substituted and unsubstituted C₁₋₈ alkyl, wherein the said alkyl groupcan be single substituted by a homocyclic 6-membered aromatic group;homocyclic 6-membered aromatic groups; —(CH₂—O—CH₂)_(x)CH₂— wherein x isan integer from 1 to 12, b) R²⁵L and —OR²⁵L, wherein R²⁵ is selectedfrom the group: linear, non-cyclic, substituted and unsubstituted C₁₋₈alkyl, wherein the said alkyl group can be single substituted by ahomocyclic 6-membered aromatic group; homocyclic 6-membered aromaticgroups; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 12; and Lis a linker which can form a covalent bond with a targeting agent, c)R²⁵U and —OR²⁵U, wherein R²⁵ is a single bond; or wherein R²⁵ isselected from the group: linear, non-cyclic, substituted andunsubstituted C₁₋₈ alkyl, wherein the said alkyl group can be singlesubstituted by a homocyclic 6-membered aromatic group; homocyclic6-membered aromatic group; —(CH₂—O—CH₂)_(x)CH₂— wherein x is an integerfrom 1 to 12; and U is a physiochemistry modifying group selected fromthe group consisting of: —(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻,—(CH₂)_(m)P(O)O₂₂; —(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³wherein m is an integer from 0 to 6, and wherein R³², R³³, areindependently of each other an alkyl group having from 1-12, preferably1-8, more preferably 1-4 C atoms, in particular methyl or ethyl; andwherein OR²⁵H, —OR²⁵L and —OR²⁵U are present only when O is attached toa C atom; or B) A₆, A₇, A₈, A₉, and A₁₀, A₁₁, A₁₂, A₁₃ are C, N, or ⁺Nand form a 6-membered aromatic ring which together with the pyrrolinderived ring to which they are attached form an indol or an azaindolsystem, and to which indol or azaindol system a further 6-membered ringis annulated which is formed by at least two of the substitutents R³,R⁴, R⁵, R⁶, or R⁷, R⁸ R⁹ R¹⁰, resulting in a trinuclear ring in which 1or 2 C atoms may be replaced by N, and which are substituted by R¹¹,R¹², R¹³, R¹⁴, and R¹⁵, R¹⁶, R¹⁷, R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, R¹⁶, R¹⁷are independently H or selected from the group consisting of: a) Halideselected from Cl, Br, I; R²⁶H and OR²⁶H, wherein R²⁶ is selected fromthe group: linear, non-cyclic, substituted and unsubstituted C₁₋₈ alkyl,wherein the said alkyl group can be single substituted by a homocyclic6-membered aromatic group; homocyclic 6-membered aromatic groups;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 12, b) R²⁶L andOR²⁶L, wherein R²⁶ is selected from the group: linear, non-cyclic,substituted and unsubstituted C₁₋₈ alkyl, wherein the said alkyl groupcan be single substituted by a homocyclic 6-membered aromatic group;homocyclic 6-membered aromatic groups; —(CH₂—O—CH₂)_(x)CH₂— wherein x isan integer from 1 to 12; and L is a linker which can form a covalentbond with a targeting agent, and c) R²⁶U, and OR²⁶U, wherein R²⁶ is asingle bond; or wherein R²⁶ is selected from the group: linear,non-cyclic, substituted and unsubstituted C₁₋₈ alkyl, wherein the saidalkyl group can be single substituted by a homocyclic 6-memberedaromatic group; homocyclic 6-membered aromatic groups;—(CH₂—O—CH₂)_(x)CH₂— wherein x is an integer from 1 to 12; and U is aphysiochemistry modifying group selected from the group consisting of:—(CH₂)_(m)SO₃ ⁻, —(CH₂)_(m)C(O)O⁻, —(CH₂)_(m)P(O)O₂ ²⁻ —(CH₂)_(m)NR₂—(CH₂)_(m)NH₂; —(CH₂)_(m)NHR³²; (CH₂)_(m)NR³²R³³ wherein m is an integerfrom 0 to 6, and wherein R³², R³³, are independently of each other analkyl group having from 1-12, preferably 1-8, more preferably 1-4 Catoms, in particular methyl or ethyl and wherein OR²⁶H, OR²⁵L and OR²⁵Uare present only when O is attached to a C atom; X and Y are selectedfrom the group consisting of: CR²⁹R³⁰, where R²⁹ and R³⁰ are eachindependently selected from H, unsubstituted and substituted C₁-C₂alkyl, E and E′ are independently selected from H and methyl and ethyl,preferably methyl.
 25. The dye according to claim 22, wherein A⁶, A⁷,A⁸, A⁹, and A¹⁰, A¹¹, A¹², A¹³ are such that they form together with thepyrrolin derived ring to which they are attached an aromatic systemselected from


26. The dye according to claim 22, wherein the at least one chelatingagent is attached to a group L in R¹, R², or R¹ and R²; R¹⁷, R¹⁸, or R¹⁷and R¹⁸; or, if the ring annulated to the pyrrol structure contains a Natom, in R³, R⁴, R⁷ and/or R⁶ attached to this N atom.
 27. The dyeaccording to any of claim 22, which is asymmetrical and does not have aC2 symmetry, caused by different ring systems or by one or moresubstituents which are present only on one side of the molecule.
 28. Thedye according to claim 22, wherein the at least one chelating agent isattached to group L in the position of any of the substituents Q, E, E′and R¹-R¹⁶.
 29. The dye according to claim 22, wherein the at least onechelating agent is attached to a group L that is —NH₂, C(O)OR²⁸, —NCO,or —NCS.
 30. The dye according to claim 22, wherein the dye of formula Ais a dye of formula E:

wherein Q′ is Cl, Br, I, —OR^(19′), —SR^(19′), or —NR^(19′)R^(20′),R^(19′) and R^(20′) are independently H or phenyl, wherein the phenylcan be substituted by C₁₋₆ alkyl, C₁₋₆ fluroalkyl, —(CH₂)₀₋₃SO₃ ⁻,—(CH₂)₀₋₃SO₃-alkali metal, —(CH₂)₀₋₃COOH, —(CH₂)₀₋₃COO-alkali metal,—NCO, —NCS, —(CH₂)₀₋₃NH₂, or —(CH₂)₀₋₃N⁺H₃, or R^(19′) and R^(20′)together with the nitrogen to which they are attached form a 5- or6-membered heterocycle optionally containing one further heteroatomselected from O and N, wherein the heterocycle can be substituted by alinear or branched, cyclic or non-cyclic C₁₋₆ alkyl group; R_(1″),R_(2″), R_(3′), and R_(7′) are independently absent, H, C₁₋₆ alkyl, or—(CH₂)₁₋₆ L′, wherein L′ is —COOH, —COO—C₁₋₆alkyl, —NH₂, —OH, —SH,—COO⁻, SO₃ ⁻, SO₃-alkali metal, —COO-succinimide, —COO-sulfosuccininide,—NCO, —NCS, —COO-nitrophenyl, or —COO-fluorophenyl; A_(6′), and A_(10′)are independently C, N, or N⁺; R_(5′), R_(6′), R_(9′), and R_(10′) areindependently H, or R_(5′) and R_(6′) together with the carbons to whichthey are attached form a benzene, or R_(9′) and R_(10′) together withthe carbons to which they are attached form a benzene, wherein thebenzene can be substituted by —(CH₂)₀₋₃ SO₃ ⁻, —(CH₂)₀₋₃ SO₃-alkalimetal, —(CH₂)₀₋₃COOH, or —(CH₂)₀₋₃COO-alkali metal; Z′ is NR^(17′) or⁺NR^(17′)R^(18′), wherein R^(17′) and R^(18′) are independently C₁₋₆alkyl, —(CH₂)₁₋₃ ethynyl, —(CH₂)₁₋₆ L′, wherein L′ is —COOH,—COO—C₁₋₆alkyl, —NH₂, —OH, —SH, —COO⁻, SO₃ ⁻, SO₃-alkali metal,—COO-succinimide, —COO-sulfosuccininide, —COO-nitrophenyl, or —COO—fluorophenyl, wherein the at least one chelating agent is attached togroup L′ at R_(1″), R_(2″), R_(3′), R_(7′), or Z′, or to linker in Q′.31. The dye according to claim 22, wherein the at least one chelatingagent is selected from1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA),1,4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA),Triethylenetetramine (TETA), Ethylenediaminetetraacetic acid (EDTA),1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA), andDiethylenetriaminepentaacetic acid (DTPA).
 32. The dye according toclaim 31, wherein the at least one chelating agent is DOTA.
 33. The dyeaccording to claim 31, wherein DOTA is a modified DOTA with a structure:


34. The dye according to claim 22, wherein the targeting agent isselected from the group comprising peptides, small molecules, aptamers,antibodies, carbohydrates, saccharides, and nucleic acids.
 35. The dyeaccording to claim 22, wherein the dye is coupled to a nanoparticle. 36.The dye according to claim 22, wherein at least one chelating agent isattached to the dye to form a compound with a structure: